var title_f35_14_36064="Valgus stress testing thumb";
var content_f35_14_36064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Valgus stress testing of the thumb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The carpometacarpal (CMC) joint and the metacarpal bone of the thumb are securely grasped by one hand while the distal thumb is firmly grasped by the other. Using the thumbs for leverage, stress is applied across the metacarpophalangeal (MP) joint to the collateral ligament located on the ulnar side of the thumb (ie, the thumb is pulled away from the palm while the MP joint is braced).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36064=[""].join("\n");
var outline_f35_14_36064=null;
var title_f35_14_36065="Tessari method of foam sclerosant preparation";
var content_f35_14_36065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Tessari method of foam sclerosant preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 644px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36065=[""].join("\n");
var outline_f35_14_36065=null;
var title_f35_14_36066="Port placement laparoscopic Heller myotomy";
var content_f35_14_36066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Port placement laparoscopic Heller myotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the locations of the trocars for performing a laparoscopic Heller myotomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36066=[""].join("\n");
var outline_f35_14_36066=null;
var title_f35_14_36067="Trans pustular melanosis";
var content_f35_14_36067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transient neonatal pustular melanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transient neonatal pustular melanosis results in pigmented macules that gradually fade over several weeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kenneth Greer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36067=[""].join("\n");
var outline_f35_14_36067=null;
var title_f35_14_36068="Advanced emergency airway management in adults";
var content_f35_14_36068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Advanced emergency airway management in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Aaron E Bair, MD, MSc, FAAEM, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36068/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/14/36068/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway management is an essential skill for clinicians caring for critically ill or injured patients and is fundamental to the practice of emergency medicine. In emergency medicine practice, rapid sequence intubation (RSI) is the most frequently used and successful means of intubating the trachea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. It is employed in approximately 70 percent of all patients requiring intubation in academic emergency departments, and about 82 percent of those without cardiac arrest. Cardiac arrest patients, who are intubated without medications, comprise the bulk of the remaining patients.",
"   </p>",
"   <p>",
"    Although RSI is generally the preferred approach in the emergency department (ED), it may be poorly suited for some patients with difficult airway attributes. Thus, a careful assessment for airway difficulty must precede the decision to use RSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss an algorithmic approach to advanced emergency airway management in adults. Other issues related to airway management, including basic airway management, difficult airway assessment, and rapid sequence intubation, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RSI AND THE DIFFICULT AIRWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should employ an approach to emergency airway management that accounts for the possibility of difficult intubation, difficult bag-mask ventilation (BMV), difficult extraglottic device ventilation (EGV), and difficult cricothyroidotomy. Methods for evaluating airway difficulty and management of difficult and failed airways are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, rapid sequence intubation (RSI) is used in patients for whom successful intubation and successful bag-mask ventilation are anticipated, despite any difficult airway attributes that may be identified. A significant number of emergency department (ED) patients in need of endotracheal intubation (ETI) have anatomic characteristics that can increase the procedure's difficulty. Nevertheless, the great majority of such patients can be managed using RSI.",
"   </p>",
"   <p>",
"    No discreet threshold exists at which RSI is deemed safe or when it is contraindicated. This is due, in part, to the lack of sensitivity and specificity of commonly used guidelines for difficult airway prediction. The LEMON&copy; mnemonic is one aid for remembering important predictors of intubation difficulty, and has been prospectively validated (",
"    <a class=\"graphic graphic_table graphicRef64336 \" href=\"mobipreview.htm?0/46/747\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Difficult airway prediction guidelines are based primarily on the anesthesia experience, which often involves elective intubations of cooperative patients, and may not be applicable to the ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Furthermore, patients frequently present to the ED in extremis, and clinicians may be unable to obtain a history or to assess the airway adequately to determine whether a difficult intubation is likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/13\">",
"     13",
"    </a>",
"    ]. Nevertheless, we suggest emergency clinicians assess any airway they may need to manage, to the extent possible given the constraints of time and patient cooperation, in order to be prepared for a potentially difficult airway.",
"   </p>",
"   <p>",
"    Few studies have assessed difficult intubation in the ED and its true incidence is unknown. The difficult airway is likely more common among patients intubated in the ED than in the operating room, where patients are generally evaluated preoperatively and airway management can be done electively.",
"   </p>",
"   <p>",
"    Part of the problem in determining the incidence of airway difficulty stems from the various ways of defining what constitutes a \"difficult airway\" or \"difficult intubation.\" Depending on the definition, estimates of the rate of difficult intubation in the ED range as high as 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/14\">",
"     14",
"    </a>",
"    ]. Fortunately, intubation failure rates are much lower; cricothyroidotomy is performed in approximately 1 percent of ED patients at major trauma centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE MAIN AIRWAY ALGORITHM&copy;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithms presented in this review were developed as part of a national airway training course and represent an initial approach to advanced emergency airway management (",
"    <a class=\"graphic graphic_algorithm graphicRef63518 \" href=\"mobipreview.htm?33/39/34430\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/17\">",
"     17",
"    </a>",
"    ]. Once the need for intubation is decided, the clinician must determine the best approach. The following questions represent the major branch points in the main airway algorithm&copy; and reflect the important principles underlying advanced airway management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the patient in arrest or an agonal state? If so, direct intubation without medications is appropriate (",
"      <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The crash airway algorithm&copy;'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Is the patient likely to respond to direct laryngoscopy (ie, gag, thrash, vomit)? If not, then the patient is unlikely to benefit from the time required to administer sedative and paralytic medications. Direct laryngoscopy, without medications, is indicated (",
"      <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The crash airway algorithm&copy;'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One exception to this recommendation is the patient who is unresponsive because of a critical intracranial insult (eg, intracranial hemorrhage). In such patients RSI provides superior control of adverse reflexes that may increase intracranial pressure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link&amp;anchor=H15#H15\">",
"       \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Head injury or stroke'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is not in arrest or an agonal state, is a difficult airway predicted? The goal is to identify characteristics likely to result in significantly difficult intubation or ventilation. In such cases, it is prudent to choose an intubation technique that allows the patient to maintain spontaneous respirations (",
"      <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"mobipreview.htm?21/54/22382\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As long as oxygenation is adequate and no significant difficulty with intubation or ventilation is anticipated, rapid sequence intubation using direct laryngoscopy is advised. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If intubation was attempted but unsuccessful, is oxygenation adequate (ie, pulse oximetry above 90 percent)? If not, and if oxygenation does not immediately improve with better bag-mask ventilation, then a failed airway exists (",
"      <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"mobipreview.htm?12/9/12446\">",
"       algorithm 4",
"      </a>",
"      ). In most circumstances, a patient who is unable to be intubated and cannot be ventilated will require a surgical airway (ie, cricothyroidotomy). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If intubation is unsuccessful despite three attempts by an experienced operator, regardless of the ability to oxygenate, this too constitutes a failed airway. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE CRASH AIRWAY ALGORITHM&copy;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crash approach is predicated on the need for immediate airway control in the unresponsive patient unlikely to benefit from medications. The \"crash\" patient is unconscious, unresponsive, and has absent or severely compromised cardiopulmonary function. The assumption is that the patient is relaxed and unresponsive, similar to the conditions achieved with rapid sequence intubation (RSI). The following questions represent the major branch points in the crash airway algorithm&copy; and reflect the important principles underlying crash airway management (",
"    <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36068/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If intubation is attempted but unsuccessful, can oxygenation be maintained adequately with a bag and mask? This often cannot be determined by pulse oximetry, because the patient may not have a pulse oximetry waveform. Instead, the provider must rely on assessment of chest rise, mask seal, and bag compliance to determine the adequacy of bag-mask ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If attempts at oxygenation are ineffective then a failed airway exists. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If oxygenation is judged effective after the failed intubation attempt, then a single dose of a muscular relaxing agent is administered before subsequent intubation attempts. In the absence of contraindications, high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      is useful to overcome residual muscular rigidity. The higher dose is recommended to increase the speed of onset in patients with severe circulatory compromise. If succinylcholine is felt to be contraindicated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If intubation is unsuccessful despite three attempts by an experienced operator then a failed airway exists. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend rapid sequence intubation (RSI) for emergency intubations when significant intubation difficulty is not anticipated and a crash airway scenario does not exist. The main airway algorithm&copy; provides an overall approach to emergency airway management (",
"      <a class=\"graphic graphic_algorithm graphicRef63518 \" href=\"mobipreview.htm?33/39/34430\">",
"       algorithm 1",
"      </a>",
"      ). The algorithm is discussed above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'The main airway algorithm&copy;'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The crash airway algorithm provides an approach to airway management in patients who are unconscious, unresponsive, and have absent or severely compromised cardiopulmonary function (",
"      <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"       algorithm 2",
"      </a>",
"      ). The algorithm is discussed above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The crash airway algorithm&copy;'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that clinicians employ an approach to emergency airway management that accounts for the possibility of difficult intubation, difficult bag-mask ventilation, difficult extra-glottic device ventilation, and difficult cricothyroidotomy. Methods for evaluating airway difficulty and management of difficult and failed airways are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=see_link\">",
"       \"The failed airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/1\">",
"      Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/2\">",
"      Bair AE, Filbin MR, Kulkarni RG, Walls RM. The failed intubation attempt in the emergency department: analysis of prevalence, rescue techniques, and personnel. J Emerg Med 2002; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/3\">",
"      Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/4\">",
"      Mandavia DP, Qualls S, Rokos I. Emergency airway management in penetrating neck injury. Ann Emerg Med 2000; 35:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/5\">",
"      Li J, Murphy-Lavoie H, Bugas C, et al. Complications of emergency intubation with and without paralysis. Am J Emerg Med 1999; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/6\">",
"      Sivilotti ML, Filbin MR, Murray HE, et al. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med 2003; 10:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/7\">",
"      Reed MJ, Dunn MJ, McKeown DW. Can an airway assessment score predict difficulty at intubation in the emergency department? Emerg Med J 2005; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/8\">",
"      Mallampati SR. Clinical sign to predict difficult tracheal intubation (hypothesis). Can Anaesth Soc J 1983; 30:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/9\">",
"      Mallampati SR, Gatt SP, Gugino LD, et al. A clinical sign to predict difficult tracheal intubation: a prospective study. Can Anaesth Soc J 1985; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/10\">",
"      Eberhart LH, Arndt C, Cierpka T, et al. The reliability and validity of the upper lip bite test compared with the Mallampati classification to predict difficult laryngoscopy: an external prospective evaluation. Anesth Analg 2005; 101:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/11\">",
"      Samsoon GL, Young JR. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/12\">",
"      Tse JC, Rimm EB, Hussain A. Predicting difficult endotracheal intubation in surgical patients scheduled for general anesthesia: a prospective blind study. Anesth Analg 1995; 81:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/13\">",
"      Levitan RM, Everett WW, Ochroch EA. Limitations of difficult airway prediction in patients intubated in the emergency department. Ann Emerg Med 2004; 44:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/14\">",
"      Bair AE, Caravelli R, Tyler K, Laurin EG. Feasibility of the preoperative Mallampati airway assessment in emergency department patients. J Emerg Med 2010; 38:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/15\">",
"      Tayal VS, Riggs RW, Marx JA, et al. Rapid-sequence intubation at an emergency medicine residency: success rate and adverse events during a two-year period. Acad Emerg Med 1999; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36068/abstract/16\">",
"      Bair AE, Panacek EA, Wisner DH, et al. Cricothyrotomy: a 5-year experience at one institution. J Emerg Med 2003; 24:151.",
"     </a>",
"    </li>",
"    <li>",
"     Walls RM. The emergency airway algorithms. In: Manual of Emergency Airway Management, 3rd ed. Walls RM, Murphy MF.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.8.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 276 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36068=[""].join("\n");
var outline_f35_14_36068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RSI AND THE DIFFICULT AIRWAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE MAIN AIRWAY ALGORITHM&copy;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE CRASH AIRWAY ALGORITHM&copy;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/276|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/39/34430\" title=\"algorithm 1\">",
"      Main airway management algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/20/24910\" title=\"algorithm 2\">",
"      Crash airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/54/22382\" title=\"algorithm 3\">",
"      Difficult airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/9/12446\" title=\"algorithm 4\">",
"      Failed airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/276|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/46/747\" title=\"table 1\">",
"      LEMON mnemonic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18228?source=related_link\">",
"      The failed airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_14_36069="Bexarotene (systemic): Patient drug information";
var content_f35_14_36069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bexarotene (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/11/28854?source=see_link\">",
"     see \"Bexarotene (systemic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12995356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Targretin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Your doctor will talk about the bad effects before starting you on this drug. Use 2 helpful kinds of birth control 1 month before starting this drug and for 1 month after care ends. A pregnancy test will be done to show that you are NOT pregnant before starting this drug and every month while you are taking it. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bexarotene or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or are taking a cholesterol-lowering drug, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin A.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697767",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for at least 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for at least 1 month after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug or within 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, if your woman partner gets pregnant while you are being treated or within 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test 1 week before you start therapy and monthly while using this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11223 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36069=[""].join("\n");
var outline_f35_14_36069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12995356\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026859\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026861\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026860\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026865\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026866\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026868\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026863\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026864\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026869\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026870\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/11/28854?source=related_link\">",
"      Bexarotene (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28916?source=related_link\">",
"      Bexarotene (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/0/12293?source=related_link\">",
"      Bexarotene (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_14_36070="Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)";
var content_f35_14_36070=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodyMassIndexBoys_form\" name=\"BodyMassIndexBoys_form\" onkeydown=\"clrResults();\" onkeyup=\"BodyMassIndexBoys_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          BMI = Weight / (Height/100)",
"          <sup>",
"           2",
"          </sup>",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"BodyMassIndexBoys_fx(); minMaxCheck();\" onchange=\"BodyMassIndexBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"BodyMassIndexBoys_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"BodyMassIndexBoys_fx(); minMaxCheck();\" onchange=\"BodyMassIndexBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BodyMassIndexBoys_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"BodyMassIndexBoys_fx(); minMaxCheck();\" onchange=\"BodyMassIndexBoys_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BodyMassIndexBoys_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              BMI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"BMI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                kg/m",
"                <sup>",
"                 2",
"                </sup>",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Z Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"BodyMassIndexBoys_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         BMI Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt;5:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Underweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=5 and &lt;85:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Healthy weight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=85 and &lt;95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Overweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Obesity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      At the extremes (&gt;97th percentile or &lt;3rd percentile), small differences in percentiles represent  clinically important differences in BMI. At these extremes, the z-score is a more precise reflection  of how far the measurement deviates from the mean, and is a useful tool for tracking changes.",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Examples",
"     </span>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"3\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"40%\">",
"       <tr>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Z-score",
"         </b>",
"        </td>",
"        <td align=\"center\" bgcolor=\"#cccccc\">",
"         <b>",
"          Percentile equivalent",
"         </b>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 1.0",
"        </td>",
"        <td align=\"center\">",
"         84",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 2.0",
"        </td>",
"        <td align=\"center\">",
"         97.5",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 2.5",
"        </td>",
"        <td align=\"center\">",
"         99.4",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\">",
"         + 3.0",
"        </td>",
"        <td align=\"center\">",
"         99.7",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Boys: BMI for Age. National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36070=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(thisparam){",
"alert(thisparam + ' is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.BodyMassIndexBoys_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodyMassIndexBoys_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.BodyMassIndexBoys_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"BMI =  Weight / power((Height / 100),2);",
"",
"if (doCalc) BMI_param.value = fixDP(BMI, dp);",
"",
"",
"",
"Age_Months =  Age * 12;",
"",
"if(Age_Months >= 24 && Age_Months < 25){L = -1.982373595; M = 16.54777487; S = 0.080127429;};",
"if(Age_Months >= 25 && Age_Months < 26){L = -1.924100169; M = 16.49442763; S = 0.079233994;};",
"if(Age_Months >= 26 && Age_Months < 27){L = -1.86549793; M = 16.44259552; S = 0.078389356;};",
"if(Age_Months >= 27 && Age_Months < 28){L = -1.807261899; M = 16.3922434; S = 0.077593501;};",
"if(Age_Months >= 28 && Age_Months < 29){L = -1.750118905; M = 16.34333654; S = 0.076846462;};",
"if(Age_Months >= 29 && Age_Months < 30){L = -1.69481584; M = 16.29584097; S = 0.076148308;};",
"if(Age_Months >= 30 && Age_Months < 31){L = -1.642106779; M = 16.24972371; S = 0.075499126;};",
"if(Age_Months >= 31 && Age_Months < 32){L = -1.592744414; M = 16.20495268; S = 0.074898994;};",
"if(Age_Months >= 32 && Age_Months < 33){L = -1.547442391; M = 16.16149871; S = 0.074347997;};",
"if(Age_Months >= 33 && Age_Months < 34){L = -1.506902601; M = 16.11933258; S = 0.073846139;};",
"if(Age_Months >= 34 && Age_Months < 35){L = -1.471770047; M = 16.07842758; S = 0.07339337;};",
"if(Age_Months >= 35 && Age_Months < 36){L = -1.442628957; M = 16.03875896; S = 0.072989551;};",
"if(Age_Months >= 36 && Age_Months < 37){L = -1.419991255; M = 16.00030401; S = 0.072634432;};",
"if(Age_Months >= 37 && Age_Months < 38){L = -1.404277619; M = 15.96304277; S = 0.072327649;};",
"if(Age_Months >= 38 && Age_Months < 39){L = -1.39586317; M = 15.92695418; S = 0.07206864;};",
"if(Age_Months >= 39 && Age_Months < 40){L = -1.394935252; M = 15.89202582; S = 0.071856805;};",
"if(Age_Months >= 40 && Age_Months < 41){L = -1.401671596; M = 15.85824093; S = 0.071691278;};",
"if(Age_Months >= 41 && Age_Months < 42){L = -1.416100312; M = 15.82558822; S = 0.071571093;};",
"if(Age_Months >= 42 && Age_Months < 43){L = -1.438164899; M = 15.79405728; S = 0.071495113;};",
"if(Age_Months >= 43 && Age_Months < 44){L = -1.467669032; M = 15.76364255; S = 0.071462106;};",
"if(Age_Months >= 44 && Age_Months < 45){L = -1.504376347; M = 15.73433668; S = 0.071470646;};",
"if(Age_Months >= 45 && Age_Months < 46){L = -1.547942838; M = 15.70613566; S = 0.071519218;};",
"if(Age_Months >= 46 && Age_Months < 47){L = -1.597896397; M = 15.67904062; S = 0.071606277;};",
"if(Age_Months >= 47 && Age_Months < 48){L = -1.653732283; M = 15.65305192; S = 0.071730167;};",
"if(Age_Months >= 48 && Age_Months < 49){L = -1.714869347; M = 15.62817269; S = 0.071889214;};",
"if(Age_Months >= 49 && Age_Months < 50){L = -1.780673181; M = 15.604408; S = 0.072081737;};",
"if(Age_Months >= 50 && Age_Months < 51){L = -1.850468473; M = 15.58176458; S = 0.072306081;};",
"if(Age_Months >= 51 && Age_Months < 52){L = -1.923551865; M = 15.56025067; S = 0.072560637;};",
"if(Age_Months >= 52 && Age_Months < 53){L = -1.999220429; M = 15.5398746; S = 0.07284384;};",
"if(Age_Months >= 53 && Age_Months < 54){L = -2.076707178; M = 15.52064993; S = 0.073154324;};",
"if(Age_Months >= 54 && Age_Months < 55){L = -2.155348017; M = 15.50258427; S = 0.073490667;};",
"if(Age_Months >= 55 && Age_Months < 56){L = -2.234438552; M = 15.48568973; S = 0.073851672;};",
"if(Age_Months >= 56 && Age_Months < 57){L = -2.313321723; M = 15.46997718; S = 0.074236235;};",
"if(Age_Months >= 57 && Age_Months < 58){L = -2.391381273; M = 15.45545692; S = 0.074643374;};",
"if(Age_Months >= 58 && Age_Months < 59){L = -2.468032491; M = 15.44213961; S = 0.075072264;};",
"if(Age_Months >= 59 && Age_Months < 60){L = -2.542781541; M = 15.43003207; S = 0.075522104;};",
"if(Age_Months >= 60 && Age_Months < 61){L = -2.61516595; M = 15.41914163; S = 0.07599225;};",
"if(Age_Months >= 61 && Age_Months < 62){L = -2.684789516; M = 15.40947356; S = 0.076482128;};",
"if(Age_Months >= 62 && Age_Months < 63){L = -2.751316949; M = 15.40103139; S = 0.076991232;};",
"if(Age_Months >= 63 && Age_Months < 64){L = -2.81445945; M = 15.39381785; S = 0.077519149;};",
"if(Age_Months >= 64 && Age_Months < 65){L = -2.87402476; M = 15.38783094; S = 0.07806539;};",
"if(Age_Months >= 65 && Age_Months < 66){L = -2.92984048; M = 15.38306945; S = 0.078629592;};",
"if(Age_Months >= 66 && Age_Months < 67){L = -2.981796828; M = 15.37952958; S = 0.079211369;};",
"if(Age_Months >= 67 && Age_Months < 68){L = -3.029831343; M = 15.37720582; S = 0.079810334;};",
"if(Age_Months >= 68 && Age_Months < 69){L = -3.073924224; M = 15.37609107; S = 0.080426086;};",
"if(Age_Months >= 69 && Age_Months < 70){L = -3.114093476; M = 15.37617677; S = 0.081058206;};",
"if(Age_Months >= 70 && Age_Months < 71){L = -3.15039004; M = 15.37745304; S = 0.081706249;};",
"if(Age_Months >= 71 && Age_Months < 72){L = -3.182893018; M = 15.37990886; S = 0.082369741;};",
"if(Age_Months >= 72 && Age_Months < 73){L = -3.21170511; M = 15.38353217; S = 0.083048178;};",
"if(Age_Months >= 73 && Age_Months < 74){L = -3.23694834; M = 15.38831005; S = 0.083741021;};",
"if(Age_Months >= 74 && Age_Months < 75){L = -3.25876011; M = 15.39422883; S = 0.0844477;};",
"if(Age_Months >= 75 && Age_Months < 76){L = -3.277281546; M = 15.40127496; S = 0.085167651;};",
"if(Age_Months >= 76 && Age_Months < 77){L = -3.292683774; M = 15.40943252; S = 0.085900184;};",
"if(Age_Months >= 77 && Age_Months < 78){L = -3.305124073; M = 15.41868691; S = 0.086644667;};",
"if(Age_Months >= 78 && Age_Months < 79){L = -3.314768951; M = 15.42902273; S = 0.087400421;};",
"if(Age_Months >= 79 && Age_Months < 80){L = -3.321785992; M = 15.44042439; S = 0.088166744;};",
"if(Age_Months >= 80 && Age_Months < 81){L = -3.326345795; M = 15.45287581; S = 0.088942897;};",
"if(Age_Months >= 81 && Age_Months < 82){L = -3.328602731; M = 15.46636218; S = 0.089728202;};",
"if(Age_Months >= 82 && Age_Months < 83){L = -3.328725277; M = 15.48086704; S = 0.090521875;};",
"if(Age_Months >= 83 && Age_Months < 84){L = -3.32687018; M = 15.49637465; S = 0.091323162;};",
"if(Age_Months >= 84 && Age_Months < 85){L = -3.323188896; M = 15.51286936; S = 0.092131305;};",
"if(Age_Months >= 85 && Age_Months < 86){L = -3.317827016; M = 15.53033563; S = 0.092945544;};",
"if(Age_Months >= 86 && Age_Months < 87){L = -3.310923871; M = 15.54875807; S = 0.093765118;};",
"if(Age_Months >= 87 && Age_Months < 88){L = -3.302612272; M = 15.56812143; S = 0.09458927;};",
"if(Age_Months >= 88 && Age_Months < 89){L = -3.293018361; M = 15.58841065; S = 0.095417247;};",
"if(Age_Months >= 89 && Age_Months < 90){L = -3.282260813; M = 15.60961101; S = 0.096248301;};",
"if(Age_Months >= 90 && Age_Months < 91){L = -3.270454609; M = 15.63170735; S = 0.097081694;};",
"if(Age_Months >= 91 && Age_Months < 92){L = -3.257703616; M = 15.65468563; S = 0.097916698;};",
"if(Age_Months >= 92 && Age_Months < 93){L = -3.244108214; M = 15.67853139; S = 0.098752593;};",
"if(Age_Months >= 93 && Age_Months < 94){L = -3.229761713; M = 15.70323052; S = 0.099588675;};",
"if(Age_Months >= 94 && Age_Months < 95){L = -3.214751287; M = 15.72876911; S = 0.100424251;};",
"if(Age_Months >= 95 && Age_Months < 96){L = -3.199158184; M = 15.75513347; S = 0.101258643;};",
"if(Age_Months >= 96 && Age_Months < 97){L = -3.18305795; M = 15.78231007; S = 0.102091189;};",
"if(Age_Months >= 97 && Age_Months < 98){L = -3.166520664; M = 15.8102856; S = 0.102921245;};",
"if(Age_Months >= 98 && Age_Months < 99){L = -3.1496103; M = 15.83904708; S = 0.103748189;};",
"if(Age_Months >= 99 && Age_Months < 100){L = -3.132389637; M = 15.86858123; S = 0.104571386;};",
"if(Age_Months >= 100 && Age_Months < 101){L = -3.114911153; M = 15.89887562; S = 0.105390269;};",
"if(Age_Months >= 101 && Age_Months < 102){L = -3.097226399; M = 15.92991765; S = 0.106204258;};",
"if(Age_Months >= 102 && Age_Months < 103){L = -3.079383079; M = 15.96169481; S = 0.107012788;};",
"if(Age_Months >= 103 && Age_Months < 104){L = -3.061423765; M = 15.99419489; S = 0.107815327;};",
"if(Age_Months >= 104 && Age_Months < 105){L = -3.043386071; M = 16.02740607; S = 0.108611374;};",
"if(Age_Months >= 105 && Age_Months < 106){L = -3.025310003; M = 16.0613159; S = 0.109400388;};",
"if(Age_Months >= 106 && Age_Months < 107){L = -3.007225737; M = 16.09591292; S = 0.110181915;};",
"if(Age_Months >= 107 && Age_Months < 108){L = -2.989164598; M = 16.13118532; S = 0.110955478;};",
"if(Age_Months >= 108 && Age_Months < 109){L = -2.971148225; M = 16.16712234; S = 0.111720691;};",
"if(Age_Months >= 109 && Age_Months < 110){L = -2.953208047; M = 16.20371168; S = 0.112477059;};",
"if(Age_Months >= 110 && Age_Months < 111){L = -2.935363951; M = 16.24094239; S = 0.1132242;};",
"if(Age_Months >= 111 && Age_Months < 112){L = -2.917635157; M = 16.27880346; S = 0.113961734;};",
"if(Age_Months >= 112 && Age_Months < 113){L = -2.900039803; M = 16.31728385; S = 0.114689291;};",
"if(Age_Months >= 113 && Age_Months < 114){L = -2.882593796; M = 16.35637267; S = 0.115406523;};",
"if(Age_Months >= 114 && Age_Months < 115){L = -2.865311266; M = 16.39605916; S = 0.116113097;};",
"if(Age_Months >= 115 && Age_Months < 116){L = -2.848204697; M = 16.43633265; S = 0.116808702;};",
"if(Age_Months >= 116 && Age_Months < 117){L = -2.831285052; M = 16.47718256; S = 0.117493042;};",
"if(Age_Months >= 117 && Age_Months < 118){L = -2.81456189; M = 16.51859843; S = 0.11816584;};",
"if(Age_Months >= 118 && Age_Months < 119){L = -2.79804347; M = 16.56056987; S = 0.118826835;};",
"if(Age_Months >= 119 && Age_Months < 120){L = -2.781736856; M = 16.60308661; S = 0.119475785;};",
"if(Age_Months >= 120 && Age_Months < 121){L = -2.765648008; M = 16.64613844; S = 0.120112464;};",
"if(Age_Months >= 121 && Age_Months < 122){L = -2.749782197; M = 16.68971518; S = 0.120736656;};",
"if(Age_Months >= 122 && Age_Months < 123){L = -2.734142443; M = 16.73380695; S = 0.121348181;};",
"if(Age_Months >= 123 && Age_Months < 124){L = -2.718732873; M = 16.77840363; S = 0.121946849;};",
"if(Age_Months >= 124 && Age_Months < 125){L = -2.703555506; M = 16.82349538; S = 0.122532501;};",
"if(Age_Months >= 125 && Age_Months < 126){L = -2.688611957; M = 16.86907238; S = 0.123104991;};",
"if(Age_Months >= 126 && Age_Months < 127){L = -2.673903164; M = 16.91512487; S = 0.123664186;};",
"if(Age_Months >= 127 && Age_Months < 128){L = -2.659429443; M = 16.96164317; S = 0.124209969;};",
"if(Age_Months >= 128 && Age_Months < 129){L = -2.645190534; M = 17.00861766; S = 0.124742239;};",
"if(Age_Months >= 129 && Age_Months < 130){L = -2.631185649; M = 17.05603879; S = 0.125260905;};",
"if(Age_Months >= 130 && Age_Months < 131){L = -2.617413511; M = 17.10389705; S = 0.125765895;};",
"if(Age_Months >= 131 && Age_Months < 132){L = -2.603872392; M = 17.15218302; S = 0.126257147;};",
"if(Age_Months >= 132 && Age_Months < 133){L = -2.590560148; M = 17.20088732; S = 0.126734613;};",
"if(Age_Months >= 133 && Age_Months < 134){L = -2.577474253; M = 17.25000062; S = 0.12719826;};",
"if(Age_Months >= 134 && Age_Months < 135){L = -2.564611831; M = 17.29951367; S = 0.127648067;};",
"if(Age_Months >= 135 && Age_Months < 136){L = -2.551969684; M = 17.34941726; S = 0.128084023;};",
"if(Age_Months >= 136 && Age_Months < 137){L = -2.539539972; M = 17.39970308; S = 0.128506192;};",
"if(Age_Months >= 137 && Age_Months < 138){L = -2.527325681; M = 17.45036072; S = 0.128914497;};",
"if(Age_Months >= 138 && Age_Months < 139){L = -2.515320235; M = 17.50138161; S = 0.129309001;};",
"if(Age_Months >= 139 && Age_Months < 140){L = -2.503519447; M = 17.55275674; S = 0.129689741;};",
"if(Age_Months >= 140 && Age_Months < 141){L = -2.491918934; M = 17.60447714; S = 0.130056765;};",
"if(Age_Months >= 141 && Age_Months < 142){L = -2.480514136; M = 17.6565339; S = 0.130410133;};",
"if(Age_Months >= 142 && Age_Months < 143){L = -2.469300331; M = 17.70891811; S = 0.130749913;};",
"if(Age_Months >= 143 && Age_Months < 144){L = -2.458272656; M = 17.76162094; S = 0.131076187;};",
"if(Age_Months >= 144 && Age_Months < 145){L = -2.447426113; M = 17.81463359; S = 0.131389042;};",
"if(Age_Months >= 145 && Age_Months < 146){L = -2.436755595; M = 17.86794729; S = 0.131688579;};",
"if(Age_Months >= 146 && Age_Months < 147){L = -2.426255887; M = 17.92155332; S = 0.131974905;};",
"if(Age_Months >= 147 && Age_Months < 148){L = -2.415921689; M = 17.97544299; S = 0.132248138;};",
"if(Age_Months >= 148 && Age_Months < 149){L = -2.405747619; M = 18.02960765; S = 0.132508403;};",
"if(Age_Months >= 149 && Age_Months < 150){L = -2.395728233; M = 18.08403868; S = 0.132755834;};",
"if(Age_Months >= 150 && Age_Months < 151){L = -2.385858029; M = 18.1387275; S = 0.132990575;};",
"if(Age_Months >= 151 && Age_Months < 152){L = -2.376131459; M = 18.19366555; S = 0.133212776;};",
"if(Age_Months >= 152 && Age_Months < 153){L = -2.366542942; M = 18.24884431; S = 0.133422595;};",
"if(Age_Months >= 153 && Age_Months < 154){L = -2.357086871; M = 18.3042553; S = 0.133620197;};",
"if(Age_Months >= 154 && Age_Months < 155){L = -2.347757625; M = 18.35989003; S = 0.133805756;};",
"if(Age_Months >= 155 && Age_Months < 156){L = -2.338549576; M = 18.41574009; S = 0.133979452;};",
"if(Age_Months >= 156 && Age_Months < 157){L = -2.3294571; M = 18.47179706; S = 0.13414147;};",
"if(Age_Months >= 157 && Age_Months < 158){L = -2.320474586; M = 18.52805255; S = 0.134292005;};",
"if(Age_Months >= 158 && Age_Months < 159){L = -2.311596446; M = 18.5844982; S = 0.134431256;};",
"if(Age_Months >= 159 && Age_Months < 160){L = -2.302817124; M = 18.64112567; S = 0.134559427;};",
"if(Age_Months >= 160 && Age_Months < 161){L = -2.294131107; M = 18.69792663; S = 0.134676731;};",
"if(Age_Months >= 161 && Age_Months < 162){L = -2.285532933; M = 18.75489278; S = 0.134783385;};",
"if(Age_Months >= 162 && Age_Months < 163){L = -2.277017201; M = 18.81201584; S = 0.134879611;};",
"if(Age_Months >= 163 && Age_Months < 164){L = -2.268578584; M = 18.86928753; S = 0.134965637;};",
"if(Age_Months >= 164 && Age_Months < 165){L = -2.260211837; M = 18.92669959; S = 0.135041695;};",
"if(Age_Months >= 165 && Age_Months < 166){L = -2.251911809; M = 18.98424378; S = 0.135108024;};",
"if(Age_Months >= 166 && Age_Months < 167){L = -2.243673453; M = 19.04191185; S = 0.135164867;};",
"if(Age_Months >= 167 && Age_Months < 168){L = -2.235491842; M = 19.09969557; S = 0.135212469;};",
"if(Age_Months >= 168 && Age_Months < 169){L = -2.227362173; M = 19.15758672; S = 0.135251083;};",
"if(Age_Months >= 169 && Age_Months < 170){L = -2.21927979; M = 19.21557707; S = 0.135280963;};",
"if(Age_Months >= 170 && Age_Months < 171){L = -2.211240187; M = 19.27365839; S = 0.135302371;};",
"if(Age_Months >= 171 && Age_Months < 172){L = -2.203239029; M = 19.33182247; S = 0.135315568;};",
"if(Age_Months >= 172 && Age_Months < 173){L = -2.195272161; M = 19.39006106; S = 0.135320824;};",
"if(Age_Months >= 173 && Age_Months < 174){L = -2.187335625; M = 19.44836594; S = 0.135318407;};",
"if(Age_Months >= 174 && Age_Months < 175){L = -2.179425674; M = 19.50672885; S = 0.135308594;};",
"if(Age_Months >= 175 && Age_Months < 176){L = -2.171538789; M = 19.56514153; S = 0.135291662;};",
"if(Age_Months >= 176 && Age_Months < 177){L = -2.163671689; M = 19.62359571; S = 0.135267891;};",
"if(Age_Months >= 177 && Age_Months < 178){L = -2.155821357; M = 19.6820831; S = 0.135237567;};",
"if(Age_Months >= 178 && Age_Months < 179){L = -2.147985046; M = 19.74059538; S = 0.135200976;};",
"if(Age_Months >= 179 && Age_Months < 180){L = -2.140160305; M = 19.7991242; S = 0.135158409;};",
"if(Age_Months >= 180 && Age_Months < 181){L = -2.132344989; M = 19.85766121; S = 0.135110159;};",
"if(Age_Months >= 181 && Age_Months < 182){L = -2.124537282; M = 19.916198; S = 0.135056522;};",
"if(Age_Months >= 182 && Age_Months < 183){L = -2.116735712; M = 19.97472615; S = 0.134997797;};",
"if(Age_Months >= 183 && Age_Months < 184){L = -2.108939167; M = 20.03323719; S = 0.134934285;};",
"if(Age_Months >= 184 && Age_Months < 185){L = -2.10114692; M = 20.09172262; S = 0.134866291;};",
"if(Age_Months >= 185 && Age_Months < 186){L = -2.093358637; M = 20.15017387; S = 0.134794121;};",
"if(Age_Months >= 186 && Age_Months < 187){L = -2.085574403; M = 20.20858236; S = 0.134718085;};",
"if(Age_Months >= 187 && Age_Months < 188){L = -2.077794735; M = 20.26693944; S = 0.134638494;};",
"if(Age_Months >= 188 && Age_Months < 189){L = -2.070020599; M = 20.32523642; S = 0.134555663;};",
"if(Age_Months >= 189 && Age_Months < 190){L = -2.062253431; M = 20.38346455; S = 0.13446991;};",
"if(Age_Months >= 190 && Age_Months < 191){L = -2.054495145; M = 20.44161501; S = 0.134381553;};",
"if(Age_Months >= 191 && Age_Months < 192){L = -2.046748156; M = 20.49967894; S = 0.134290916;};",
"if(Age_Months >= 192 && Age_Months < 193){L = -2.039015385; M = 20.5576474; S = 0.134198323;};",
"if(Age_Months >= 193 && Age_Months < 194){L = -2.031300282; M = 20.6155114; S = 0.134104101;};",
"if(Age_Months >= 194 && Age_Months < 195){L = -2.023606828; M = 20.67326189; S = 0.134008581;};",
"if(Age_Months >= 195 && Age_Months < 196){L = -2.015942013; M = 20.73088905; S = 0.133912066;};",
"if(Age_Months >= 196 && Age_Months < 197){L = -2.008305745; M = 20.7883851; S = 0.133814954;};",
"if(Age_Months >= 197 && Age_Months < 198){L = -2.000706389; M = 20.84574003; S = 0.133717552;};",
"if(Age_Months >= 198 && Age_Months < 199){L = -1.993150137; M = 20.90294449; S = 0.1336202;};",
"if(Age_Months >= 199 && Age_Months < 200){L = -1.985643741; M = 20.95998909; S = 0.133523244;};",
"if(Age_Months >= 200 && Age_Months < 201){L = -1.97819451; M = 21.01686433; S = 0.133427032;};",
"if(Age_Months >= 201 && Age_Months < 202){L = -1.970810308; M = 21.07356067; S = 0.133331914;};",
"if(Age_Months >= 202 && Age_Months < 203){L = -1.96349954; M = 21.1300685; S = 0.133238245;};",
"if(Age_Months >= 203 && Age_Months < 204){L = -1.956271141; M = 21.18637813; S = 0.133146383;};",
"if(Age_Months >= 204 && Age_Months < 205){L = -1.949134561; M = 21.24247982; S = 0.13305669;};",
"if(Age_Months >= 205 && Age_Months < 206){L = -1.942099744; M = 21.29836376; S = 0.132969531;};",
"if(Age_Months >= 206 && Age_Months < 207){L = -1.935177101; M = 21.35402009; S = 0.132885274;};",
"if(Age_Months >= 207 && Age_Months < 208){L = -1.92837748; M = 21.40943891; S = 0.132804292;};",
"if(Age_Months >= 208 && Age_Months < 209){L = -1.921712136; M = 21.46461026; S = 0.132726962;};",
"if(Age_Months >= 209 && Age_Months < 210){L = -1.915192685; M = 21.51952414; S = 0.132653664;};",
"if(Age_Months >= 210 && Age_Months < 211){L = -1.908831065; M = 21.57417053; S = 0.132584784;};",
"if(Age_Months >= 211 && Age_Months < 212){L = -1.902639482; M = 21.62853937; S = 0.132520711;};",
"if(Age_Months >= 212 && Age_Months < 213){L = -1.896630358; M = 21.68262062; S = 0.132461838;};",
"if(Age_Months >= 213 && Age_Months < 214){L = -1.890816268; M = 21.73640419; S = 0.132408563;};",
"if(Age_Months >= 214 && Age_Months < 215){L = -1.885209876; M = 21.78988003; S = 0.132361289;};",
"if(Age_Months >= 215 && Age_Months < 216){L = -1.879823505; M = 21.84303819; S = 0.132320427;};",
"if(Age_Months >= 216 && Age_Months < 217){L = -1.874670324; M = 21.8958685; S = 0.132286382;};",
"if(Age_Months >= 217 && Age_Months < 218){L = -1.869760299; M = 21.94836168; S = 0.1322596;};",
"if(Age_Months >= 218 && Age_Months < 219){L = -1.865113245; M = 22.00050569; S = 0.132240418;};",
"if(Age_Months >= 219 && Age_Months < 220){L = -1.860734944; M = 22.05229242; S = 0.13222933;};",
"if(Age_Months >= 220 && Age_Months < 221){L = -1.85663384; M = 22.10371305; S = 0.132226801;};",
"if(Age_Months >= 221 && Age_Months < 222){L = -1.852827186; M = 22.15475603; S = 0.132233201;};",
"if(Age_Months >= 222 && Age_Months < 223){L = -1.849323204; M = 22.20541249; S = 0.132248993;};",
"if(Age_Months >= 223 && Age_Months < 224){L = -1.846131607; M = 22.255673; S = 0.132274625;};",
"if(Age_Months >= 224 && Age_Months < 225){L = -1.843261294; M = 22.30552831; S = 0.132310549;};",
"if(Age_Months >= 225 && Age_Months < 226){L = -1.840720248; M = 22.3549693; S = 0.132357221;};",
"if(Age_Months >= 226 && Age_Months < 227){L = -1.83851544; M = 22.40398706; S = 0.132415103;};",
"if(Age_Months >= 227 && Age_Months < 228){L = -1.83665586; M = 22.45257182; S = 0.132484631;};",
"if(Age_Months >= 228 && Age_Months < 229){L = -1.835138046; M = 22.50071778; S = 0.132566359;};",
"if(Age_Months >= 229 && Age_Months < 230){L = -1.833972004; M = 22.54841437; S = 0.132660699;};",
"if(Age_Months >= 230 && Age_Months < 231){L = -1.833157751; M = 22.59565422; S = 0.132768153;};",
"if(Age_Months >= 231 && Age_Months < 232){L = -1.83269562; M = 22.64242956; S = 0.132889211;};",
"if(Age_Months >= 232 && Age_Months < 233){L = -1.832584342; M = 22.68873292; S = 0.133024368;};",
"if(Age_Months >= 233 && Age_Months < 234){L = -1.832820974; M = 22.73455713; S = 0.133174129;};",
"if(Age_Months >= 234 && Age_Months < 235){L = -1.833400825; M = 22.7798953; S = 0.133338999;};",
"if(Age_Months >= 235 && Age_Months < 236){L = -1.834317405; M = 22.82474087; S = 0.133519496;};",
"if(Age_Months >= 236 && Age_Months < 237){L = -1.83555752; M = 22.86908912; S = 0.133716192;};",
"if(Age_Months >= 237 && Age_Months < 238){L = -1.837119466; M = 22.91293151; S = 0.133929525;};",
"if(Age_Months >= 238 && Age_Months < 239){L = -1.838987063; M = 22.95626373; S = 0.134160073;};",
"if(Age_Months >= 239 && Age_Months < 240){L = -1.841146139; M = 22.99908062; S = 0.134408381;};",
"if(Age_Months >= 240 && Age_Months < 241){L = -1.843580575; M = 23.04137734; S = 0.134675001;};",
"Z_Score =  (power((BMI / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"rrclr();",
"if (Percentile <5){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Percentile >=5) && (Percentile <85)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Percentile >=85) && (Percentile <95)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if (Percentile >=95){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexBoys_form){",
"",
"if (Age_param.value && isNaN(Age_param.value)){ Age_param.value = ''; alertNaN('Age'); }",
"if (Age_param.value && Age < 2) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 2 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 19.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 19.99 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && isNaN(Height_param.value)){ Height_param.value = ''; alertNaN('Height'); }",
"if (Height_param.value && Height < 50) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 50 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 300) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 300 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && isNaN(Weight_param.value)){ Weight_param.value = ''; alertNaN('Weight'); }",
"if (Weight_param.value && Weight < 5) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 5 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 300) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 300 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexBoys_form){",
"",
"BMI_param.value = '';",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f35_14_36070=null;
var title_f35_14_36071="Muscle compartments of the thigh";
var content_f35_14_36071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Muscle compartments of the thigh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thigh has three muscle compartments:",
"    <ul>",
"     <li>",
"      Anterior compartment (pink) &mdash; Sartorius and quadriceps muscles (rectus femoris, vastus lateralis, vastus intermedius, vastus medialis). The femoral nerve and superficial femoral artery supply these muscles.",
"     </li>",
"     <li>",
"      Medial compartment (green) &mdash; Pectineus, obturator externus, gracilis and adductor muscles (longus, brevis, magnus, minimus). The obturator nerve innervates the medial compartment.",
"     </li>",
"     <li>",
"      Posterior compartment (blue) &mdash; Biceps femoris, semimembranous and semitendinous muscles. The sciatic nerve innervates the posterior compartment. The deep femoral artery supplies the posterior compartment.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36071=[""].join("\n");
var outline_f35_14_36071=null;
var title_f35_14_36072="Allergy to meats";
var content_f35_14_36072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergy to meats",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Scott P Commins, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36072/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/14/36072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meat allergy is uncommon in the developed world, despite relatively high levels of meat consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1\">",
"     1",
"    </a>",
"    ]. Childhood meat allergy is usually associated with atopic dermatitis and outgrown during the first years of life. Meat allergy can also develop in adulthood.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and natural history of allergy to meats will be discussed in this topic review. General issues related to food allergies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND CAUSATIVE MEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meat allergy is relatively uncommon, although the overall incidence and prevalence of allergies to meat in the general population are not known. Among patients with food allergies, meat allergy has been reported in about 3 to 15 percent of pediatric cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and 3 percent of adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/4\">",
"     4",
"    </a>",
"    ]. The low prevalence of meat allergy may be in part attributable to the fact that most meats are eaten in cooked forms, and cooking usually (not always) reduces the immunogenicity of allergens. (See",
"    <a class=\"local\" href=\"#H25949760\">",
"     'Allergens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The type of meats that cause allergy appear to be related to their prominence in the diet, and geographical variations are evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beef is the most commonly reported allergy, with a prevalence of beef allergy ranging from 1.5 to 6.5 percent among children with atopic dermatitis or food",
"    <span class=\"nowrap\">",
"     allergies/intolerances",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. However, the prevalence of beef allergy can be as high as 20 percent in children allergic to cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Patterns of cross-reactivity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Allergic reactions to pork, lamb, rabbit, chicken, and turkey are also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Case reports describe allergies to kangaroo meat in Australia, as well as seal and whale meats in native Alaskan populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Overall, allergy to mammalian meats is more prevalent than allergy to poultry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178955257\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of allergy to meats have not been defined. However, the epidemiology of meat allergy suggests that children with atopic dermatitis or cow&rsquo;s milk allergy are at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Some patients with gelatin allergy may also be sensitized or clinically reactive to meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25949260\">",
"    <span class=\"h1\">",
"     CLINICAL REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both IgE-mediated and non IgE-mediated forms of meat allergy have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11265525\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with meat allergy often have atopic dermatitis and present with exacerbations of skin inflammation following ingestion of certain meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/15\">",
"     15",
"    </a>",
"    ], although they can also develop other symptoms, such as pruritus, urticaria, or even asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of allergy in atopic dermatitis (eczema)\", section on 'Food allergies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, skin symptoms are also common during allergic reactions to meat. One series of 10 patients with symptoms beginning in adulthood reported that the most common symptoms after meat and milk ingestion were cutaneous (70 percent), followed by gastrointestinal symptoms (40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/16\">",
"     16",
"    </a>",
"    ]. However, in adults, pruritus and urticaria were more prominent than eczematous reactions. Other responses included contact urticaria of the oral mucosa (oral allergy syndrome) and anaphylaxis. These 10 patients developed symptoms after ingestion, but not in response to contact or inhalational exposures. All 10 patients had specific IgE to one or more meats or milk upon serologic testing.",
"   </p>",
"   <p>",
"    One unusual feature of IgE-mediated allergic reactions to meat is that symptoms can be relatively delayed in onset. In patients with convincing evidence of IgE-mediated allergy, reactions began as quickly as several minutes or as delayed as three to six hours after ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This disparity in time to symptoms may be explained by the nature of the allergen (ie, protein versus carbohydrate) (See",
"    <a class=\"local\" href=\"#H11265746\">",
"     'Carbohydrate allergens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25949760\">",
"    <span class=\"h3\">",
"     Allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited information is available about the allergens responsible for meat allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/20\">",
"     20",
"    </a>",
"    ]. Both protein and carbohydrate allergens have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11265619\">",
"    <span class=\"h4\">",
"     Serum proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum albumins and immunoglobulins appear to be the primary allergenic proteins in beef and other mammalian meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. Albumins have been implicated in allergies to beef, pork, lamb, rabbit, as well as chicken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/9-11,21,22\">",
"     9-11,21,22",
"    </a>",
"    ]. The International Union of Immunological Societies lists just three meat proteins in its official listing of important food allergens; two of bovine origin (a serum albumin, Bos d 6, and an immunoglobulin, Bos d 7) and one from chicken (serum albumin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link\">",
"     \"Molecular features of food allergens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequence homology between bovine serum albumin (BSA) and pig, sheep, and chicken serum albumins were 80, 92, and 44, respectively, supporting the clinical observation that individuals tend to react to mammalian meats or poultry, but rarely both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Cross-reactivity between beef and whey proteins from milk has been attributed to serum albumins and gamma-immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Meats and other foods'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The low prevalence of meat allergy may be in part attributable to the heat-labile properties of serum albumins and the fact that most meats are eaten in cooked forms.",
"   </p>",
"   <p>",
"    Additional proteins in meat that may act as major and minor allergens have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/11-13,21,26-28\">",
"     11-13,21,26-28",
"    </a>",
"    ]. As an example, denatured type I bovine collagen has been identified as the major allergenic component of bovine gelatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/29\">",
"     29",
"    </a>",
"    ]. The clinical significance of some meat allergens is not known. These proteins are diverse and likely represent light chain immunoglobulins, heavy chain immunoglobulins, and muscle proteins, such as actin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11265746\">",
"    <span class=\"h4\">",
"     Carbohydrate allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most known food allergens are proteins. However, carbohydrate epitopes can also act as allergens. Galactose-alpha-1,3-galactose (alpha-gal) is a carbohydrate moiety abundantly expressed on cells and tissues of all non-primate mammalian species (ie, beef, pork, lamb) and patients sensitized to alpha-gal reported delayed symptoms to a wide range of mammalian meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17\">",
"     17",
"    </a>",
"    ]. Some also reported reactions to gelatins and milk, which contain alpha-gal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/14\">",
"     14",
"    </a>",
"    ]. As mentioned previously, the onset of symptoms was significantly later compared with typical IgE-mediated reactions, beginning three to six hours after ingestion. The reasons for this temporal pattern have not yet been elucidated.",
"   </p>",
"   <p>",
"    Most patients in this group had urticaria, angioedema, or anaphylaxis, although a few individuals had gastrointestinal symptoms accompanied by pre-syncope or syncope without urticaria or angioedema, a presentation that is more difficult to recognize as an allergic reaction. The authors of this study identified IgE to alpha-gal in 1 to 3 percent of the population in selected areas of the southeastern US, although there are not yet formal studies of prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587435\">",
"    <span class=\"h3\">",
"     Role of cooking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Domestic or industrial processing of meat can alter the allergenicity of meat by modifying or inactivating the epitopes for IgE binding. In most cases (not all), this results in no change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/31\">",
"     31",
"    </a>",
"    ] or decreased reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1,18,21,24\">",
"     1,18,21,24",
"    </a>",
"    ], and this is probably true for meat allergens as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link&amp;anchor=H2#H2\">",
"     \"Molecular features of food allergens\", section on 'Protein stability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other forms of processing, such as homogenization or freeze-drying, can also alter allergenicity. A study of 12 children with clinically documented beef allergy found that all the children reacted to home-cooked beef during oral challenges and some of them reacted to heated BSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/32\">",
"     32",
"    </a>",
"    ]. However, none reacted to either homogenized or freeze-dried beef (the industrial processes that are usually used in the production of baby foods). Homogenization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    freeze-drying have been shown to decrease the content of blood albumins and immunoglobulins (eg, the primary allergenic proteins) in meat. Digestion with pepsin was also shown to nearly eliminate allergenicity for most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19470775\">",
"    <span class=\"h2\">",
"     Eosinophilic esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic esophagitis (EE) typically presents with symptoms of gastroesophageal reflux unresponsive to acid suppression and dysphagia for solids, especially in young men or boys. The majority of patients (90 percent) are sensitized to both food and aeroallergens, yet only 10 to 30 percent have a history of food anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/33\">",
"     33",
"    </a>",
"    ]. The diagnosis is based upon the presence of characteristic clinical features, a large number of eosinophils on esophageal biopsy, and the exclusion of other causes. The pathogenesis of eosinophilic esophagitis is believed to involve both IgE-mediated and non IgE-mediated hypersensitivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beef, chicken, and cow&rsquo;s milk have been implicated as causing esophageal inflammation in patients with EE. Patients typically develop symptoms in response to more than one food. In one study, an average of three to six problematic foods per patient were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/33\">",
"     33",
"    </a>",
"    ]. The foods most often implicated were milk, egg, soy, chicken, wheat, beef, corn, and peanuts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28810259\">",
"    <span class=\"h2\">",
"     Food protein-induced enterocolitis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food protein-induced enterocolitis syndrome (FPIES) represents a non IgE-mediated form of food allergy that usually presents in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. Symptoms of typical FPIES are delayed by a median of two hours and include vomiting, diarrhea, and",
"    <span class=\"nowrap\">",
"     lethargy/dehydration",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/35\">",
"     35",
"    </a>",
"    ]. Bloody diarrhea may be present, and infants are generally ill-appearing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although cow's milk and soy protein are the most common triggers, food protein-induced enterocolitis can be triggered by other proteins, including beef, chicken, and turkey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/36\">",
"     36",
"    </a>",
"    ]. The author is not aware of published reports of enterocolitis caused by meats beginning in adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATTERNS OF CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical syndromes have been described that involve cross-reactivity or cross-sensitization between meat allergens and other types of allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Meats from different animal species",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of cross-reactivity is increased the more closely related the animals are evolutionarily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients allergic to beef may react to mutton or pork, but rarely to poultry or fish. Similarly, patients may react to chicken and turkey, but not to mammalian meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/11\">",
"     11",
"    </a>",
"    ]. Cross-reactivity among goose, duck, turkey, and chicken meat has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/37\">",
"     37",
"    </a>",
"    ]. In many cases, cross-reactivity has been shown to be due to IgE specific for common determinants on serum albumins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25949760\">",
"     'Allergens'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meats and other foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been made about cross-reactivity between meats and other animal-derived foods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beef and cow&rsquo;s milk: Allergy to cow&rsquo;s milk is present in 73 to 93 percent of beef allergic patients, most of whom are children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/23,37\">",
"       23,37",
"      </a>",
"      ]. Sensitization to bovine serum albumin is the main predictive marker of this cross-reactivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/37\">",
"       37",
"      </a>",
"      ]. Milk allergy is reviewed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=see_link\">",
"       \"Milk allergy: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40087?source=see_link\">",
"       \"Milk allergy: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beef and beef gelatin: Allergy to beef gelatin is seen in some patients with allergy to beef. The responsible allergen may be galactose-alpha-1,3-galactose (alpha-gal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients with gelatin allergy may report reactions to vaccines or foods that do not contain obvious meats. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link&amp;anchor=H7#H7\">",
"       \"Allergic reactions to vaccines\", section on 'Gelatin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, patients with a meat allergy may not react to other",
"    <span class=\"nowrap\">",
"     foods/inhalants",
"    </span>",
"    derived from the same animal source. As example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis due to ingestion of porcine gut and kidney, with tolerance of pork meat, has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/27\">",
"       27",
"      </a>",
"      ]. This patient also reacted to lamb gut. This case illustrates that allergens can be tissue-specific.",
"     </li>",
"     <li>",
"      Adults have been described who are allergic to poultry meat, but tolerant of eggs and not allergic to poultry feathers or dander [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/11,38\">",
"       11,38",
"      </a>",
"      ]. The responsible allergen(s) have not been identified, although they are likely different from the allergens that cause bird-egg syndrome (see next paragraph).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Meats and animal dander/epithelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients allergic to meats may show cross-reactivity with animal epithelia or dander. The following have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bird-egg syndrome is a term used to describe adults with allergic respiratory disease provoked by the inhalation of bird feathers or dander, who also develop allergic symptoms with hen&rsquo;s egg ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/39\">",
"       39",
"      </a>",
"      ]. Alpha livetin (aka, chicken serum albumin, Gal d 5), found in the dander and yolk proteins of chicken egg, is the major allergen responsible for these reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. This allergen is also present in chicken meat, but only a minority of patients with bird feather allergy report chicken meat allergy, most likely because the allergen is altered by cooking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cross-reactivity between horse meat and horse epithelium was demonstrated in a young female who was sensitized to horse epithelium and experienced anaphylaxis after unknowingly eating a meal with horse meat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cross-reactivity between cat epithelia and pork meat due to homologous serum albumins also exists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. A case of fatal anaphylaxis was described in a patient who had known allergy to pork and ingested wild boar meat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/47\">",
"       47",
"      </a>",
"      ]. This patient was also sensitized to cat albumin (Fel d 2). The term pork-cat syndrome was coined by the group who reported this case. Sensitization to cat serum albumin was also demonstrated in a series of eight patients from the US [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/46\">",
"       46",
"      </a>",
"      ]. The reactions to pork began soon (within two hours) after ingestion, distinguishing this syndrome from allergy to carbohydrate allergens. Of note, patients with pork-cat syndrome may",
"      <strong>",
"       not",
"      </strong>",
"      have allergic rhinitis symptoms to cat dander. Most patients with allergic symptoms to cat dander are sensitized to a different allergen (Fel d 1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meats and monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cross-reactive carbohydrate determinant (CCD), galactose-alpha-1,3-galactose (aka, alpha-gal), which is present on a range of mammalian meats, has been shown to be a potent allergen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17\">",
"     17",
"    </a>",
"    ]. Alpha-gal is present in the tissues of all mammals except humans, chimpanzees, and old world monkeys. Patients who have IgE to alpha-gal can develop severe hypersensitivity reactions to the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , which also contains alpha-gal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/48\">",
"     48",
"    </a>",
"    ]. This association was made after a group of patients experienced anaphylaxis upon their initial exposure to cetuximab, indicating that they had been previously sensitized to some component of the drug. A subset of these patients living in the Southeastern United States described delayed anaphylaxis to beef, pork, or lamb, despite having tolerated these meats previously. Many of these patients reported that allergic symptoms to meat ingestion had begun after a series of tick bites. This, combined with other evidence, suggests that patients in this region can become sensitized to alpha-gal through the bite of the tick species Amblyomma americanum (ie, the lone star tick) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/49\">",
"     49",
"    </a>",
"    ]. The IgE response to alpha-gal has been found in adults as well as children. These reactions are atypical for IgE-mediated allergy in that they do not start until several hours after meat ingestion and are associated with negative or very weak wheal responses to prick tests with meat extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar patients have now been reported in Europe and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/19,50\">",
"     19,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27268533\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of meat allergy can be challenging. Several studies have described poor correlation between the clinical history, skin test results, immunoassays to food-specific IgE, and outcomes of food challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1,20,51-53\">",
"     1,20,51-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series described 13 patients with convincing clinical histories of chicken, beef, or pork allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/51\">",
"       51",
"      </a>",
"      ]. Three had life-threatening reactions and positive skin tests to the suspect meat and so were not challenged, but the remaining 10 underwent double-blind placebo-controlled food challenge (DBPCFC) with up to 50 grams of well-cooked meat. Only 3 of the 10 challenged patients reacted to challenge, however, other beef challenge protocols have identified positive reactions at higher doses, such as 75 grams (see next bullet). Thus, meat allergy was confirmed in 6 of 13 patients. Just one of the challenge-positive individuals had positive skin tests to a commercial extract of the suspect meat. Two patients had demonstrable meat-specific IgE (by ImmunoCAP testing). Five of the seven patients with a",
"      <strong>",
"       negative",
"      </strong>",
"      challenge test showed evidence of specific IgE to the suspect meat, either by skin testing or immunoassay, reflecting a state of \"silent sensitization.&rdquo; This study illustrated that conventional diagnostic techniques for food allergy have low sensitivity and specificity in the diagnosis of allergy to meats.",
"     </li>",
"     <li>",
"      In another report of 12 patients with suspected beef allergy, all 12 patients had positive immunoassays to beef and 7 of the 12 reacted to either a labial or open food challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/52\">",
"       52",
"      </a>",
"      ]. Two of the patients with positive challenges ingested 75 grams of beef before symptoms appeared, despite each having an IgE response of at least class III.",
"     </li>",
"     <li>",
"      In a third study of 10 adults with a history of recurrent food allergy symptoms on exposure to milk and meat, skin prick testing with standard extracts for beef, pork, chicken, and milk produced negative results in all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/16\">",
"       16",
"      </a>",
"      ]. Immunoassays to meats and milk were positive in nine patients.",
"     </li>",
"     <li>",
"      Some published data indicates that wheal reactions are consistently larger with fresh meat, suggesting the usefulness of the native allergen in meat allergy skin testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17,54\">",
"       17,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the utility of IgE-determinations, either by skin testing or immunoassay, is less certain for the diagnosis of meat allergy than for many other food allergies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588113\">",
"    <span class=\"h2\">",
"     Testing options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following forms of testing",
"    <strong>",
"     may",
"    </strong>",
"    be required to demonstrate meat-specific IgE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epicutaneous (prick) skin testing (SPT) with commercial extracts of meat.",
"     </li>",
"     <li>",
"      Epicutaneous skin testing (SPT) with fresh meats (also called &ldquo;prick&ndash;by-prick testing&rdquo;): Details of patient&rsquo;s history should guide preparation of the meat for testing. The meat should be cooked in a manner similar to the way the meat was prepared when it allegedly caused symptoms. As an example, if rare steak seemed to cause the reaction, then raw beef should be purchased and cooked rare just prior to the testing. We advise the patient to have a family member or friend cook the meat, to avoid having the patient handle raw meat to which they could be allergic.",
"     </li>",
"     <li>",
"      IgE immunoassays to individual meats.",
"     </li>",
"     <li>",
"      IgE immunoassays to galactose-alpha-1,3-galactose, which are commercially available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgE immunoassay to cat serum albumin, which is commercially available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Food challenge, or if feasible, double-blind, placebo-controlled challenge. The total amount ingested during a challenge should mimic the amount ingested by the patient prior to developing symptoms. As mentioned previously, one study found that 75 grams of beef was necessary to identify allergy in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17934162\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the issues discussed above, the best approach to diagnosis of meat allergy is not known. The author&rsquo;s approach is described here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who report the relatively immediate onset of allergic symptoms following ingestion of meat, we perform SPT to the meat(s) in question using commercial extracts initially. We also include a meat that the patient tolerates as a negative control. If the SPT results are consistent with the patient&rsquo;s clinical history, a diagnosis of meat allergy is made for the specific meat(s). In the author&rsquo;s experience, commercial extracts produce small wheals (eg, usually, &le;4 mm in diameter) in sensitized patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If SPT using commercial extracts is negative, we then perform SPT using fresh meat (so-called prick-by-prick testing), again including a meat that is tolerated as a negative control. If this testing is positive to clinically suspected meat(s), then the diagnosis of meat allergy is confirmed.",
"      <br/>",
"      <br/>",
"      If prick-by-prick testing with fresh meats is negative, immunoassays are sent for the clinically suspected meats and a tolerated meat.",
"      <br/>",
"      <br/>",
"      In patients with suspected pork reactions who have not had reactions to beef or lamb, we also test for sensitization to cat, either with cat extract or with an immunoassay to cat serum albumin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/57\">",
"       57",
"      </a>",
"      ], to identify those patients with pork-cat syndrome. These patients usually report symptoms that begin within two hours of eating pork products, rather than the delayed reactions seen in patients sensitized to alpha-gal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Meats and animal dander/epithelium'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If all testing is negative, then food challenge is indicated if the patient wishes to pursue a more certain diagnosis. When feasible, this should be performed in a single- or double-blinded manner. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who report symptoms that occur three to six hours after eating mammalian meat (or consistently occur at night, even if the association with meat ingestion is not clear), SPT are performed to commercial extracts of beef, pork, lamb, chicken, turkey, milk, and cat and dog dander.",
"      <br/>",
"      <br/>",
"      We include poultry in the testing to determine if the patient is sensitized to mammalian meats only, or to an allergen found on non-mammalian meats also.",
"      <br/>",
"      <br/>",
"      Dog and cat are included for this reason too, and to detect possible pork-cat syndrome.",
"      <br/>",
"      <br/>",
"      Milk is included because it contains alpha-gal and many patients with IgE to alpha-gal report difficulty tolerating milk.",
"      <br/>",
"      <br/>",
"      We also include a meat that the patient tolerates as a negative control.",
"      <br/>",
"      <br/>",
"      It has been our experience that testing with commercial extracts is often negative in patients who have IgE to alpha-gal.",
"      <br/>",
"      <br/>",
"      If SPT using commercial extracts is negative, we then perform prick-by-prick testing with fresh meat, again including a meat that is tolerated as a negative control. If this testing is positive to clinically suspected meat(s), then the diagnosis of meat allergy is confirmed.",
"      <br/>",
"      <br/>",
"      If testing with fresh meats is not feasible or the results are negative, then immunoassays to detect IgE to galactose-alpha-1,3-galactose may be performed. Immunoassays are commercially available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If all testing is negative, then food challenge is indicated if the patient wishes to pursue a more certain diagnosis and there is a setting available in which challenges can be safely performed. When feasible, this should be performed in a single or double blinded manner. In our center, we have administered challenges to patients with negative tests as a single &ldquo;dose&rdquo; followed by three to six hours of observation. Food challenges are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588614\">",
"    <span class=\"h2\">",
"     Diagnosis of non IgE-mediated forms of allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with eosinophilic esophagitis or food-protein induced enterocolitis syndrome who are suspected to have sensitivity to foods is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2250?source=see_link&amp;anchor=H15042708#H15042708\">",
"     \"Food protein-induced enterocolitis syndrome (FPIES)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=see_link&amp;anchor=H14#H14\">",
"     \"Future diagnostic tools for food allergy\", section on 'Gastrointestinal food allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25948959\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following disorders can mimic meat allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic reactions to antibiotics in meat, particularly penicillin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse reactions to naturally occurring chemicals in food (eg, histamine, serotonin, and tyramine), as well as reactions to preservatives (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/6/32866?source=see_link\">",
"       sodium benzoate",
"      </a>",
"      and sulphites) or colorings (carmine red or annatto). Allergic and asthmatic reactions to food additives are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=see_link\">",
"       \"Allergic and asthmatic reactions to food additives\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588666\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, management of food allergy requires avoidance of the culprit meat(s). If the patient reacted to raw or rare meat, then it may be helpful to determine if the meat is tolerated in a well-cooked form, as the patient may be able to keep the food in their diet in cooked forms. Patients with IgE-mediated meat allergy should be equipped with an epinephrine autoinjector and taught how and when to use it. General issues in food-induced anaphylaxis and food allergen avoidance are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cow's milk allergy who are also allergic to beef (representing the largest group of meat allergic children) tend to outgrow both the beef and cow's milk sensitivities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/60\">",
"     60",
"    </a>",
"    ]. In one study, tolerance of beef was reached after a median duration of three years and has been reported to occur prior to tolerance to cow's milk in those allergic to both foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little published data regarding the natural history of meat allergy in adults. Case reports suggest that some individuals who acquired the allergy as adults lose the sensitivity over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/61\">",
"     61",
"    </a>",
"    ]. One case report described a middle-aged patient with IgE-mediated allergy to several mammalian meats, who subsequently developed an allergy to bovine serum albumin (BSA). Three years later, he began to tolerate ingestion of cooked lamb and pork [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/62\">",
"     62",
"    </a>",
"    ]. A review of 12 cases of beef allergy also reported that some patients became tolerant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36072/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meat allergy is uncommon. Exceptions are noted among children with atopic dermatitis and an emerging syndrome of delayed anaphylaxis in the Southeastern US. The prevalence of allergies to specific meats appears to be related to the prominence of a given meat in the diet. Allergy to beef is reported most commonly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and causative meats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both IgE-mediated and non IgE-mediated forms of meat allergy have been described. IgE-mediated reactions may be immediate or delayed up to three to six hours after ingestion. Non IgE-mediated disorders in which meats have been implicated include eosinophilic esophagitis and pediatric food-protein induced enterocolitis syndrome. (See",
"      <a class=\"local\" href=\"#H25949260\">",
"       'Clinical reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main allergens in meats are serum albumins and immunoglobulins, both of which are significantly altered by cooking. This may partly explain why meat allergy is uncommon. A carbohydrate allergen has also been identified, galactose-alpha-1,3-galactose (alpha-gal), which seems to be particularly prevalent in patients in the Southeastern United States. (See",
"      <a class=\"local\" href=\"#H25949760\">",
"       'Allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The similarity of various serum albumins leads to cross-sensitization among meats",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      allergy to milk and animal dander. Sensitization to alpha-gal can cause cross-sensitization to gelatins and the monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patterns of cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of meat allergy involves history, objective testing, and possibly food challenge. However, the sensitivity and specificity of tests for meat-specific IgE are relatively poor. The use of fresh meat for skin testing may improve sensitivity. (See",
"      <a class=\"local\" href=\"#H27268533\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management largely consists of avoidance of the causative meat and patient education about how to self-inject epinephrine if needed for accidental exposures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"       \"Food-induced anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"       \"Management of food allergy: Avoidance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many children and some adults become tolerant to meat over time. (See",
"      <a class=\"local\" href=\"#H588666\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/1\">",
"      Werfel SJ, Cooke SK, Sampson HA. Clinical reactivity to beef in children allergic to cow's milk. J Allergy Clin Immunol 1997; 99:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/2\">",
"      Crespo JF, Pascual C, Burks AW, et al. Frequency of food allergy in a pediatric population from Spain. Pediatr Allergy Immunol 1995; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/3\">",
"      Steinke M, Fiocchi A, Kirchlechner V, et al. Perceived food allergy in children in 10 European nations. A randomised telephone survey. Int Arch Allergy Immunol 2007; 143:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/4\">",
"      Etesamifar M, Wuethrich B. IgE-mediated food allergies including oral allergy syndrome in 383 patients. Allergologie 1998; 21:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/5\">",
"      Hadley C. Food allergies on the rise? Determining the prevalence of food allergies, and how quickly it is increasing, is the first step in tackling the problem. EMBO Rep 2006; 7:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/6\">",
"      Mills EN, Mackie AR, Burney P, et al. The prevalence, cost and basis of food allergy across Europe. Allergy 2007; 62:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/7\">",
"      Fiocchi A, Restani P, Riva E, et al. Meat allergy: I--Specific IgE to BSA and OSA in atopic, beef sensitive children. J Am Coll Nutr 1995; 14:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/8\">",
"      Ranc&eacute; F, Kanny G, Dutau G, Moneret-Vautrin DA. Food hypersensitivity in children: clinical aspects and distribution of allergens. Pediatr Allergy Immunol 1999; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/9\">",
"      Sabbah A, Lauret MG, Ch&egrave;ne J, et al. [The pork-cat syndrome or crossed allergy between pork meat and cat epithelia (2)]. Allerg Immunol (Paris) 1994; 26:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/10\">",
"      Palacios Benito R, Alv&aacute;rez-Lovel MC, Mart&iacute;nez-C&oacute;cera C, et al. Allergy to meat. Allergy 2002; 57:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/11\">",
"      Cahen YD, Fritsch R, W&uuml;thrich B. Food allergy with monovalent sensitivity to poultry meat. Clin Exp Allergy 1998; 28:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/12\">",
"      Bourne HC, Restani P, Moutzouris M, Katelaris CH. An unusual pattern of meat allergy. Allergy 2005; 60:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/13\">",
"      Moore LM, Rathkopf MM, Sanner CJ, et al. Seal and whale meat: two newly recognized food allergies. Ann Allergy Asthma Immunol 2007; 98:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/14\">",
"      Mullins RJ, James H, Platts-Mills TA, Commins S. Relationship between red meat allergy and sensitization to gelatin and galactose-&alpha;-1,3-galactose. J Allergy Clin Immunol 2012; 129:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/15\">",
"      Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004; 34:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/16\">",
"      Choi GS, Kim JH, Shin YS, et al. Food allergy to meat and milk in adults. Allergy 2010; 65:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/17\">",
"      Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/18\">",
"      Restani P, Ballabio C, Tripodi S, Fiocchi A. Meat allergy. Curr Opin Allergy Clin Immunol 2009; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/19\">",
"      Nu&ntilde;ez R, Carballada F, Gonzalez-Quintela A, et al. Delayed mammalian meat-induced anaphylaxis due to galactose-&alpha;-1,3-galactose in 5 European patients. J Allergy Clin Immunol 2011; 128:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/20\">",
"      Ayuso R, Lehrer SB, Tanaka L, et al. IgE antibody response to vertebrate meat proteins including tropomyosin. Ann Allergy Asthma Immunol 1999; 83:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/21\">",
"      Ayuso R, Lehrer SB, Lopez M, et al. Identification of bovine IgG as a major cross-reactive vertebrate meat allergen. Allergy 2000; 55:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/22\">",
"      Asero R, Mistrello G, Falagiani P. Oral allergy syndrome from pork. Allergy 1997; 52:684.",
"     </a>",
"    </li>",
"    <li>",
"     Allergen Nomenclature Sub-Committee of the International Union of Immunological Societies. Allergen Nomenclature. file://www.allergen.org/Allergen.aspx (Accessed on August 17, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/24\">",
"      Kanny G, de Hauteclocque C, Moneret-Vautrin DA. Food anaphylaxis to bovine serum albumin. J Allergy Clin Immunol 1998; 101:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/25\">",
"      Beretta B, Conti A, Fiocchi A, et al. Antigenic determinants of bovine serum albumin. Int Arch Allergy Immunol 2001; 126:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/26\">",
"      Restani P, Beretta B, Fiocchi A, et al. Cross-reactivity between mammalian proteins. Ann Allergy Asthma Immunol 2002; 89:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/27\">",
"      Ll&aacute;tser R, Polo F, De La Hoz F, Guillaumet B. Alimentary allergy to pork. Crossreactivity among pork kidney and pork and lamb gut. Clin Exp Allergy 1998; 28:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/28\">",
"      Restani P, Fiocchi A, Beretta B, et al. Meat allergy: III--Proteins involved and cross-reactivity between different animal species. J Am Coll Nutr 1997; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/29\">",
"      Wahl R, Kleinhans D. IgE-mediated allergic reactions to fruit gums and investigation of cross-reactivity between gelatine and modified gelatine-containing products. Clin Exp Allergy 1989; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     Commins S, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/31\">",
"      Fiocchi A, Bouygue GR, Sarratud T, et al. Clinical tolerance of processed foods. Ann Allergy Asthma Immunol 2004; 93:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/32\">",
"      Fiocchi A, Restani P, Riva E, et al. Meat allergy: II--Effects of food processing and enzymatic digestion on the allergenicity of bovine and ovine meats. J Am Coll Nutr 1995; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/33\">",
"      Spergel JM. Eosinophilic esophagitis in adults and children: evidence for a food allergy component in many patients. Curr Opin Allergy Clin Immunol 2007; 7:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/34\">",
"      Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005; 95:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/35\">",
"      Sicherer SH. Food protein-induced enterocolitis syndrome: case presentations and management lessons. J Allergy Clin Immunol 2005; 115:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/36\">",
"      Levy Y, Danon YL. Food protein-induced enterocolitis syndrome--not only due to cow's milk and soy. Pediatr Allergy Immunol 2003; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/37\">",
"      Zacharisen MC. Severe allergy to chicken meat. WMJ 2006; 105:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/38\">",
"      Liccardi G, Sz&eacute;pfalusi Z, Noschese P, et al. Allergy to chicken meat without sensitization to egg proteins: a case report. J Allergy Clin Immunol 1997; 100:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/39\">",
"      de Maat-Bleeker F, van Dijk AG, Berrens L. Allergy to egg yolk possibly induced by sensitization to bird serum antigens. Ann Allergy 1985; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/40\">",
"      Mandallaz MM, de Weck AL, Dahinden CA. Bird-egg syndrome. Cross-reactivity between bird antigens and egg-yolk livetins in IgE-mediated hypersensitivity. Int Arch Allergy Appl Immunol 1988; 87:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/41\">",
"      de Blay F, Hoyet C, Candolfi E, et al. Identification of alpha livetin as a cross reacting allergen in a bird-egg syndrome. Allergy Proc 1994; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/42\">",
"      Sz&eacute;pfalusi Z, Ebner C, Pandjaitan R, et al. Egg yolk alpha-livetin (chicken serum albumin) is a cross-reactive allergen in the bird-egg syndrome. J Allergy Clin Immunol 1994; 93:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/43\">",
"      Quirce S, Mara&ntilde;&oacute;n F, Umpi&eacute;rrez A, et al. Chicken serum albumin (Gal d 5*) is a partially heat-labile inhalant and food allergen implicated in the bird-egg syndrome. Allergy 2001; 56:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/44\">",
"      Drouet M, Boutet S, Lauret MG, et al. [The pork-cat syndrome or crossed allergy between pork meat and cat epithelia (1)]. Allerg Immunol (Paris) 1994; 26:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/45\">",
"      Hilger C, Kohnen M, Grigioni F, et al. Allergic cross-reactions between cat and pig serum albumin. Study at the protein and DNA levels. Allergy 1997; 52:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/46\">",
"      Posthumus J, James HR, Lane CJ, et al. Initial description of pork-cat syndrome in the United States. J Allergy Clin Immunol 2013; 131:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/47\">",
"      Drouet M, Sabbah A, Le Sellin J, et al. [Fatal anaphylaxis after eating wild boar meat in a patient with pork-cat syndrome]. Allerg Immunol (Paris) 2001; 33:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/48\">",
"      Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/49\">",
"      Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-&alpha;-1,3-galactose. J Allergy Clin Immunol 2011; 127:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/50\">",
"      Van Nunen SA, O'Connor KS, Clarke LR, et al. An association between tick bite reactions and red meat allergy in humans. Med J Aust 2009; 190:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/51\">",
"      Theler B, Brockow K, Ballmer-Weber BK. Clinical presentation and diagnosis of meat allergy in Switzerland and Southern Germany. Swiss Med Wkly 2009; 139:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/52\">",
"      Orhan F, Sekerel BE. Beef allergy: a review of 12 cases. Allergy 2003; 58:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/53\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/54\">",
"      Fiocchi A, Bouygue GR, Restani P, et al. Accuracy of skin prick tests in IgE-mediated adverse reactions to bovine proteins. Ann Allergy Asthma Immunol 2002; 89:26.",
"     </a>",
"    </li>",
"    <li>",
"     Available from ViracorIBT Laboratories. Search test menu on \"Alpha-Gal IgE\" www.viracoribt.com (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     University of Virginia Medical Laboratories performs testing for IgE to alpha gal. Information is available at: file://www.healthsystem.virginia.edu/alive/medlabs/LabTestSearch/LabTests.cfm?searchType=detail&amp;LabTest_ID=19520 (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     Cat serum albumin is available commercially from Phadia ImmunoCAP (allergen code e220). file://www.phadia.com/en/Allergen-information/ImmunoCAP-Allergens/ (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/58\">",
"      Raison-Peyron N, Messaad D, Bousquet J, Demoly P. Anaphylaxis to beef in penicillin-allergic patient. Allergy 2001; 56:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/59\">",
"      Kanny G, Puygrenier J, Beaudoin E, Moneret-Vautrin DA. [Alimentary anaphylactic shock: implication of penicillin residues]. Allerg Immunol (Paris) 1994; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/60\">",
"      Martelli A, De Chiara A, Corvo M, et al. Beef allergy in children with cow's milk allergy; cow's milk allergy in children with beef allergy. Ann Allergy Asthma Immunol 2002; 89:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/61\">",
"      Eigenmann PA. Anaphylaxis to cow's milk and beef meat proteins. Ann Allergy Asthma Immunol 2002; 89:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36072/abstract/62\">",
"      Fuentes Aparicio V, S&aacute;nchez Marc&eacute;n I, P&eacute;rez Montero A, et al. Allergy to mammal's meat in adult life: immunologic and follow-up study. J Investig Allergol Clin Immunol 2005; 15:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2393 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36072=[""].join("\n");
var outline_f35_14_36072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND CAUSATIVE MEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178955257\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25949260\">",
"      CLINICAL REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11265525\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25949760\">",
"      - Allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11265619\">",
"      Serum proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11265746\">",
"      Carbohydrate allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H587435\">",
"      - Role of cooking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19470775\">",
"      Eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28810259\">",
"      Food protein-induced enterocolitis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATTERNS OF CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Meats from different animal species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meats and other foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Meats and animal dander/epithelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meats and monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27268533\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H588113\">",
"      Testing options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17934162\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H588614\">",
"      Diagnosis of non IgE-mediated forms of allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25948959\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H588666\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2250?source=related_link\">",
"      Food protein-induced enterocolitis syndrome (FPIES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40087?source=related_link\">",
"      Milk allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=related_link\">",
"      Molecular features of food allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_14_36073="Overview of Vibrio cholerae infection";
var content_f35_14_36073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Vibrio cholerae infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Joan R Butterton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36073/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/14/36073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3618908\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera is a diarrheal illness caused by infection with the gram-negative bacterium Vibrio cholerae. Cholera is characterized by severe, watery diarrhea, which can rapidly lead to dehydration and death in untreated patients.",
"   </p>",
"   <p>",
"    The clinical manifestations of cholera, the methods of arriving at a presumptive clinical and a confirmatory laboratory diagnosis, and the therapeutic approach to patients with the disease will be reviewed here. The pathogenesis of Vibrio cholerae infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3618915\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera is a vastly underreported disease, with an estimated 3 to 5 million cases and 100,000 deaths annually. Cholera is endemic in the developing countries of Asia and Africa and has caused epidemics in Asia, the Middle East, and South and Central America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In 2009, the number of cases of cholera reported to the World Health Organization increased by 16 percent over the previous year (221,226 cases from 45 countries) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/6\">",
"     6",
"    </a>",
"    ]. Globally, a high incidence in the Americas in the early 1990s has shifted to a high incidence in Africa in the 2000s, with few cases in Asia.",
"   </p>",
"   <p>",
"    Recent cholera epidemics include the 2008-2009 epidemic in Zimbabwe and the 2010 epidemic following the January earthquake in Haiti [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The V. cholerae strain responsible for the Haiti epidemic is nearly identical to the El Tor O1 strains predominant in southeast Asia; the ancestry is distinct from that of circulating Latin American and East African strains of V. cholerae, suggesting introduction of the strain from Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/10\">",
"     10",
"    </a>",
"    ]. During the first two years of the 2010 Haiti epidemic the cumulative attack rate was 6.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/11\">",
"     11",
"    </a>",
"    ]. The same strain was subsequently identified in cholera cases in the Dominican Republic and in Florida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Microbiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the United States, approximately 10 laboratory-confirmed cases of cholera are reported to the Centers for Disease Control and Prevention each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/13\">",
"     13",
"    </a>",
"    ]. Of these, about half are acquired outside the United States; the rest are acquired via consumption of contaminated seafood. Toxigenic Vibrio cholerae infection was reported in Louisiana in October 2005, related to consumption of contaminated and improperly cooked seafood after Hurricanes Katrina and Rita [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The V. cholerae serogroups responsible for epidemic cholera in humans are O1 and O139. All others are grouped as \"non-O1\" strains; these are associated with sporadic cases of gastroenteritis and occasionally other infections. Serogroup O75 appears to be an emerging strain; between 2003 and 2007, serogroup O75 strains possessing the cholera toxin gene were isolated from six patients in the southeastern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18502?source=see_link\">",
"     \"Infections due to non-O1/O139 Vibrio cholerae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New cholera strains have been identified in Bangladesh, East Africa, and Asia. These strains appear to be more virulent than previous strains, causing more severe cholera episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Multidrug resistant strains have also been isolated in Bangladesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholera should be included in the differential diagnosis of patients with severe watery diarrhea and vomiting, especially those with rapid and severe dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with suspected cholera need to be treated prior to laboratory confirmation, since death by dehydration can occur within hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrio cholerae is divided into more than 200 serotypes, determined by the O antigen of the cell surface lipopolysaccharide. Only V. cholerae of the O1 and O139 serotypes are responsible for epidemic cholera in humans. All other serotypes are generally grouped as \"non-O1\" strains; they are associated with sporadic cases of gastroenteritis but not with epidemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. cholerae O1 is divided into two biotypes, classical and El Tor, which are differentiated on the basis of a number of biochemical characteristics and susceptibility to specific phages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/20\">",
"     20",
"    </a>",
"    ]. Both biotypes are further divided into Inaba, Ogawa, and Hikojima serotypes depending upon the subspecificity of the O1 antigen. The biotype of the infecting strain may have an influence on the risk of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major virulence factor for V. cholerae O1 and O139 is cholera toxin, a multimeric protein composed of one A subunit and five B subunits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/22\">",
"     22",
"    </a>",
"    ]. Toxin binding to enterocytes leads to an elevation in cyclic AMP within the intestinal mucosa, causing an increase in chloride secretion and a reduction in sodium absorption. This leads to massive loss of fluid and electrolytes, and produces the signs and symptoms of cholera gravis, or severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most V. cholerae infections are asymptomatic, ranging from one clinical case per 30 to 100 infections with the currently circulating El Tor biotype; the classical biotype, no longer circulating, produced one clinical case per two to four infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Mild cholera cannot be reliably distinguished from gastroenteritis caused by other pathogens. Patients may have a few episodes of watery stools with minimal mucus and no blood, may not have nausea and vomiting, and may not become clinically dehydrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During epidemics, however, most patients with diarrhea will be found to have V. cholerae infection. During the 1992 epidemic in Peru, for example, 79 percent of patients with diarrhea had V. cholerae O1 recovered from their stools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/30\">",
"     30",
"    </a>",
"    ], while during flood-associated epidemics in Bangladesh in 1988, 1998, and 2004, V. cholerae O1 was the most commonly identified cause of diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period of cholera ranges from a few hours to five days, with most cases presenting within one to three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Since the organisms must pass the gastric acid barrier, the incubation period is shortest among patients with a high gastric pH and a high inoculum of ingested organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diarrhea in the setting of cholera may begin suddenly or gradually. Stools rapidly become watery with flecks of mucus, leading to their description as \"rice water\" stools, since they have the appearance of water in which rice has been washed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/36\">",
"     36",
"    </a>",
"    ]. The stools often have a mild \"fishy\" odor. Vomiting, frequently watery, is common, and may begin either before or after the onset of diarrhea. Patients may have abdominal cramping but do not have the frank abdominal pain classically associated with dysentery; fever is infrequent. Although cholera is considered a prototypical non-invasive infection, there is increasing evidence for a role of inflammation in the host response. In particular, a polymorphonuclear infiltrate is observed in the lamina propria in the acute phase of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/37\">",
"     37",
"    </a>",
"    ], along with the upregulation of broadly proinflammatory cytokines including IL-1beta and TNF alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A healthy adult can quickly become severely ill with cholera. Patients may present after only a few hours of illness with massive volume loss of between 500 and 1000 mL per hour, and rapidly can lose more than 10 percent of their body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/29\">",
"     29",
"    </a>",
"    ]. In patients treated with proper rehydration, diarrhea is most severe during the first two days and ends after four to six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The total volume loss over the course of illness may be up to 100 percent of body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of severe cholera are due to the massive volume and electrolyte losses. Cholera stools contain high concentrations of sodium, potassium, chloride, and bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, in addition to volume depletion (which can cause renal failure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/43\">",
"     43",
"    </a>",
"    ], other common complications include potentially severe hypokalemia (which can cause arrhythmias, ileus, and, in combination with volume depletion, leg cramps) and metabolic acidosis. Although the metabolic acidosis associated with diarrhea is typically associated with a normal anion gap, an elevated anion gap can occur in cholera. This elevated anion gap may be secondary to hypoperfusion-induced lactic acidosis, volume contraction-induced hyperalbuminemia, or hyperphosphatemia resulting from acidemia-induced movement of phosphate out of the cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoglycemia is a poor prognostic sign in cholera, especially in children. It may contribute to the mental status changes and seizures that can be seen with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality of cholera in untreated patients may reach 50 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In areas where cholera is endemic, the mortality risk is increased in children (10 times greater than in adults) and in pregnant women (including a 50 percent risk of fetal death during the third trimester) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Patients can die within two to three hours of the first signs of illness, although death in untreated patients usually occurs after several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera should be considered in all cases of severe watery diarrhea and vomiting, especially those with rapid, severe dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/2\">",
"     2",
"    </a>",
"    ]. Dehydrating diarrhea in children can be caused by many different microbial pathogens, but dehydration in an adult should lead to questioning about recent travel to areas endemic for cholera or where cholera outbreaks are occurring, including Africa, Asia, or South and Central America, or ingestion of undercooked or raw shellfish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/2,51,52\">",
"     2,51,52",
"    </a>",
"    ]. However, there are no clinical features that can unequivocally distinguish cholera from other infectious causes of severe watery diarrhea, such as enterotoxigenic Escherichia coli, bacterial food poisoning, or viral gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is imperative that treatment for suspected cholera begins before laboratory identification of the causative organism is available, since death due to dehydration can occur within hours. Stool specimens should be collected soon after the onset of diarrhea and, if possible, before antibiotic treatment.",
"   </p>",
"   <p>",
"    Clinical diagnostic tools include Gram",
"    <span class=\"nowrap\">",
"     stain/culture",
"    </span>",
"    (augmented with methods for detection of toxinogenic strains) and dark field microscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram stain of stools may show sheets of curved gram-negative rods; untreated patients can have 10(6) to 10(8) organisms per mL of stool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/53\">",
"       53",
"      </a>",
"      ]. Culture techniques consist of plating samples from stool or rectal swabs directly onto a selective medium such as thiosulfate citrate bile salts-sucrose agar (TCBS) or tellurite taurocholate gelatin agar (TTGA), which inhibit the growth of most enteric bacteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/54\">",
"       54",
"      </a>",
"      ]. V. cholerae colonies on TCBS are large, yellow, smooth and opaque (",
"      <a class=\"graphic graphic_picture graphicRef62812 \" href=\"mobipreview.htm?6/22/6511\">",
"       picture 1",
"      </a>",
"      ), and El Tor strains may produce a small zone of surrounding hemolysis. V. cholerae colonies on TTGA are flat with a black center surrounded by a cloudy halo in the agar (best seen with transillumination), caused by the production of gelatinase.",
"      <br/>",
"      <br/>",
"      Colonies may subsequently be subcultured and biochemically confirmed as V. cholerae. V. cholerae O1 and O139 strains can be serotyped with specific antisera [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/54\">",
"       54",
"      </a>",
"      ]. Toxinogenic strains can be detected with the polymerase chain reaction, enzyme-linked immunosorbent assays, or a latex agglutination assay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]. Antibiotic susceptibility testing should be performed on isolated strains to guide antimicrobial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Samples can be placed on blotting paper and kept in sealed plastic bags for up to five weeks before testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/59\">",
"       59",
"      </a>",
"      ]. Ideally specimens should be placed in semi-solid Cary-Blair transport medium and kept at room temperature; liquid specimens should be refrigerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/60\">",
"       60",
"      </a>",
"      ]. In convalescent carriers, growth of stool in alkaline peptone water for six to eight hours selects for the alkaline-tolerant vibrios and allows increased recovery of V. cholerae from stool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/54,60\">",
"       54,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vibrios can be detected by dark field or phase contrast microscopy of stool. The organisms are motile and resemble \"shooting stars\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/54\">",
"       54",
"      </a>",
"      ]. Specific antisera can be used to inhibit motility, enhancing diagnostic specificity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic methods used primarily in epidemiological studies include the detection of V. cholerae in stool specimens by polymerase chain reaction and antibody-based tests including monoclonal antibody-based stool tests and serologic tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Vibriocidal antibodies, which react to cell surface lipopolysaccharide and other surface molecules, peak seven days after infection. Thus, serologic tests can be used to confirm the diagnosis of V. cholerae infection retrospectively, but not for diagnosis during the acute phase. A fourfold rise between acute (days 1 to 5) and early convalescent (days 7 to 21) sera, or a fourfold fall in antibody titers between early and late (greater than two months) convalescent sera is considered diagnostic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/64\">",
"     64",
"    </a>",
"    ]. Antibodies to cholera toxin, which rise one to four weeks after infection and remain elevated, may also be diagnostic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/65\">",
"     65",
"    </a>",
"    ]. Serologic studies have little clinical utility for diagnosis and are primarily used in epidemiologic surveys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for cholera is correction of hypovolemic dehydration. The degree of dehydration determines the route, rate, and type of fluid used for volume replacement. The World Health Organization (WHO) guidelines for the rapid determination of the severity of dehydration are given in the Table (",
"    <a class=\"graphic graphic_table graphicRef68271 \" href=\"mobipreview.htm?36/63/37883\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361867432\">",
"    <span class=\"h2\">",
"     Rehydration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral rehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate use of oral rehydration solutions (ORS) can reduce mortality from cholera from over 50 percent to less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/66\">",
"     66",
"    </a>",
"    ]. Use of reduced osmolarity oral rehydration solutions in patients with hypovolemia due to diarrhea can diminish stool output, vomiting, and the need for supplemental intravenous fluid; this has been described in a meta-analysis of randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/67\">",
"     67",
"    </a>",
"    ]. Per liter of water, the WHO reduced osmolality solution contains 2.6 g sodium chloride, 2.9 g trisodium citrate, 1.5 g",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    and 13.5 g glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/67\">",
"     67",
"    </a>",
"    ]. Commercially available ORS vary in osmolality and sodium concentration (",
"    <a class=\"graphic graphic_table graphicRef62757 \" href=\"mobipreview.htm?37/17/38172\">",
"     table 2",
"    </a>",
"    ). Oral rehydration solutions containing rice or cereal as the carbohydrate source may be more effective than glucose-based solutions in shortening the duration of diarrhea and reducing stool volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/50,68\">",
"     50,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a low risk of hyponatremia associated with reduced osmolality ORS formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. In two studies evaluating the safety of reduced osmolality ORS among more than 50,000 adults and children with diarrhea in Bangladesh, no symptomatic hyponatremia was detected in adults; symptomatic hyponatremia among children developed in 0.03 to 0.05 percent of cases studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Despite this potential risk of hyponatremia, the reduced osmolality ORS formulation is warranted for patients of all ages and with diarrhea of any etiology.",
"   </p>",
"   <p>",
"    Patients with no or mild volume depletion (less than 5 percent of body weight) or moderate volume depletion (5 to 10 percent of body weight) according to the criteria in the Table can be treated with oral solutions (",
"    <a class=\"graphic graphic_table graphicRef82172 \" href=\"mobipreview.htm?30/54/31595\">",
"     table 3",
"    </a>",
"    ). Patients need rapid volume repletion therapy, which must include replacement of ongoing fluid and electrolyte losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/73\">",
"     73",
"    </a>",
"    ]. Guidelines for rehydration and maintenance therapy with oral rehydration solutions are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef57007 \" href=\"mobipreview.htm?30/52/31563\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to administration of oral rehydration therapy for children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Intravenous volume repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have lost more than 10 percent of body weight from dehydration or who are unable to drink because of vomiting or mental status changes should be managed with intravenous volume repletion. Therapy is initially directed toward restoring extracellular volume as quickly as possible using an isotonic solution (",
"    <a class=\"graphic graphic_table graphicRef62757 \" href=\"mobipreview.htm?37/17/38172\">",
"     table 2",
"    </a>",
"    ). The treatment of hypovolemia and hypovolemic shock is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ongoing stool losses must be replaced during the repletion phase. As soon as patients can drink, oral rehydration solutions should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8785057\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is an adjunct to appropriate rehydration. Antibiotics are usually given orally, after initial rehydration and when the patient is no longer vomiting. They are not part of the emergency treatment of cholera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/64\">",
"     64",
"    </a>",
"    ]. Antibiotics have two beneficial effects in the setting of cholera: they reduce the duration of diarrhea by about 50 percent and the duration of Vibrio excretion to about one day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/39,74\">",
"     39,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetracyclines are the antibiotic class for which there is greatest clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/74\">",
"     74",
"    </a>",
"    ]. Single dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has been shown to be as effective as multiple doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ; this was illustrated in a randomized trial including 261 patients in Bangladesh randomized to receive doxycycline (300 mg single dose) or tetracycline (500 mg every six hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/75\">",
"     75",
"    </a>",
"    ]. Doxycycline (300 mg single dose) was as effective as tetracycline (multiple dose) with respect to stool output, duration of diarrhea, vomiting and requirement for oral rehydration solution.",
"   </p>",
"   <p>",
"    Some strains of V. cholerae harbor plasmids carrying antibiotic resistance genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/76\">",
"     76",
"    </a>",
"    ]. In regions where",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    resistance is common, fluoroquinolones and macrolides are reasonable alternative agents. Most V. cholerae O139 strains and many O1 El Tor strains are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and furazolidone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of fluoroquinolones has been illustrated in several trials. In a randomized trial including 202 adults with V. cholerae O1 in Peru,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (250 mg a day for three days) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg four times a day for three days) had equivalent clinical and bacteriologic efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/77\">",
"     77",
"    </a>",
"    ]. In a randomized trial including 66 adults with V. cholerae O1 and O139 in Bangladesh, ciprofloxacin (1000 mg single dose) was effective against both strains, and superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (300 mg single dose) in eradicating organisms from stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/78\">",
"     78",
"    </a>",
"    ]. In a randomized trial including 111 adults with V. cholerae O139 in India,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    (400 mg twice a day for three days) was superior to doxycycline (300 mg single dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of macrolides was illustrated in a randomized treatment trial of 180 children with V. cholerae in Bangladesh treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours for three days) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/80\">",
"     80",
"    </a>",
"    ]. Erythromycin was as effective as ciprofloxacin with respect to clinical endpoints; erythromycin was more effective than ciprofloxacin in eradicating V. cholerae from stool by day three of therapy (58 versus 30 percent, respectively). Another randomized trial including 246 adults in Bangladesh demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram single dose) was superior to ciprofloxacin (1 g every 12 hours for one day followed by 500 mg every 12 hours for two days) in resolution of diarrhea within 48 hours and in clearing V. cholerae from stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/81\">",
"     81",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Regional antibiotic susceptibility patterns should be used to guide the choice of therapy (",
"    <a class=\"graphic graphic_table graphicRef71548 \" href=\"mobipreview.htm?20/46/21228\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8785158\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some strains of V. cholerae harbor plasmids carrying antibiotic resistance genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/76\">",
"     76",
"    </a>",
"    ]. Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/46,76,82\">",
"     46,76,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolone resistance in Vibrio cholerae O1 isolates has been described in Asia and Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/18,80,83\">",
"     18,80,83",
"    </a>",
"    ]. The in vitro susceptibility of V. cholerae O1 to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in Bangladesh diminished in the period between 2001 and early 2002, to late 2002 to 2004, from a mean minimal inhibitory concentration [MIC] of 0.023",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    to 0.250",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/18,80\">",
"     18,80",
"    </a>",
"    ]. The clinical significance of this 10-fold increase in ciprofloxacin MICs was illustrated in a randomized trial of 195 men with severe cholera in the later period in which higher ciprofloxacin MICs were seen; patients were treated with ciprofloxacin (1 g single dose) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 g single dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/18\">",
"     18",
"    </a>",
"    ]. Azithromycin was significantly more effective than ciprofloxacin for both clinical success (cessation of watery stools within 48 hours; 73 versus 27 percent) and bacteriologic success (absence of V. cholerae in stool culture; 78 versus 10 percent). This trial emphasizes the critical problem of increasing antimicrobial resistance in resource limited settings in which identifying resistant strains may be difficult.",
"   </p>",
"   <p>",
"    Strains of V. cholerae O1 resistant to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    have also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pregnant women and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    are not recommended for pregnant women and children under the age of eight years, since they may cause permanent tooth discoloration. Quinolones are not recommended for use in children because of the toxicity to cartilage seen in animal studies; this concern has diminished as more experience with the use of these drugs in children has accumulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    are reasonable agents for treatment of cholera in children and pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/76\">",
"     76",
"    </a>",
"    ]. A randomized trial among 128 children in Bangladesh found that azithromycin (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose) was as effective as erythromycin (12.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours for three days) in eliminating diarrhea within 48 hours and in clearing V. cholerae from stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/86\">",
"     86",
"    </a>",
"    ]. Azithromycin was associated with less vomiting than erythromycin. A randomized trial among 180 children in India found that azithromycin (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose) was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose) in resolution of diarrhea within 24 hours and in clearing V. cholerae from stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient feeding during and after the diarrheal illness should be encouraged, to prevent development of malnutrition and chronic enteropathy. Management of severe malnutrition is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with persistent diarrhea, the loss of zinc in stool can be as high as 300",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/88\">",
"     88",
"    </a>",
"    ]. Zinc supplementation is an effective means of reducing the stool output and duration of diarrhea among children with cholera. This was illustrated in a study of 179 Bangladeshi children with cholera treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and randomized to receive elemental zinc (30 mg) or placebo until resolution of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/89\">",
"     89",
"    </a>",
"    ]. Those who received zinc had shorter duration of diarrhea (12 percent less) and less stool output (11 percent less) than those treated with antibiotics alone. Many studies have shown similar beneficial effects of zinc supplementation in children under 3 years with diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. cholerae infection is spread by contaminated food and water. Therefore, prevention depends upon the interruption of fecal-oral transmission. During outbreaks in Peru in the early 1990s, for example, most cases were associated with contamination of urban municipal water supplies with infected feces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/30,94\">",
"     30,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers to regions with cholera should follow precautions for the prevention of travelers' diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/95\">",
"     95",
"    </a>",
"    ]. This includes avoidance of tap water, food from street vendors, raw or undercooked seafood, and raw vegetables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/2\">",
"     2",
"    </a>",
"    ]. Water can be treated with chlorine or iodine, by filtration, or by boiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=see_link&amp;anchor=H22624029#H22624029\">",
"     \"Travel advice\", section on 'Food and water'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis of household contacts of patients with cholera can be effective in limiting the spread of disease in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. In practice, prophylaxis is limited by insufficient resources and inappropriate antibiotic use. Mass chemotherapy of entire communities is not effective and is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis of household contacts of patients with cholera in the United States is not recommended; since 1961, no cholera case in the United States has been associated with secondary transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/51,101\">",
"     51,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera vaccine is not available in the United States. Outside the United States there are two licensed commercial oral vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/102-106\">",
"     102-106",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WC-rBS (Dukoral): Killed whole cells of V. cholerae O1 (Inaba and Ogawa, classical and El Tor) plus recombinant cholera toxin B subunit",
"     </li>",
"     <li>",
"      Modified WC-only vaccines (mORCVAX and Shanchol): Killed whole cells of V. cholerae O1 (Inaba and Ogawa, classical and El Tor) and O139 (bivalent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    WC-rBS vaccine is an inactivated monovalent whole-cell recombinant cholera toxin B subunit vaccine licensed in Europe for use in individuals &ge;2 years of age. It is given in two doses at intervals of &ge;1 week (three doses at intervals of &ge;1 week for children 2 to 6 years of age); protection is obtained seven days after the second dose (seven days after the third dose for children aged 2 to 6 years). The primary immunization series provides short-term protection (six months) against V. cholerae O1 with protective efficacy of 80 to 85 percent; it is not effective against V. cholerae O139 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/107\">",
"     107",
"    </a>",
"    ]. The vaccine also provides some protection against infection with enterotoxigenic Escherichia coli. Protection declines rapidly in young children after six months but remains as high as 60 percent in adult recipients.",
"   </p>",
"   <p>",
"    The efficacy of WC-rBS vaccine has been evaluated in two studies that occurred in outbreak settings in Mozambique and Zanzibar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. In both studies, oral cholera vaccination was undertaken prior to the outbreak, and in both studies receipt of one or more doses of vaccine was associated with 78 percent protection. Vaccination was equally effective in children &le;5 years and in older persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/108\">",
"     108",
"    </a>",
"    ]. The WC-rBS vaccine also appears to provide herd immunity when high levels of vaccine coverage are attained. In a retrospective analysis of vaccine trial data collected in Bangladesh, unvaccinated individuals in family units where vaccine coverage was high (&gt;50 percent) had lower risk of cholera infection than non-vaccinated individuals in family units where vaccine coverage was low (&lt;28 percent): 1.5 versus 7 cases per 1000 placebo recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modified WC-only vaccines (Shanchol and mORCVAX) are killed whole-cell vaccines containing 01 and 0139 serotypes licensed in India and Vietnam, respectively. They have been demonstrated to be safe and effective in endemic populations; their use in travelers has not been evaluated rigorously. In a cluster-randomized trial among more than 65,000 individuals in India who received two doses of vaccine or placebo, the efficacy was 67 percent; the protective efficacy did not differ significantly between age groups, and there were no serious vaccine-related adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36073/abstract/111\">",
"     111",
"    </a>",
"    ]. Additional follow up is needed to establish durability of protection.",
"   </p>",
"   <p>",
"    Despite the fact that these two cholera vaccines are licensed, they are not widely used for the prevention of cholera.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6692010\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholera is a diarrheal illness caused by infection with the gram-negative bacterium Vibrio cholerae. Cholera is characterized by severe, watery diarrhea, which can rapidly lead to dehydration and death in untreated patients. (See",
"      <a class=\"local\" href=\"#H3618908\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholera is endemic in the developing countries of Asia and Africa and has caused epidemics in Asia, the Middle East, and South and Central America. In the United States, approximately 10 cases of cholera are reported each year. About half of these are acquired overseas; the remainder is acquired via consumption of contaminated seafood. (See",
"      <a class=\"local\" href=\"#H3618915\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The V. cholerae serogroups responsible for epidemic cholera in humans are O1 and O139. All others are grouped as \"non-O1\" strains; these are associated with sporadic cases of gastroenteritis and occasionally other illnesses. V. cholerae O1 is divided into two biotypes, classical and El Tor. The major virulence factor for V. cholerae O1 and O139 is cholera toxin, which binds to enterocytes. Toxin action leads to increased chloride secretion and reduced sodium absorption, resulting in massive loss of fluid and electrolytes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations range from mild to severe disease. Mild disease may consist of a few episodes of watery stools without clinically significant hypovolemia. Severe disease can present with diarrhea, vomiting, and massive volume loss within hours of illness. Complications include hypovolemia, electrolyte disturbances, and death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical diagnostic tools include Gram stain, dark field microscopy, and traditional culture techniques, augmented by methods for detection of toxinogenic strains. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment consists of rehydration, antibiotic therapy, and nutrition management. Oral rehydration is appropriate for patients who have lost less than 10 percent body weight due to dehydration (",
"      <a class=\"graphic graphic_table graphicRef68271 \" href=\"mobipreview.htm?36/63/37883\">",
"       table 1",
"      </a>",
"      ). We suggest oral rehydration with reduced osmolarity solution (",
"      <a class=\"graphic graphic_table graphicRef62757 \" href=\"mobipreview.htm?37/17/38172\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Intravenous rehydration should be administered for patients who have lost more than 10 percent of body weight due to dehydration or who are unable to drink because of vomiting or mental status changes. (See",
"      <a class=\"local\" href=\"#H361867432\">",
"       'Rehydration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic therapy is an adjunct to appropriate rehydration and should be administered if available. Antibiotics are usually given orally, after initial rehydration and when the patient is no longer vomiting. We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (300 mg single dose) (",
"      <a class=\"graphic graphic_table graphicRef71548 \" href=\"mobipreview.htm?20/46/21228\">",
"       table 5",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In areas with antimicrobial resistance, alternative agents include fluoroquinolones and macrolides. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In outbreak situations, we suggest use of cholera vaccination in conjunction with other control measures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For travelers to endemic areas in high risk situations (such as health care and emergency relief workers), we suggest vaccination with Dukoral if available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Cholera vaccine is not available in the United States. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/1\">",
"      Tauxe RV, Blake PA. Epidemic cholera in Latin America. JAMA 1992; 267:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/2\">",
"      Swerdlow DL, Ries AA. Cholera in the Americas. Guidelines for the clinician. JAMA 1992; 267:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/3\">",
"      Cholera, 1999. Wkly Epidemiol Rec 2000; 75:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/4\">",
"      Cholera, 1998. Wkly Epidemiol Rec 1999; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Etiology and epidemiology of cholera. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: Centers for Disease Control and Prevention, 1999:37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/6\">",
"      Cholera annual report 2009. Wkly Epidemiol Rec 2010; 85:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/7\">",
"      Mason PR. Zimbabwe experiences the worst epidemic of cholera in Africa. J Infect Dev Ctries 2009; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Update: cholera outbreak --- Haiti, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Update: outbreak of cholera ---Haiti, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/10\">",
"      Chin CS, Sorenson J, Harris JB, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 2011; 364:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/11\">",
"      Barzilay EJ, Schaad N, Magloire R, et al. Cholera surveillance during the Haiti epidemic--the first 2 years. N Engl J Med 2013; 368:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Update on cholera --- Haiti, Dominican Republic, and Florida, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1637.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/nationalsurveillance/PDFs/Jackson_Vibrio_CSTE2008_FINAL.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Two cases of toxigenic Vibrio cholerae O1 infection after Hurricanes Katrina and Rita--Louisiana, October 2005. MMWR Morb Mortal Wkly Rep 2006; 55:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/15\">",
"      Tobin-D'Angelo M, Smith AR, Bulens SN, et al. Severe diarrhea caused by cholera toxin-producing vibrio cholerae serogroup O75 infections acquired in the southeastern United States. Clin Infect Dis 2008; 47:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/16\">",
"      Siddique AK, Nair GB, Alam M, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010; 138:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/17\">",
"      S&aacute;nchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 2008; 65:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/18\">",
"      Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/19\">",
"      Morris JG Jr. Non-O group 1 Vibrio cholerae: a look at the epidemiology of an occasional pathogen. Epidemiol Rev 1990; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     Butterton JR, Calderwood SB. Vibrio cholerae O1 and O139. In: Infections of the Gastrointestinal Tract, Second Edition, Blaser MJ, Smith PD, Ravdin JI, et al (Eds), Lippincott Willimas &amp; Wilkins, Philadelphia 2002. p.535.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/21\">",
"      Beyhan S, Tischler AD, Camilli A, Yildiz FH. Differences in gene expression between the classical and El Tor biotypes of Vibrio cholerae O1. Infect Immun 2006; 74:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/22\">",
"      Gill DM. The arrangement of subunits in cholera toxin. Biochemistry 1976; 15:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/23\">",
"      Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 1981; 292:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/24\">",
"      Lai CY. The chemistry and biology of cholera toxin. CRC Crit Rev Biochem 1980; 9:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/25\">",
"      Moss J, Vaughan M. Activation of adenylate cyclase by choleragen. Annu Rev Biochem 1979; 48:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/26\">",
"      Gilman AG. G proteins and dual control of adenylate cyclase. Cell 1984; 36:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/27\">",
"      Woodward WE, Mosley WH. The spectrum of cholera in rural Bangladesh. II. Comparison of El Tor Ogawa and classical Inaba infection. Am J Epidemiol 1972; 96:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/28\">",
"      Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis 1970; 121:Suppl 121:17+.",
"     </a>",
"    </li>",
"    <li>",
"     Rabbani GH, Greenough WB 3rd. Pathophysiology and clinical aspects of cholera. In: Cholera, Barua D, Greenough, WB (Eds), Plenum Press, New York 1992. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/30\">",
"      Swerdlow DL, Mintz ED, Rodriguez M, et al. Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk. Lancet 1992; 340:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/31\">",
"      Schwartz BS, Harris JB, Khan AI, et al. Diarrheal epidemics in Dhaka, Bangladesh, during three consecutive floods: 1988, 1998, and 2004. Am J Trop Med Hyg 2006; 74:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/32\">",
"      Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 1974; 129:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/33\">",
"      Hornick RB, Music SI, Wenzel R, et al. The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med 1971; 47:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/34\">",
"      Oseasohn R, Ahmad S, Islam MA, Rahman AS. Clinical and bacteriological findings among families of cholera patients. Lancet 1966; 1:340.",
"     </a>",
"    </li>",
"    <li>",
"     Glass RI, Black RE. The epidemiology of cholera. In: Cholera, Barua D, Greenough WB (Eds), Plenum Press, New York 1992. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/36\">",
"      Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/37\">",
"      Qadri F, Bhuiyan TR, Dutta KK, et al. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 2004; 53:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/38\">",
"      Flach CF, Qadri F, Bhuiyan TR, et al. Broad up-regulation of innate defense factors during acute cholera. Infect Immun 2007; 75:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/39\">",
"      Carpenter CC, Barua D, Wallace CK, et al. Clinical studies in Asiatic cholera. IV. Antibiotic therapy in cholera. Bull Johns Hopkins Hosp 1966; 118:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/40\">",
"      Hirschhorn N, Kinzie JL, Sachar DB, et al. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med 1968; 279:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/41\">",
"      Pierce NF, Banwell JG, Mitra RC, et al. Controlled comparison of tetracycline and furazolidone in cholera. Br Med J 1968; 3:277.",
"     </a>",
"    </li>",
"    <li>",
"     Seas C, Gotuzzo E. Vibrio cholerae. In: Principles and Practice of Infectious Diseases, Sixth Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2536.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/43\">",
"      BENYAJATI C, KEOPLUG M, BEISEL WR, et al. Acute renal failure in Asiatic cholera: clinicopathologic correlations with acute tubular necrosis and hypokalemic nephropathy. Ann Intern Med 1960; 52:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/44\">",
"      Wang F, Butler T, Rabbani GH, Jones PK. The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med 1986; 315:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/45\">",
"      Bennish ML, Azad AK, Rahman O, Phillips RE. Hypoglycemia during diarrhea in childhood. Prevalence, pathophysiology, and outcome. N Engl J Med 1990; 322:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/46\">",
"      Siddique AK, Salam A, Islam MS, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995; 345:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/47\">",
"      Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967; 36:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/48\">",
"      Mosley WH, Benenson AS, Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ 1968; 38:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/49\">",
"      Hirschhorn N, Chowdhury AK, Lindenbaum J. Cholera in pregnant women. Lancet 1969; 1:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/50\">",
"      Molla AM, Ahmed SM, Greenough WB 3rd. Rice-based oral rehydration solution decreases the stool volume in acute diarrhoea. Bull World Health Organ 1985; 63:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/51\">",
"      Centers for Disease Control (CDC). Update: cholera--Western Hemisphere, 1991. MMWR Morb Mortal Wkly Rep 1991; 40:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/52\">",
"      Vugia DJ, Koehler JE, Ries AA. Surveillance for epidemic cholera in the Americas: an assessment. MMWR CDC Surveill Summ 1992; 41:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/53\">",
"      Gorbach SL, Banwell JG, Jacobs B, et al. Intestinal microflora in Asiatic cholera. I. \"Rice-water\" stool. J Infect Dis 1970; 121:32.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Isolation and identification of Vibrio cholerae serogroups O1 and O139. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: Centers for Disease Control and Prevention, 1999:41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/55\">",
"      Almeida RJ, Hickman-Brenner FW, Sowers EG, et al. Comparison of a latex agglutination assay and an enzyme-linked immunosorbent assay for detecting cholera toxin. J Clin Microbiol 1990; 28:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/56\">",
"      Fields PI, Popovic T, Wachsmuth K, Olsvik O. Use of polymerase chain reaction for detection of toxigenic Vibrio cholerae O1 strains from the Latin American cholera epidemic. J Clin Microbiol 1992; 30:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/57\">",
"      Keasler SP, Hall RH. Detecting and biotyping Vibrio cholerae O1 with multiplex polymerase chain reaction. Lancet 1993; 341:1661.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Antimicrobial susceptibility testing. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: Centers for Disease Control and Prevention, 1999:61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/59\">",
"      Barua D, Gomez CZ. Blotting-paper strips for transportation of cholera stools. Bull World Health Organ 1967; 37:798.",
"     </a>",
"    </li>",
"    <li>",
"     Pal SC. Laboratory diagnosis. In: Cholera, Barua D, Greenough WB III (Eds), Plenum Press, New York 1992. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/61\">",
"      BENENSON AS, ISLAM MR, GREENOUGH WB 3rd. RAPID IDENTIFICATION OF VIBRIO CHOLERAE BY DARKFIELD MICROSCOPY. Bull World Health Organ 1964; 30:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/62\">",
"      Albert MJ, Islam D, Nahar S, et al. Rapid detection of Vibrio cholerae O139 Bengal from stool specimens by PCR. J Clin Microbiol 1997; 35:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/63\">",
"      Qadri F, Hasan JA, Hossain J, et al. Evaluation of the monoclonal antibody-based kit Bengal SMART for rapid detection of Vibrio cholerae O139 synonym Bengal in stool samples. J Clin Microbiol 1995; 33:732.",
"     </a>",
"    </li>",
"    <li>",
"     Young CR, Wachsmuth IK, Olsvik O, Feeley JC. Immune response to Vibrio cholerae. In: Manual of Clinical Immunology, Rose NR, Friedman H, Fahey JL (Eds), American Society for Microbiology, Washington, DC 1986. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/65\">",
"      Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Cholera. WHO Report on Global Surveillance of Epidemic-Prone Infectious Diseases. Geneva, 2000. Report No.: WHO/CDS/CSR/ISR/2000.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/67\">",
"      Hahn S, Kim Y, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review. BMJ 2001; 323:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/68\">",
"      Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000; 342:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/69\">",
"      Alam NH, Majumder RN, Fuchs GJ. Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double-blind clinical trial. CHOICE study group. Lancet 1999; 354:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/70\">",
"      Duggan C, Fontaine O, Pierce NF, et al. Scientific rationale for a change in the composition of oral rehydration solution. JAMA 2004; 291:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/71\">",
"      Alam NH, Yunus M, Faruque AS, et al. Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution. JAMA 2006; 296:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/72\">",
"      Musekiwa A, Volmink J. Oral rehydration salt solution for treating cholera: &le; 270 mOsm/L solutions vs &ge; 310 mOsm/L solutions. Cochrane Database Syst Rev 2011; :CD003754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/73\">",
"      Duggan C, Santosham M, Glass RI. The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. Centers for Disease Control and Prevention. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/74\">",
"      GREENOUGH WB 3rd, GORDON RS Jr, ROSENBERG IS, et al. TETRACYCLINE IN THE TREATMENT OF CHOLERA. Lancet 1964; 1:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/75\">",
"      Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990; 300:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/76\">",
"      Kitaoka M, Miyata ST, Unterweger D, Pukatzki S. Antibiotic resistance mechanisms of Vibrio cholerae. J Med Microbiol 2011; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/77\">",
"      Gotuzzo E, Seas C, Echevarr&iacute;a J, et al. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 1995; 20:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/78\">",
"      Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996; 348:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/79\">",
"      Dutta D, Bhattacharya SK, Bhattacharya MK, et al. Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. J Antimicrob Chemother 1996; 37:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/80\">",
"      Saha D, Khan WA, Karim MM, et al. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005; 366:1085.",
"     </a>",
"    </li>",
"    <li>",
"     Khan WA, Ahmed S, Salam MA, et al. Single-Dose Azithromycin Is Superior to 6-Dose Ciprofloxacin in Adult Cholera: Results of a Double-Blind Randomized Controlled Trial. Abstract 207. Infectious Diseases Society of America, Vancouver, Canada 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/82\">",
"      Siddique AK, Zaman K, Majumder Y, et al. Simultaneous outbreaks of contrasting drug resistant classic and El Tor Vibrio cholerae O1 in Bangladesh. Lancet 1989; 2:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/83\">",
"      Islam MS, Midzi SM, Charimari L, et al. Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA 2009; 302:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/84\">",
"      Faruque AS, Alam K, Malek MA, et al. Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 2007; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/85\">",
"      Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/86\">",
"      Khan WA, Saha D, Rahman A, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002; 360:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/87\">",
"      Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr 2010; 47:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/88\">",
"      Rothbaum RJ, Maur PR, Farrell MK. Serum alkaline phosphatase and zinc undernutrition in infants with chronic diarrhea. Am J Clin Nutr 1982; 35:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/89\">",
"      Roy SK, Hossain MJ, Khatun W, et al. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 2008; 336:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/90\">",
"      Roy SK, Tomkins AM, Akramuzzaman SM, et al. Randomised controlled trial of zinc supplementation in malnourished Bangladeshi children with acute diarrhoea. Arch Dis Child 1997; 77:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/91\">",
"      Roy SK, Tomkins AM, Mahalanabis D, et al. Impact of zinc supplementation on persistent diarrhoea in malnourished Bangladeshi children. Acta Paediatr 1998; 87:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/92\">",
"      Bhutta ZA, Bird SM, Black RE, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr 2000; 72:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/93\">",
"      Dutta P, Mitra U, Datta A, et al. Impact of zinc supplementation in malnourished children with acute watery diarrhoea. J Trop Pediatr 2000; 46:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/94\">",
"      Ries AA, Vugia DJ, Beingolea L, et al. Cholera in Piura, Peru: a modern urban epidemic. J Infect Dis 1992; 166:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/95\">",
"      DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/96\">",
"      Craun G, Swerdlow D, Tauxe R, et al. Prevention of water-borne cholera in the United States. J Am Waterworks Assoc 1991; 83:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/97\">",
"      McCormack WM, Chowdhury AM, Jahangir N, et al. Tetracycline prophylaxis in families of cholera patients. Bull World Health Organ 1968; 38:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/98\">",
"      Gupta PG, Sircar BK, Mondal S, et al. Effect of doxycycline on transmission of Vibrio cholerae infection among family contacts of cholera patients in Calcutta. Bull World Health Organ 1978; 56:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/99\">",
"      Weil AA, Khan AI, Chowdhury F, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis 2009; 49:1473.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. First steps for managing an outbreak of acute diarrhoea, 2004 file://whqlibdoc.who.int/hq/2004/WHO_CDS_CSR_NCS_2003.7_Rev.1_eng.pdf (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/101\">",
"      Synder JD, Blake PA. Is cholera a problem for US travelers? JAMA 1982; 247:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/102\">",
"      Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 2006; 6:361.",
"     </a>",
"    </li>",
"    <li>",
"     Holmgren J, Jertborn M, Svennerholm AM. New and improved vaccines against cholera: Part II: Oral B subunit killed whole-cell cholera vaccine. In: New Generation Vaccines, Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, New York 1997. p.459.",
"    </li>",
"    <li>",
"     Kaper JB, Tacket CO, Levine MM. New and improved vaccines against cholera: I: Attenuated Vibrio cholerae O1 and O139 strains as live oral cholera vaccines. In: New Generation Vaccines, Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, New York 1997.",
"    </li>",
"    <li>",
"     file://www.who.int/immunization/sage/1_Background_Paper_Cholera_Vaccines_FINALdraft_13_oct_v2.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/106\">",
"      Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/108\">",
"      Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/109\">",
"      Khatib AM, Ali M, von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 2012; 12:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/110\">",
"      Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36073/abstract/111\">",
"      Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1694.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2704 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36073=[""].join("\n");
var outline_f35_14_36073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6692010\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3618908\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3618915\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361867432\">",
"      Rehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral rehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Intravenous volume repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8785057\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8785158\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pregnant women and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6692010\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2704|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/22/6511\" title=\"picture 1\">",
"      Vibrio on TCBS agar",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/63/37883\" title=\"table 1\">",
"      Guidelines for assessment of dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/17/38172\" title=\"table 2\">",
"      Common solutions for rehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/54/31595\" title=\"table 3\">",
"      Fluids for patients without dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/52/31563\" title=\"table 4\">",
"      Replacement fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/46/21228\" title=\"table 5\">",
"      Oral antibiotics for suspected cholera",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18502?source=related_link\">",
"      Infections due to non-O1/O139 Vibrio cholerae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=related_link\">",
"      Pathogenesis of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=related_link\">",
"      Severe malnutrition in children in developing countries: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_14_36074="Cancer of the appendix and pseudomyxoma peritonei";
var content_f35_14_36074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer of the appendix and pseudomyxoma peritonei",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Richard Swanson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Jeffrey A Meyerhardt, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/14/36074/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/14/36074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms of the appendix are rare. They are found in about 1 percent of appendectomy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/1\">",
"     1",
"    </a>",
"    ] and account for only about one-half of 1 percent of intestinal neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/2\">",
"     2",
"    </a>",
"    ]. Carcinoid tumors are the most common, comprising over 50 percent of appendiceal neoplasms in most series (",
"    <a class=\"graphic graphic_table graphicRef69317 \" href=\"mobipreview.htm?28/57/29595\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the distribution of appendiceal neoplasms might be changing over time. In a large series of appendiceal tumors derived from the Surveillance, Epidemiology and End Results (SEER) database of the National Cancer Institute between 1973 to 2003, the most frequent histology was a mucinous adenocarcinoma followed by intestinal-type adenocarcinoma; carcinoid tumors comprised only 11 percent (",
"    <a class=\"graphic graphic_table graphicRef55911 \" href=\"mobipreview.htm?2/2/2092\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/3\">",
"     3",
"    </a>",
"    ]. The difference in natural history of these different histologies is illustrated by their differing five-year disease-specific survival rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARCINOID TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;carcinoid&rdquo; is generally applied to neuroendocrine tumors originating in the digestive tract, lungs, or rare primary sites such as kidneys or ovaries. Use of the term carcinoid usually implies well-differentiated histology, but the term can be applied to the rare high-grade or poorly differentiated neuroendocrine tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H799311#H799311\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other intestinal carcinoid tumors, appendiceal carcinoids can secrete serotonin and other vasoactive substances (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"mobipreview.htm?34/59/35771\">",
"     table 3",
"    </a>",
"    ). These substances are responsible for the carcinoid syndrome, which is characterized by episodic flushing, wheezing, diarrhea, and right-sided valvular heart disease. Midgut carcinoids (ie, appendix, small bowel) are more commonly associated with the classic carcinoid syndrome than are those that arise in the foregut or hindgut (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"mobipreview.htm?17/7/17531\">",
"     table 4",
"    </a>",
"    ). More than 90 percent of patients with the carcinoid syndrome have metastatic disease, typically to the liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appendiceal carcinoids are detected most commonly in patients in their forties, which is much younger than the average age for other primary malignant appendiceal neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Epidemiologic studies show a slight but consistently higher incidence in women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Appendix'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of carcinoids are located in the distal one-third of the appendix where they are unlikely to cause obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. As a result, most patients are asymptomatic. Symptoms are more likely with large tumors and with metastases beyond the regional lymph nodes. Approximately 10 percent of appendiceal carcinoids are located at the base of the appendix, where they can cause obstruction, leading to appendicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The endoscopic appearance of appendiceal carcinoid is pictured in the figure (",
"    <a class=\"graphic graphic_picture graphicRef79971 \" href=\"mobipreview.htm?0/62/993\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Staging and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 AJCC staging manual contains a TNM staging system for appendiceal carcinoids for the first time (",
"    <a class=\"graphic graphic_table graphicRef50547 \" href=\"mobipreview.htm?4/18/4397\">",
"     table 5",
"    </a>",
"    ). It differs from the TNM staging systems for carcinoids arising at other sites within the gastrointestinal tract and lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/9\">",
"     9",
"    </a>",
"    ]. Goblet cell carcinoids are considered more aggressive and classified according to the criteria for appendiceal carcinomas (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Goblet cell carcinomas'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6982135\">",
"    <span class=\"h3\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only rarely do appendiceal carcinoids metastasize to the liver. To assess possible liver involvement, consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    recommend a helical, contrast enhanced, triple-phase CT scan or MRI. Contrast-enhanced MRI is preferred by some physicians because of its greater sensitivity for liver metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H31868289#H31868289\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Somatostatin receptor scintigraphy (SRS, Octreoscan) offers whole-body imaging and is the most sensitive imaging modality for diagnosis and staging of metastatic disease outside of the liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H31868296#H31868296\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in general, radiographic investigation with any of these modalities is unnecessary unless there is evidence of intraabdominal or mesenteric disease, tumor size larger than 2 cm, incomplete resection, or symptoms suggestive of carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6982325\">",
"    <span class=\"h3\">",
"     Assay of tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is suspicion for liver metastases or the carcinoid syndrome, measurement of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in a 24-hour urine collection is indicated. As a general rule, serum concentration of chromogranin A (CGA, a protein that is stored and released with peptides and amines in neuroendocrine tumors) parallel 5-HIAA excretion. Although serum levels of CGA are a more sensitive marker than urinary 5-HIAA for neuroendocrine tumors, including carcinoids, they are less specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/10\">",
"     10",
"    </a>",
"    ]. Elevated CGA levels are present in a number of other conditions (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"mobipreview.htm?40/9/41116\">",
"     table 6",
"    </a>",
"    ), and specificity depends on the cutoff value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6982142\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical behavior and prognosis are best predicted by tumor size. Tumors less than 2 cm (found in approximately 95 percent of patients) are unlikely to have metastasized, while up to one-third of larger lesions are metastatic at diagnosis but usually to regional nodes rather than the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/8,11-13\">",
"     8,11-13",
"    </a>",
"    ]. In one series of 150 patients with appendiceal carcinoids from the Mayo Clinic, none of 127 patients with tumors &lt;2 cm metastasized, compared to 3 of 14 with tumors 2 to 3 cm, and four of nine with tumors larger than 4 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcome is stage dependent (",
"    <a class=\"graphic graphic_table graphicRef50547 \" href=\"mobipreview.htm?4/18/4397\">",
"     table 5",
"    </a>",
"    ). However, there are no data assessing prognosis using the stage groupings from the 2010 AJCC staging classification. Prognosis was addressed in an analysis of 900 appendiceal carcinoid tumors derived from the Surveillance, Epidemiology and End Results (SEER) registry of the National Cancer Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/14\">",
"     14",
"    </a>",
"    ]. Five-year appendiceal carcinoid-specific survival rates were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor size &lt;3 cm without regional nodal or distant metastases &mdash; 100 percent",
"     </li>",
"     <li>",
"      Tumor size &ge;2 but &lt;3 cm with regional node metastases or tumor size &ge;3 cm with or without regional nodal or distant metastases &mdash; 78 percent",
"     </li>",
"     <li>",
"      Distant metastatic spread &mdash; 32 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic significance of mesoappendiceal invasion is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal surgical management for appendiceal carcinoids is subject to some debate. Because most are discovered incidentally in an appendectomy specimen done for other reasons, a decision must be made whether or not to return the patient to the operating room for a right colectomy. Unlike simple appendectomy, colectomy removes the draining lymph nodes of the appendix and any residual disease that might remain at the base of the appendix or in the mesoappendix.",
"   </p>",
"   <p>",
"    Data from the large Mayo Clinic series cited above suggest that tumor size is an important determinant of the need for further surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/11\">",
"     11",
"    </a>",
"    ]. None of the 120 patients with tumors less than 2 cm developed disease recurrence after simple appendectomy, compared to one of 12 with a larger tumor. Furthermore, in a compilation of reports from single centers and large population and literature surveys, the risk of nodal metastases was 0, 7.5, and 33 percent for patients with appendiceal carcinoid tumors &lt;1.0, 1 to 1.9, and &gt;2 cm, respectively (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"mobipreview.htm?14/6/14444\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data, taken together with the fact that as many as 88 percent of those with regional nodal metastases survive for five years or longer, support the view that patients with tumors &gt;2 cm in size should undergo right colectomy.",
"   </p>",
"   <p>",
"    On the other hand, whether or not a colectomy should be performed in some patients with smaller tumors is unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the Mayo Clinic series suggests that appendectomy is sufficient in such cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/11\">",
"       11",
"      </a>",
"      ], at least two reports demonstrate a higher potential for metastatic spread with small tumors in the setting of mesoappendiceal invasion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of the Surveillance, Epidemiology and End Results (SEER) database of the National Cancer institute reported much higher rates of lymph node metastases than previously appreciated for tumors &lt;2 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/17\">",
"       17",
"      </a>",
"      ]. Among patients reported to the database between 1988 and 2003, lymph node metastases were found in 15 percent of patients (4 of 27) with typical appendiceal carcinoids less than 1 cm and in 47 percent of patients (16 of 34) with carcinoids between 1.0 and 1.9 cm. The 10 year survival in these two groups was 100 and 92 percent, respectively, while it was 91 percent in patients with carcinoids &gt;2 cm, despite the fact that 86 percent of them had lymph node metastases.&nbsp;Whether these excellent outcomes reflected favorable biology or the impact of surgical removal of nodal metastases is unclear.",
"     </li>",
"     <li>",
"      A second SEER-based series reported only a 24 percent incidence of lymph node metastases for appendiceal carcinoids of all histologic types and sizes, but the analysis included a large number of patients lacking complete pathologic data, as it extended from 1977 to 2004 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there is limited evidence on which to base clear indications for right hemicolectomy in patients with a diagnosis of appendiceal carcinoid. Consensus-based guidelines from the North American Neuroendocrine Tumor Society (NANETS) and European Neuroendocrine Tumor Society (ENETS) suggest completion hemicolectomy for all tumors &gt;2 cm, and for smaller tumors between 1 and 2 cm in the presence of deep mesoappendiceal invasion, positive or unclear margins, higher proliferative rate (grade 2), angioinvasion, and with mixed histology [goblet cell carcinoid, adenocarcinoid] [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. We agree with these guidelines, and pursue completion right colectomy for all tumors &gt;2 cm and for those tumors &lt;2 cm if there is evidence of mesoappendiceal or vascular invasion, positive or uncertain margins, and mixed histology. However, others disagree and consider that appendectomy alone is adequate for tumors &lt;2 cm, even with mesoappendiceal invasion or other adverse histologic features.",
"   </p>",
"   <p>",
"    For carcinoids between 1.0 and 1.9 cm in the absence of mesoappendiceal invasion and for tumors less than 1 cm in size, there is general agreement that simple appendectomy alone is adequate. Prior to the procedure, a full colonoscopy should be undertaken to rule out a synchronous colon cancer.",
"   </p>",
"   <p>",
"    The surgeon should also perform a complete inspection of the bowel since up to 25 percent of midgut carcinoids (small bowel, proximal colon) may be multifocal, and sometimes associated with malignant gastrointestinal tumors of other histologic types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Posttreatment follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trial data or evidence-based guidelines for follow-up after resection of a carcinoid tumor at any site. Recommendations are generally based upon risk and anticipated patterns of recurrence based upon the primary tumor characteristics. Various organizations have put forth recommendations for follow-up surveillance after resection:",
"   </p>",
"   <p>",
"    Recommendations from the National Comprehensive Cancer Network (NCCN) are based on size of the tumor. Patients with tumors &lt;2 cm do not require routine surveillance and tests should only be ordered as clinically indicated. For tumors &gt;2 cm, NCCN recommends history and physical between 3 and 12 months after resection and consideration of tumor markers (5-HIAA, chromogranin) and consideration of abdominal imaging; after the first year, NCCN recommends history and physical, consideration of tumor markers every 6 to 12 months and imaging as clinically indicated.",
"   </p>",
"   <p>",
"    The North American Neuroendocrine Tumor Society (NANETS) has similar recommendations as NCCN with the exception that tumors &lt;1 cm do not generally require further surveillance but tumors between 1 to 2 cm with poor prognostic features (nodal metastases, lymphovascular invasion, mesoappendiceal invasion, intermediate or high grade or mixed histology) should trigger surveillance similar to tumors &gt;2 cm with history and physical, tumor markers (5-HIAA and chromogranin), and consideration of CT or MRI imaging within three to six months of surgery and subsequently every 6 to 12 months for at least seven years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The European Neuroendocrine Tumor Society (ENETS) suggest consideration of periodic radiographic imaging and SRS for T2-3 tumors of the appendix, and tumor markers only in the presence of a tumor visualized by imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we generally follow the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For appendiceal carcinoids &le;2 cm and confined to the appendix treated by simple appendectomy, no follow-up is required.",
"     </li>",
"     <li>",
"      For larger or node-positive tumors treated by right hemicolectomy, between 3 and 12 months postresection, we perform a history and physical examination, obtain chromogranin testing and consider CT imaging.",
"     </li>",
"     <li>",
"      Beyond one year postresection, we perform a history and physical examination every 6 to 12 months along with chromogranin testing and radiographic imaging studies annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment of metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    -avid disease, symptoms of carcinoid syndrome can often be well controlled with somatostatin analogs. However, few patients have an objective tumor regression. The benefit of somatostatin analogs in asymptomatic patients is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best systemic therapy option for patients with progressive metastatic carcinoid tumors is not established. As a result, there is no standard regimen, and the role of chemotherapy continues to be debated. The management of metastatic carcinoid tumors is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190948991#H190948991\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver resection for selected patients may be beneficial, particularly for symptom relief. If liver resection is not feasible, then embolization of the hepatic artery might be considered. Although palliation of symptoms is obtained in over 50 percent of selected patients, response duration is short.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPITHELIAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature regarding classification of epithelial tumors of the appendix is confusing, particularly for mucinous tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/23\">",
"     23",
"    </a>",
"    ]. Most attempt to classify the tumors as either benign or malignant according to their clinical behavior, but there is some overlap. As an example, mucoceles that develop from cystadenomas can be completely eradicated with complete excision. But \"benign\" cystadenomas that perforate can recur as disseminated peritoneal mucinous tumors. The term pseudomyxoma peritonei (PMP) is typically applied to this clinical scenario. PMP is discussed in more detail below (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Pseudomyxoma peritonei'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The spectrum of epithelial tumors ranges from the benign mucocele to an aggressive adenocarcinoma. Survival differs according to histologic type (",
"    <a class=\"graphic graphic_table graphicRef78023 \" href=\"mobipreview.htm?10/41/10907\">",
"     table 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/1\">",
"     1",
"    </a>",
"    ]. The different types of epithelial tumors will be discussed according to their level of aggressiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Appendiceal mucoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the broadest sense, the term appendiceal mucocele refers to any lesion that is characterized by a distended, mucus-filled appendix; it may be associated with either a benign or malignant condition. The course and prognosis of appendiceal mucoceles relate to their histologic subtypes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=see_link\">",
"     \"Appendiceal (ileocecal) mucoceles\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucosal hyperplasia, which is histologically similar to a hyperplastic colon polyp",
"     </li>",
"     <li>",
"      Simple or retention cysts, characterized by degenerative epithelial changes due to obstruction (eg, fecalith) and distention",
"     </li>",
"     <li>",
"      Mucinous cystadenomas, which are histologically benign, and morphologically reminiscent of adenomatous colon polyps or villous adenomas",
"     </li>",
"     <li>",
"      Mucinous cystadenocarcinomas, which demonstrate glandular invasion into the stroma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pseudomyxoma peritonei",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mucoceles that are due to hyperplasia or that arise from an accumulation of mucus distal to an obstruction in the appendiceal lumen, even if they rupture, are not associated with recurrence of the problem. In contrast, mucoceles that develop from true neoplasms (cystadenomas or cystadenocarcinomas) secrete mucin. Rupture can lead to intraperitoneal spread of neoplastic cells and the clinical picture of PMP. This syndrome is discussed in detail below.",
"   </p>",
"   <p>",
"    Benign appendiceal mucoceles are usually asymptomatic. They are present in 0.3 percent of appendectomy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/24\">",
"     24",
"    </a>",
"    ] or more commonly, found incidentally on a CT scan done for another purpose. Cystadenomas may also be detected at the time of a screening colonoscopy (",
"    <a class=\"graphic graphic_picture graphicRef63184 \" href=\"mobipreview.htm?31/23/32113\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=see_link\">",
"     \"Appendiceal (ileocecal) mucoceles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On a CT scan, a mucocele appears as a low-attenuation, well-defined mass in the right lower quadrant adjacent to the cecum; the majority are retrocecal. A lack of appendiceal inflammation helps to distinguish mucocele from acute appendicitis. The thickness of the wall is variable and does not help to differentiate neoplastic from nonneoplastic causes of the mucocele. The presence of an intramural nodule, on the other hand, should raise suspicion for a cystadenocarcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection should be pursued, even for a benign-appearing appendiceal mucocele, since lesions that appear to be benign on imaging studies may harbor a cystadenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Because rupture of a neoplastic mucocele, even a \"benign\" cystadenoma, may result in peritoneal dissemination of potentially malignant cells, a preoperative diagnosis of mucocele can help the surgeon to ensure careful handling and resection of the lesion while avoiding peritoneal contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/25\">",
"     25",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Pseudomyxoma peritonei'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Survival is excellent (91 to 100 percent) after standard appendectomy for retention cysts, mucosal hyperplasia, or cystadenomas. Even in the presence of a cystadenocarcinoma without mesenteric or adjacent organ involvement, standard appendectomy with resection of the appendiceal mesentery appears to be adequate. A right hemicolectomy is indicated in patients with a complicated mucocele with involvement of the terminal ileum or cecum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=see_link&amp;anchor=H6#H6\">",
"     \"Appendiceal (ileocecal) mucoceles\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic removal may be considered if there is a homogeneous \"cyst\" involving the appendix with no nodularity of the wall and no hint of spread; these lesions are highly likely to be benign (either a mucocele not associated with neoplasm or a benign cystadenoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/29\">",
"     29",
"    </a>",
"    ]. Laparoscopic removal entails stapling through the base of the cecum to avoid injury to a possible cystadenoma. The tumor can then be placed in a plastic bag and removed through a small incision without spreading cells or mucin.",
"   </p>",
"   <p>",
"    If there is no evidence of peritoneal disease and the final pathology shows a cystadenocarcinoma, a right colectomy could be considered to remove lymph nodes; however, the chance of nodal spread is quite small relative to the typical appendiceal adenocarcinoma (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Adenocarcinoma'",
"    </a>",
"    below). An acceptable approach (assuming negative resection margins) is to do nothing further.",
"   </p>",
"   <p>",
"    If, on the other hand, there is evidence of peritoneal disease at laparoscopy, then the procedure should be converted to an open laparotomy for debulking.",
"   </p>",
"   <p>",
"    An association between appendiceal mucoceles and other tumors involving the gastrointestinal tract, ovary, breast, and kidney has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. In particular, synchronous colonic adenocarcinomas may be found in up to 20 percent of patients with appendiceal mucoceles. This possibility should be evaluated either preoperatively or intraoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=see_link&amp;anchor=H6#H6\">",
"     \"Appendiceal (ileocecal) mucoceles\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data addressing posttreatment surveillance. In our view, if a mucinous cystadenoma of the appendix is removed without violating the tumor or spilling mucin, there is in theory no chance of recurrence, and specific follow-up is not needed. If there was spillage of mucin, we perform a follow-up CT at one year, and nothing further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pseudomyxoma peritonei",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomyxoma peritonei (PMP) is a unique condition characterized by diffuse collections of gelatinous material in the abdomen and pelvis and mucinous implants on the peritoneal surfaces. The term PMP was originally applied to intraperitoneal mucinous spread originating from a cystadenoma of the appendix. As the tumor grows and occludes the lumen, mucus accumulates and the appendix ruptures. The peritoneum is then seeded with mucus-producing cells, which continue to proliferate and produce mucus. The progressive accumulation of copious amounts of mucinous fluid gradually fills the peritoneal cavity, resulting in the characteristic \"jelly belly\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30\">",
"     30",
"    </a>",
"    ]. Inevitably, this condition progresses to intestinal obstruction, which is fatal without treatment.",
"   </p>",
"   <p>",
"    Over the years, the term PMP began to be used more generally by some authors and clinicians to signify not only intraperitoneal mucinous dissemination from rupture of a benign cystadenoma, but also peritoneal dissemination of mucus-producing adenocarcinomas of the appendix, large and small bowel, lung, breast, pancreas, stomach, bile ducts, gallbladder, and fallopian",
"    <span class=\"nowrap\">",
"     tubes/ovary",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in my view, and that of others, the term PMP should be limited to \"a pathologically and prognostically homogeneous group of cases characterized by histologically benign peritoneal tumors that are frequently associated with an appendiceal mucinous adenoma\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These cases are more recently categorized as disseminated peritoneal adenomucinosis (DPAM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this narrow definition creates a more homogeneous entity for the purpose of evaluating treatment efficacy, it makes comparison of published results difficult, as the definition has not been widely accepted. Although some consider that disseminated mucin-producing adenocarcinomas of the appendix (referred to as peritoneal mucinous carcinomatosis) fall into the category of PMP, this variant is an aggressive subset of peritoneal mucinous tumors that does not behave similarly to the more indolent DPAM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The prognostic differences between histologic subgroups have been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, the age-adjusted five-year survival for patients with DPAM was 84 percent, compared to 7 percent for those with peritoneal mucinous carcinomatosis, and 38 percent for those with intermediate features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective multicenter series of 2298 patients presenting with PMP and undergoing cytoreductive surgery and intraperitoneal chemotherapy, the five-year survival rate for patients with DPAM was 81 percent, compared to 59 percent for those with peritoneal mucinous carcinomatosis, and 78 percent for those with intermediate features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Aggressive cytoreduction and intraperitoneal chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMP is more common in females and is found unexpectedly in about two of every 10,000 laparotomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/31\">",
"     31",
"    </a>",
"    ]. The most common presenting symptom in both men and women is increasing abdominal girth; in men the second most common symptom is an inguinal hernia (accounting for some 25 percent of cases), while for women it is an ovarian mass palpated at the time of a routine pelvic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30\">",
"     30",
"    </a>",
"    ]. When mucoid fluid is encountered at the time of a hernia repair, recovery of the fluid and hernia sac for histologic study is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The radiographic appearance of PMP is characteristic. On CT scan, the mucinous material is similar in density to fat and appears heterogeneous. Scalloping of the liver, spleen, and mesentery is easily demonstrated, and calcifications are common. The undersurface of the diaphragm may be greatly thickened by large cystic masses of mucinous tumor. A striking early finding is the characteristic peripheral location of tumor within the abdomen and pelvis and relative sparing and central displacement of the small bowel and mesentery (termed the \"redistribution phenomenon\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30,38\">",
"     30,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the presence of tumor implants &gt;5 cm on the jejunum, proximal ileum, or adjacent mesentery is more consistent with mucinous adenocarcinoma with secondary peritoneal carcinomatosis than DPAM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. The presence of segmental obstruction of the small bowel also raises suspicion for peritoneal adenocarcinomatosis, and both findings predict a less favorable outcome from aggressive cytoreduction and intraperitoneal (IP) heated chemotherapy (IPHC, see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38\">",
"     38",
"    </a>",
"    ]. Whether gadolinium-enhanced MRI can permit the preoperative distinction between DPAM and peritoneal mucinous carcinomatosis is under study and not yet established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment for PMP (defined throughout the rest of this review as the benign form, DPAM) is repeated surgical debulking for symptomatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/31\">",
"     31",
"    </a>",
"    ]. This treatment is not curative but aims to resect gross disease to limit the buildup of mucus and its pressure effect. Disease recurrence requires repeated and progressively more difficult surgery due to adhesions and fibrosis.",
"   </p>",
"   <p>",
"    The addition of external beam radiotherapy, intraperitoneal radioisotopes, intraperitoneal chemotherapy, and systemic chemotherapy have been attempted to improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/31\">",
"     31",
"    </a>",
"    ]. Whether any of these additional treatments prolongs survival is unclear because randomized clinical trials have not been performed, and agreement on definitions of clinical subsets is lacking. Retrospective data from small groups of patients treated at three different centers using a combination of these approaches demonstrate that a reasonable percentage of patients live five years (probably reflecting the indolent natural history of this condition), but survival is clearly diminished at ten years (",
"    <a class=\"graphic graphic_table graphicRef72427 \" href=\"mobipreview.htm?26/56/27531\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/32,40,41\">",
"     32,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Aggressive cytoreduction and intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more aggressive approach that includes radical surgical removal of all intraabdominal and pelvic disease and the administration of intraperitoneal heated chemotherapy has been adopted by some clinicians, aiming for cure. In view of the rarity of extraperitoneal spread in patients with PMP or DPAM, it would seem intuitive that intraperitoneal chemotherapy (which can permit a several-fold increase in drug concentration in the abdominal cavity compared to systemic administration) might control growth of peritoneal disease. However, despite this regional advantage, penetration into tumor tissue is limited to a maximum of 1 to 2 mm from the surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug penetration may be enhanced by heating the perfusate containing chemotherapy, an approach termed intraperitoneal hyperthermic chemotherapy (IPHC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30,44\">",
"     30,44",
"    </a>",
"    ]. This approach is best suited to patients with minimal residual disease (deposits smaller than 2 to 2.5 mm) after surgical cytoreduction. It is unlikely that even a heated solution of chemotherapy could penetrate large tumor deposits.",
"   </p>",
"   <p>",
"    Sugarbaker and colleagues have written the most extensively about treatment of peritoneal surface malignancy with aggressive surgical debulking and IPHC. His group uses four clinical assessments to select patients who are most likely to benefit from combined treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38,44\">",
"     38,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histopathologic assessment &ndash; Noninvasive malignancies such as PMP or mesothelioma are more likely to be made visibly disease-free through a peritonectomy procedure and are less likely that other invasive histologies to have spread to regional nodes, liver or other systemic sites. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link\">",
"       \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preoperative contrast (oral and IV)-enhanced CT of the chest, abdomen and pelvis &ndash; In addition to excluding liver or other systemic metastases, the two radiologic criteria that are most useful to predict a poor outcome from aggressive cytoreduction and IPHC are segmental obstruction of the small bowel and the presence of tumor nodules &gt;5 cm in diameter on small bowel surfaces or directly adjacent to the small bowel mesentery in the jejunum or upper ileum (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Others report that extensive disease in the right upper quadrant on preoperative CT appears to be particularly related to a poorer survival outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other clinical indices, the peritoneal cancer index (PCI, a quantitative indicator of prognosis derived from the size and distribution of nodules on the peritoneal surface) and the completeness of cytoreduction score (the size of persisting tumor nodules after maximal cytoreduction), are derived intraoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specifics of the Sugarbaker approach to heated intraoperative (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ) and early postoperative intraperitoneal chemotherapy (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) have been described in detail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38,44\">",
"     38,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the three largest series are detailed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2001 report from Sugarbaker&rsquo;s group included 108 patients with PMP treated over a 10 year period (1983 to 1993) with surgical debulking and intraoperative intraperitoneal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (with or without heating) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/34\">",
"       34",
"      </a>",
"      ]. The chemotherapy regimen also included intraperitoneal 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (5-FU) during postoperative days 1 to 6, and three subsequent courses of adjuvant intravenous mitomycin and intraperitoneal 5-FU.",
"      <br/>",
"      <br/>",
"      The patient population was heterogeneous. One group (n = 65) had DPAM, characterized by a histologically bland or low-grade adenomatous mucinous epithelium with abundant extracellular mucin associated with fibrosis; a second group (n = 29) had peritoneal mucinous carcinoma (all of the appendiceal mucinous adenocarcinomas were of the signet ring cell variant, see below); a third group (n = 14) had intermediate features. Histology was closely related to survival, with patients in the DPAM group doing significantly better than those in the other groups combined (",
"      <a class=\"graphic graphic_table graphicRef81384 \" href=\"mobipreview.htm?13/36/13899\">",
"       table 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The influence of histology on outcomes was addressed in an earlier report from Sugarbaker&rsquo;s group that included 385 patients with peritoneal surface spread of appendiceal malignancy who underwent aggressive surgical debulking and heated or unheated intraperitoneal chemotherapy from 1989 to 1999 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. In multivariate analysis, prognostic factors for survival included: completeness of cytoreduction, the histopathology of the appendiceal malignancy, and the extent of previous surgical interventions. Patients who underwent complete cytoreduction for adenomucinosis (DPAM) had a five-year survival rate of 86 percent; with those with \"hybrid\" pathology, the five&ndash;year survival rate was 50 percent. Patients who had incomplete cytoreduction (&gt;2.5 mm residual) had markedly worse outcomes (five- and 10-year survival rates of 20 and 0 percent, respectively).",
"      <br/>",
"      <br/>",
"      The poor prognosis of this group was confirmed in later report of 174 patients undergoing incomplete cytoreduction (out of a total 645 patients with epithelial peritoneal surface malignancy of appendiceal origin undergoing surgical debulking and IPHC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/48\">",
"       48",
"      </a>",
"      ]. Survival rates at one, three and five years were 71, 34, and 15 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other groups have reported their results using radical surgery followed by IPHC in series that generally consist of a heterogeneous group of patients with both classically defined PMP (DPAM) and peritoneal mucinous carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/35,49\">",
"     35,49",
"    </a>",
"    ]. A compilation of results (as well as reported perioperative morbidity and mortality rates) from recently reported series is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef71289 \" href=\"mobipreview.htm?10/22/10605\">",
"     table 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/35,46,50-56\">",
"     35,46,50-56",
"    </a>",
"    ]. Results in populations with peritoneal mucinous carcinomatosis are addressed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Intraperitoneal hyperthermic chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Results seem to be most favorable in patients with the DPAM histology, as evidenced by the following reports (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Pseudomyxoma peritonei'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/57\">",
"       57",
"      </a>",
"      ] included 382 patients with the histology of DPAM only, whose results with radical surgery and IPHC were reported in five case series, three from the Sugarbaker group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/32,34,49,57,58\">",
"       32,34,49,57,58",
"      </a>",
"      ]. Five-year survival rates ranged from 70 to 86 percent, while at 10 years, 60 and 68 percent of patients in two different series were still alive (",
"      <a class=\"graphic graphic_table graphicRef59700 \" href=\"mobipreview.htm?10/22/10604\">",
"       table 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A multi-institutional registry-based series of 2298 patients undergoing CRC and HIPEC for PMP included 1419 with DPAM, 700 with peritoneal mucinous adenocarcinoma, and 140 with hybrid histology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/36\">",
"       36",
"      </a>",
"      ]. Five and ten-year survival rates for those with DPAM histology were 81 and 70 percent; for those with peritoneal mucinous carcinomatosis, they were 59 and 49 percent, and for hybrid histology, they were 78 and 63 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are impressive survival statistics, particularly for patients with DPAM. What is not clear is whether the results can be attributed to the aggressive treatment, patient selection, or both. There is insufficient evidence to conclude whether prolonged survival is due to treatment or to biologic features that allow these patients to undergo complete cytoreductive surgery.",
"   </p>",
"   <p>",
"    Furthermore, the quality of the cytoreductive surgery is dependent upon the skills and level of experience of the surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/59\">",
"     59",
"    </a>",
"    ]. The favorable results (particularly with regard to treatment-related toxicity) achieved by international experts in the field may not be replicated in routine clinical practice. An international list of centers with expertise in treatment of peritoneal surface malignancies is available on Dr. Sugarbaker's website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional information on US centers is available through a patient-oriented website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials are clearly needed to determine the benefit of IPHC and aggressive debulking in the treatment of PMP. Until such a national trial is opened, my practice is to perform periodic debulking without IPHC for patients with symptomatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Goblet cell carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, goblet cell carcinomas (adenocarcinoids) have features of both adenocarcinomas and carcinoids. They are more aggressive than carcinoids and are classified and staged as appendiceal carcinomas (",
"    <a class=\"graphic graphic_table graphicRef70538 \" href=\"mobipreview.htm?17/62/18414\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/9,62\">",
"     9,62",
"    </a>",
"    ]. Prognosis is worse than with malignant carcinoid but better than appendiceal adenocarcinoma (",
"    <a class=\"graphic graphic_table graphicRef55911 \" href=\"mobipreview.htm?2/2/2092\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/3,63\">",
"     3,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients most often present with acute or chronic abdominal pain; very few are incidentally found at appendectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/64\">",
"     64",
"    </a>",
"    ]. The average age at presentation is 52 to 58, closer to the age of presentation of adenocarcinomas (approximately 60) than carcinoids (approximately 38) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4,64,65\">",
"     4,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The five-year survival rate for all stages combined is about 78 percent (",
"    <a class=\"graphic graphic_table graphicRef78023 \" href=\"mobipreview.htm?10/41/10907\">",
"     table 8",
"    </a>",
"    ). Five-year survival rates according to disease stage at presentation (",
"    <a class=\"graphic graphic_table graphicRef59700 \" href=\"mobipreview.htm?10/22/10604\">",
"     table 12",
"    </a>",
"    ) in a series of 57 patients treated at the Mayo Clinic were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &ndash; 100 percent",
"     </li>",
"     <li>",
"      Stage II &ndash; 76 percent",
"     </li>",
"     <li>",
"      Stage III &ndash; 22 percent",
"     </li>",
"     <li>",
"      Stage IV &ndash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characteristic pattern is that of submucosal growth without a discernible tumor mass. Of all the tumor types listed in Table 6, adenocarcinoids have the lowest frequency of regional nodal metastases (17 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4\">",
"     4",
"    </a>",
"    ]), but they have the potential to spread intraperitoneally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4,66\">",
"     4,66",
"    </a>",
"    ]. In the McCusker series, which included 227 adenocarcinoids, 51 percent had either spread through the serosa or had mesoappendiceal invasion, while 14 percent extended to other organs or the peritoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4\">",
"     4",
"    </a>",
"    ]. In women, adenocarcinoids may also present with ovarian metastases (a Krukenberg tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/64,67\">",
"     64,67",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for an adenocarcinoid tumor is unclear. Some suggest simple appendectomy for localized low-grade tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/68\">",
"     68",
"    </a>",
"    ], while others advocate right colectomy for all goblet cell carcinoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/18,19,69,70\">",
"     18,19,69,70",
"    </a>",
"    ]. Still others suggest right colectomy only if the tumor is &gt;2 cm in size, involves the base of the appendix, is associated with nodal metastases, or has atypical histologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/66,71-74\">",
"     66,71-74",
"    </a>",
"    ]. In our own practice, we generally recommend most patients with adenocarcinoid tumors to have complete right hemicolectomy within three months of initially appendectomy if the patient is fit for additional surgery.",
"   </p>",
"   <p>",
"    As noted above, intraperitoneal spread is a common occurrence, and the intraperitoneal metastatic deposits are typically adenocarcinoma rather than carcinoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Such cases behave as aggressively as an appendiceal adenocarcinoma with peritoneal spread (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Intraperitoneal hyperthermic chemotherapy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/66,77,78\">",
"     66,77,78",
"    </a>",
"    ]. Aggressive debulking of intraabdominal metastases may improve symptom control and prolong survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy responsiveness may be higher with appendiceal adenocarcinoids than it is for other appendiceal adenocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. At least one case report documents a complete and persistent remission with the FOLFOX regimen (5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 14",
"    </a>",
"    )) in a patient with metastatic disease at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H29#H29\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line oxaliplatin plus 5-FU/LV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adjuvant therapy for patients who have early stage goblet cell carcinomas is unknown. Although there are no data to support this practice, some oncologists would consider adjuvant chemotherapy therapy in the setting of node-positive disease, similar to appendiceal adenocarcinoma. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Adenocarcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other appendiceal neoplasms, the majority of patients with adenocarcinomas present with a picture of acute appendicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients may also present with ascites, an abdominal mass, or generalized abdominal pain. In less than 20 percent of cases, the cancer is found incidentally at surgery for other reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appendiceal adenocarcinomas fall into one of three separate histologic types. The most common mucinous type produces abundant mucin, the less common intestinal or colonic type closely mimics adenocarcinomas found in the colon, and the least common, signet ring cell adenocarcinoma, is quite virulent and associated with a poor prognosis (",
"    <a class=\"graphic graphic_table graphicRef55911 \" href=\"mobipreview.htm?2/2/2092\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contrast between intestinal-type and mucinous appendiceal adenocarcinomas has been given much consideration. Intestinal-type tumors typically manifest as a focal mass without mucocele formation. Although they have a poorer prognosis in many series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/26,82,83\">",
"     26,82,83",
"    </a>",
"    ], others suggest that this is the case only if the disease is locoregionally advanced at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mucinous type seems to spread more often throughout the peritoneal cavity, while differences in the frequency of nodal metastases between the two types are not as clear. Some series report that intestinal-type tumors have a higher frequency of nodal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/84\">",
"     84",
"    </a>",
"    ], but other reports are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4,80\">",
"     4,80",
"    </a>",
"    ]. In the McCusker series, the incidence of nodal metastases was not significantly different between mucinous and colonic type adenocarcinomas (26 and 31 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef69547 \" href=\"mobipreview.htm?26/6/26731\">",
"     table 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4\">",
"     4",
"    </a>",
"    ]. On the other hand, in a series of 36 patients with appendiceal adenocarcinoma from our institution, 17 of whom had full histologic information, nodal metastases were present in one of 10 colonic adenocarcinomas compared to two of seven mucinous adenocarcinomas (10 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Staging and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and prognosis of appendiceal adenocarcinomas differ from adenocarcinomas arising in other large bowel sites (",
"    <a class=\"graphic graphic_table graphicRef74667 \" href=\"mobipreview.htm?25/8/25739\">",
"     table 16",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/85\">",
"     85",
"    </a>",
"    ]. The 2010 edition of the AJCC (American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer)/UICC",
"    </span>",
"    (International Union Against Cancer) TNM staging system contains a separate staging system for appendiceal carcinomas (",
"    <a class=\"graphic graphic_table graphicRef70538 \" href=\"mobipreview.htm?17/62/18414\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Appendix cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five-year survival rates for 931 cases of appendiceal carcinoma diagnosed between 1991 and 2000 and stratified according to stage are presented in the table (",
"    <a class=\"graphic graphic_figure graphicRef64182 \" href=\"mobipreview.htm?24/5/24671\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/9\">",
"     9",
"    </a>",
"    ]. However, prognosis varies according to histologic type (",
"    <a class=\"graphic graphic_table graphicRef55911 \" href=\"mobipreview.htm?2/2/2092\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/3\">",
"     3",
"    </a>",
"    ], a distinction that is not evident in most series that stratify according to disease stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the optimal treatment for most appendiceal adenocarcinomas is a right colectomy, although this is debated. Several retrospective series that are uncontrolled for stage suggest that survival is better with colectomy as compared to simple appendectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/2,26,80-82,86\">",
"     2,26,80-82,86",
"    </a>",
"    ]. In contrast, a survival benefit for right colectomy (versus simple appendectomy) was not demonstrated in a report of 120 patients with appendiceal adenocarcinomas and peritoneal seeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/84\">",
"     84",
"    </a>",
"    ]. Interpretation of these data is complicated by the fact that all patients were treated with debulking and intraperitoneal hyperthermic chemotherapy (see below).",
"   </p>",
"   <p>",
"    Some authors advocate a simple appendectomy for adenocarcinomas that are confined to the mucosa or well-differentiated lesions that invade no deeper than the submucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/87\">",
"     87",
"    </a>",
"    ]. Although this distinction can be difficult to make intraoperatively, a more common scenario is the unexpected finding of an adenocarcinoma when the surgical report of an appendectomy specimen is finalized. In such cases, a right colectomy need not be pursued for appendiceal adenocarcinomas that are confined to the mucosa or well-differentiated lesions that invade no deeper than the submucosa.",
"   </p>",
"   <p>",
"    Routine oophorectomy has been proposed at the time of colectomy because the ovaries are a common organ for metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/26,82,86\">",
"     26,82,86",
"    </a>",
"    ]. Resection of ovaries that are involved with metastatic spread is clearly beneficial. As an example, in the Mayo series described above, women who underwent resection of ovarian metastases had a 31 percent five-year survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/26\">",
"     26",
"    </a>",
"    ]. However, no series has shown an improvement in survival with prophylactic oophorectomy, and this approach is not recommended.",
"   </p>",
"   <p>",
"    The role of adjuvant chemotherapy for adenocarcinoma of the appendix is unknown. The rarity of this disease has precluded the performance of randomized studies, and few institutions see sufficient numbers of patients to report series of homogeneously treated patients. Despite the lack of available data, many medical oncologists extrapolate from data showing the efficacy of adjuvant 5-FU-based chemotherapy for node-positive colon cancer, particularly for patients with intestinal type adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .) However, specific benefit from this approach is unproven, and there are no published recommendations from expert groups.",
"   </p>",
"   <p>",
"    The benefit of adjuvant radiation therapy is also uncertain; as with chemotherapy, randomized trials have not been conducted. One small retrospective study suggested that postoperative external beam radiotherapy improves local control and survival for patients with locally advanced but nonmetastatic disease (14 of 15 had clinical bowel perforation and seven [47 percent] had microscopic residual disease after surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/88\">",
"     88",
"    </a>",
"    ]. Five of 10 patients failed locally after surgery alone; in contrast, only one of five failed locally after postoperative radiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Intraperitoneal hyperthermic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that adenocarcinoma of the appendix often fails with intraperitoneal spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/88\">",
"     88",
"    </a>",
"    ], it would seem intuitive that an aggressive approach that includes surgical removal of all intraabdominal and pelvic disease and the administration of intraperitoneal heated chemotherapy (IPHC) might control growth of peritoneal disease. This rationale is the same as applied to the treatment of pseudomyxoma peritonei (PMP). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pseudomyxoma peritonei'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in contrast to PMP, aggressive cytoreductive surgery and IPHC are less likely to produce lasting benefit for mucinous peritoneal carcinomatosis, and patient selection is critical. Rapid recurrence of the peritoneal surface disease, combined with progression of nodal or extraperitoneal systemic disease, interferes with long-term benefit. This approach is best suited to asymptomatic patients with small volume peritoneal carcinomatosis who are likely to be successfully cytoreduced (leaving behind deposits &lt;2.5 mm) with surgical debulking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, Sugarbaker's group uses four clinicopathologic assessments to select patients with peritoneal surface malignancy who are most likely to benefit from combined treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38\">",
"     38",
"    </a>",
"    ]. In general, noninvasive malignancies such as PMP or cystic mesothelioma are much more likely to undergo successful debulking and less likely than invasive adenocarcinomas to have spread to regional nodes, liver or other systemic sites.",
"   </p>",
"   <p>",
"    Although CT scans can sometimes not distinguish diffuse peritoneal adenomucinosis (DPAM) from mucinous peritoneal carcinomatosis, the presence of tumor implants &gt;5 cm on the jejunum, proximal ileum, or adjacent mesentery is more consistent with mucinous adenocarcinoma with secondary peritoneal carcinomatosis than DPAM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. In addition, the presence of segmental obstruction of the small bowel also raises suspicion for peritoneal adenocarcinomatosis, and both findings predict a less favorable outcome from aggressive cytoreduction and intraperitoneal heated chemotherapy (IPHC, see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38\">",
"     38",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Pseudomyxoma peritonei'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Aggressive cytoreduction and IPHC has been tried for secondary peritoneal carcinomatosis in several centers throughout the world, although only one prospective controlled trial has been completed. This Dutch trial randomly assigned 105 patients with peritoneal carcinomatosis from appendiceal (n = 18) or colorectal (n = 87) cancer without evidence of other metastases to surgical debulking (aiming to achieve deposits &le;2.5 mm) with IPHC versus systemic chemotherapy without debulking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/89\">",
"     89",
"    </a>",
"    ]. Only palliative surgery was permitted in the control patients, and they received 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    given weekly until progression. In the experimental group, after debulking, the abdominal cavity was perfused for 90 minutes with isotonic dialysis fluid containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    and heated to 41 degrees C. After IPHC, anastomoses were completed and the abdomen closed. Systemic chemotherapy similar to the control arm was started six weeks after cytoreduction and IPHC.",
"   </p>",
"   <p>",
"    After a median follow-up of 22 months, median survival (the major endpoint) was significantly longer in the IPHC group (22.4 versus 12.6 months, p = 0.032). The study has been criticized because the experimental group differed from controls not only in the use of IPHC, but also in surgical debulking. It is possible that the important treatment was the surgical debulking, and the IPHC made little difference.",
"   </p>",
"   <p>",
"    Several institutions have published their experience with this approach for peritoneal mucinous carcinomatosis from an appendiceal adenocarcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from Australia, 46 patients with peritoneal metastases from mucinous or nonmucinous appendiceal adenocarcinoma underwent surgical debulking and heated intraperitoneal chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      early postoperative intraperitoneal chemotherapy with intraperitoneal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/90\">",
"       90",
"      </a>",
"      ]. The median survival for the entire group was 56.4 months, and the three-year overall and disease-free survival rates were 59 and 30 percent, respectively.",
"     </li>",
"     <li>",
"      The most recent update of Sugarbaker's experience with mucinous carcinoma of the appendix and peritoneal seeding included 501 patients treated with surgical debulking and IPHC over a 17-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/84\">",
"       84",
"      </a>",
"      ]. Peritoneal tumor spread was present at initial diagnosis in 418, while it was confirmed at reoperation in 83. At the time of last follow-up, 236 remained free of disease recurrence, and the overall five- and ten-year survival rates were 72 and 54 percent, respectively.",
"     </li>",
"     <li>",
"      Another retrospective analysis included 282 patients with peritoneal mucinous carcinomatosis of appendiceal origin treated with CRS; most had IPHC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/91\">",
"       91",
"      </a>",
"      ]. Before undergoing the procedure, 39 percent received systemic chemotherapy. Intraoperatively, a complete surgical cytoreduction was achieved in 82 percent, despite a high peritoneal cancer index (PCI) of 14, as assessed by the Dutch simplified PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/92\">",
"       92",
"      </a>",
"      ]. Most received HIPEC using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      . Major postoperative morbidity occurred in 25 percent of patients and the 60-dady mortality rate was 1.1 percent. &nbsp;",
"      <br/>",
"      <br/>",
"      At a median follow-up of 1.98 years, 202 patients remained alive, 82 without evidence of disease. The three and five-year rates of overall survival were 67 and 53 percent, respectively. The corresponding rates of progression-free survival were 45 and 32 percent, respectively. Outcomes were better among those whose postoperative completeness of cytoreduction score was 0 (no visible residual disease) than those with visible residual tumor, even as small as 2.5 mm. The authors concluded that meaningful long-term survival can be achieved using an aggressive approach to therapy, even in patients with extensive peritoneal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is difficult to know whether debulking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    addition of IPHC impacted survival, these long-term outcomes are far superior to any reported for similar group of patients with peritoneal spread from appendiceal adenocarcinoma who were treated without debulking and IPHC. Nevertheless, the possibility of selection bias cannot be discounted, since all of these are single institution series representing highly selected patient populations. A randomized trial is warranted in which the only treatment variable is the IPHC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h5\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-related morbidity may be substantial, particularly in patients with peritoneal spread of adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/84,93,94\">",
"     84,93,94",
"    </a>",
"    ]. This was illustrated in a Dutch series of 102 patients undergoing surgical cytoreduction followed by IPHC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/93\">",
"     93",
"    </a>",
"    ]. According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/95\">",
"     95",
"    </a>",
"    ], grade 3 (not immediately life-threatening but hospitalization or prolongation of hospitalization required), 4 (life-threatening consequences, urgent intervention indicated) or 5 (fatal) toxicity was observed in 66 (65 percent); eight died of treatment-related causes. Surgical complications (defined as a postoperative event requiring reintervention) occurred in 36 patients; fistulas were frequently encountered (18 patients). The risk of a complicated recovery was significant higher in patients undergoing the procedure for recurrent colorectal cancer, those needing three or more anastomoses, having more than five regions affected, and with an incomplete initial cytoreduction.",
"   </p>",
"   <p>",
"    On the other hand, the importance of technique and surgeon experience to the success and safety of IPHC cannot be overemphasized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/96\">",
"     96",
"    </a>",
"    ]. As with the treatment of PMP, the surgeon with the most published experience (and the lowest reported complication rates) with this approach for mucinous peritoneal carcinomatosis is Sugarbaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/46,84,97,98\">",
"     46,84,97,98",
"    </a>",
"    ], although other groups have reported favorable results as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/96,99\">",
"     96,99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One review from Sugarbaker's group included 46 patients undergoing surgical palliation with total abdominal colectomy, pelvic peritonectomy and end ileostomy followed by IPHC for extensive mucinous peritoneal carcinomatosis (a group who might be expected to have the highest rates of surgical morbidity and mortality) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/97\">",
"       97",
"      </a>",
"      ]. Although there were four postoperative deaths (mortality rate 8.6 percent), the incidence of postoperative grade 3 or 4 toxicity was significantly lower than seen in the Dutch study (19.5 percent), and there was only one reported rectourethral fistula.",
"     </li>",
"     <li>",
"      A second report from this group included 356 procedures (cytoreductive surgery plus perioperative intraperitoneal chemotherapy) to treat either DPAM or peritoneal mucinous adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/98\">",
"       98",
"      </a>",
"      ]. The total 30-day or in-hospital mortality rate was 2 percent, and 19 percent of the procedures were complicated by at least one grade 4 event (most commonly hematologic [28 percent] or gastrointestinal [26 percent]). Eleven percent of patients had to be returned to the operative room.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of systemic chemotherapy for metastatic appendiceal adenocarcinoma and PMP has not been systematically studied. As a result, much is unknown.",
"   </p>",
"   <p>",
"    Historically these tumors (particularly mucinous adenocarcinomas) have been considered refractory to intravenous 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU)-based chemotherapy, although the following data suggest this is not the case:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from M. D. Anderson included 54 patients with a mucinous adenocarcinoma, signet ring cell adenocarcinoma, or PMP, each originating from the appendix, who received at least two courses of chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/100\">",
"       100",
"      </a>",
"      ]. Several different regimens were used, although the majority (84 percent) received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      or 5-FU with or without a platinum drug. Clinical benefit was achieved in 30 patients (55 percent), with a median progression-free survival duration of 7.6 months. There were two complete responses, 11 partial responses (objective response rate 24 percent), and 17 cases of prolonged stable disease (32 percent). The median overall survival was 55 months, reflective of the predominance of well-differentiated tumors in this cohort.",
"     </li>",
"     <li>",
"      Benefit for combination chemotherapy was also shown in a retrospective analysis of 78 patients with metastatic poorly differentiated or signet ring appendiceal adenocarcinoma who were treated with a variety of regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/101\">",
"       101",
"      </a>",
"      ]. The overall response rate was approximately 45 percent, and median progression-free and overall survival was 6.9 and 20.4 months, respectively.",
"     </li>",
"     <li>",
"      The only published phase II trial in advanced unresectable PMP suggested activity for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/102\">",
"       102",
"      </a>",
"      ]. Eligible patients had unresectable DPAM (n = 27) or peritoneal mucinous carcinomatosis without (n = 3) or with (n = 10) intermediate or discordant features; those with bowel obstruction or any condition that might affect the oral absorption of capecitabine were excluded. At the time of enrollment, 23 patients (58 percent) had progressing disease while 17 (42 percent) had a stable pattern of tumor growth. Treatment consisted of capecitabine (1250",
"      <span class=\"nowrap\">",
"       mg/",
"       <sup>",
"        m2",
"       </sup>",
"      </span>",
"      twice daily on days 1 to 14 every 21 days) and mitomycin (7",
"      <span class=\"nowrap\">",
"       mg/",
"       <sup>",
"        m2",
"       </sup>",
"      </span>",
"      on day 1 every six weeks).",
"      <br/>",
"      <br/>",
"      After six months, three of the 23 patients whose disease was progressive at baseline had a sustained reduction in the volume of mucus, one of whom also had a reduction in the solid component of the disease; nine others (41 percent) had stabilization of tumor growth. Of the 17 patients with stable disease prior to trial entry, three had a reduction in the volume of mucus which was maintained at three and six months; nine others had persisting stable disease, and five progressed. Two patients with initially unresectable disease were able to undergo potentially curative surgical cytoreduction after chemotherapy. Thus, of 39 assessable patients, 15 (38 percent) appeared to benefit from treatment.",
"      <br/>",
"      <br/>",
"      Overall, therapy was reasonable well tolerated. Only 6 percent of cycles were complicated by grade 3 or 4 toxicity (all hand-foot syndrome), and cumulative hematologic toxicity related to mitomycin was not observed.",
"     </li>",
"     <li>",
"      As previously noted, a durable response has been reported using an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen in a patient with advanced goblet cell carcinoma (adenocarcinoid) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Goblet cell carcinomas'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One problem is accurate response assessment, as illustrated by a prospective study of 34 consecutive patients with mucinous peritoneal carcinomatosis who received neoadjuvant treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX, (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 14",
"    </a>",
"    )) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/103\">",
"     103",
"    </a>",
"    ]. By radiographic (CT) assessment, 22 patients (65 percent) were thought to have stable disease, seven (20 percent) to have progression, and five (15 percent), a partial response. However, intraoperative findings were consistent with progressive disease in 50 percent of cases, and 29 percent of patients had histologic evidence to support some response to therapy.",
"   </p>",
"   <p>",
"    There is no clear evidence supporting the superiority of any particular chemotherapy regimen in patients with appendiceal adenocarcinoma or PMP. Given the greater antitumor efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and irinotecan-based regimens compared to 5-FU alone (with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) in patients with metastatic colorectal adenocarcinoma, trials utilizing these regimens for appendiceal adenocarcinoma are urgently needed. The role of molecularly targeted therapies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (all approved for treatment of metastatic colorectal cancer) in addition to chemotherapy is unknown in this disease.",
"   </p>",
"   <p>",
"    Despite the paucity of data on efficacy, medical oncologists typically utilize combinations of these agents in a manner that is similar to that used in the treatment of metastatic colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599450834\">",
"    <span class=\"h2\">",
"     Utility of tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of serum markers have been associated with gastrointestinal tract tumors, particularly carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9, and CA-125. For example, in the case of colorectal cancer, CEA is useful for prognostication at the time of initial diagnosis, and for posttreatment surveillance as a means of detecting disease recurrence in those who have undergone potentially curative resection. In addition, when levels of serum tumor markers are elevated, serial assay is useful for monitoring response to therapy. In general, tumor markers are NOT useful diagnostically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link&amp;anchor=H1620032#H1620032\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Role of tumor markers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H12#H12\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Carcinoembryonic antigen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911707#H183911707\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Assessment during therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link&amp;anchor=H2#H2\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'Treatment endpoints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of information on the utility of serum tumor markers in appendiceal malignancies relative to the more common gastrointestinal tract tumors. However, the available data suggest that tumor markers (most commonly CEA, CA 19-9, and CA-125) are elevated in the majority of patients with advanced appendiceal mucinous tumors and adenocarcinomas, and that, in this setting, levels correlate with treatment outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/104-108\">",
"     104-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If initially elevated, tumor markers such as CEA, CA 19-9, or CA-125 may be useful in the posttreatment follow-up of patients with advanced disease; in one report, elevations in tumor markers predated radiographic evidence of disease recurrence by up to nine months following cytoreductive surgery and HIPEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/14/36074/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no definitive data for use of tumor markers in surveillance after curative intent surgery for appendiceal adenocarcinomas; however, extrapolation of data from colorectal cancer is reasonable to apply in this setting. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H12#H12\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Carcinoembryonic antigen'",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appendix cancer is rare and most commonly found incidentally in an appendectomy specimen that was obtained for an unrelated condition. The main histologic types are carcinoids, adenocarcinomas, adenocarcinoids, cystadenomas, and cystadenocarcinomas (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For appendiceal carcinoids, there is limited evidence on which to base clear indications for right hemicolectomy. However, we suggest reoperation and right colectomy for tumors larger than 2 cm and for tumors 1 to 1.9 cm with mesoappendiceal or vascular invasion, positive or uncertain margins, or mixed histology (eg, adenocarcinoid) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Most patients have localized disease, and the prognosis is excellent.",
"      <br/>",
"      <br/>",
"      Simple appendectomy alone is sufficient for tumors &lt;1.0 cm in the absence of mesoappendiceal invasion and for tumors 1 to 1.9 cm that lack mesoappendiceal invasion or other adverse histologic features. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Carcinoid tumors'",
"      </a>",
"      above.).",
"      <br/>",
"      <br/>",
"      Following treatment, we follow the NCCN guidelines for posttreatment surveillance (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Posttreatment follow-up'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For appendiceal carcinoids &le;2 cm and confined to the appendix treated by simple appendectomy, no follow-up is required.",
"     </li>",
"     <li>",
"      For larger or node-positive tumors treated by right hemicolectomy, between 3 and 12 months postresection, we perform a history and physical examination, obtain chromogranin testing, and consider CT imaging.",
"     </li>",
"     <li>",
"      Beyond one year postresection, we perform a history and physical examination every 6 to 12 months along with chromogranin testing and consideration of radiographic imaging studies annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of epithelial tumors of the appendix ranges from the benign mucocele to an aggressive adenocarcinoma. Simple appendectomy, taking care not to rupture the tumor intraoperatively, is sufficient therapy for benign appendiceal mucoceles, cystadenomas, and some cystadenocarcinomas. A right colectomy is indicated for cystadenocarcinomas with mesenteric or adjacent organ involvement, complicated mucoceles with involvement of the terminal ileum or cecum, cystadenocarcinomas, and for goblet cell carcinoids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Appendiceal mucoceles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=see_link&amp;anchor=H6#H6\">",
"       \"Appendiceal (ileocecal) mucoceles\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudomyxoma peritonei (PMP) is a unique condition characterized by diffuse collections of gelatinous material in the abdomen and pelvis, associated with mucinous implants on the peritoneal surfaces. In our view, this term should be reserved for the clinical situation in which a ruptured cystadenoma seeds the peritoneal cavity with mucus-producing epithelial cells, termed diffuse peritoneal adenomucinosis (DPAM). The natural history is one of indolent but progressive growth, and if left untreated, this is a fatal condition.",
"      <br/>",
"      <br/>",
"      Standard treatment for PMP is repeated surgical debulking for symptomatic disease. This treatment is not curative but aims to limit the buildup of mucus and its pressure effect. A more aggressive approach using radical surgical cytoreduction of all intraabdominal and pelvic disease and intraperitoneal heated chemotherapy (IPHC) has been adopted by some clinicians, aiming for cure. Although randomized trials have not been conducted, five-year survival rates of 70 to 86 percent have been reported for highly selected patients (",
"      <a class=\"graphic graphic_table graphicRef59700 \" href=\"mobipreview.htm?10/22/10604\">",
"       table 12",
"      </a>",
"      ). The importance of surgical technique and surgeon experience to the success and safety of this approach cannot be overemphasized. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pseudomyxoma peritonei'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to other appendiceal tumors, adenocarcinomas more often present with a clinical picture of acute appendicitis. Standard treatment is a right colectomy. The role of adjuvant chemotherapy for adenocarcinoma of the appendix is unknown. Despite the lack of available data, we suggest adjuvant 5-FU-based chemotherapy for patients with node-positive intestinal type adenocarcinoma, extrapolating from data on adjuvant chemotherapy for node-positive colon cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal treatment of patients with intraperitoneal dissemination of appendiceal adenocarcinoma (mucinous peritoneal carcinomatosis as distinguished from DPAM) is unclear. Selected patients treated with aggressive surgical cytoreduction and IPHC may do well long-term, but patient selection and the experience of the treating team are critical. In uncontrolled series from experienced institutions, long-term survival rates in highly selected patients range from 28 to 72 percent at three to 10 years. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intraperitoneal hyperthermic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of systemic chemotherapy for advanced disease is unknown. Although mucinous appendiceal adenocarcinomas have been thought to be relatively chemotherapy-refractory, case reports suggest some level of benefit for therapy in individual patients. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Systemic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/1\">",
"      Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998; 41:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/2\">",
"      HESKETH KT. The management of primary adenocarcinoma of the vermiform appendix. Gut 1963; 4:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/3\">",
"      Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012; 19:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/4\">",
"      McCusker ME, Cot&eacute; TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/5\">",
"      Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/6\">",
"      Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 1998; 93:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/7\">",
"      Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg 1993; 217:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/8\">",
"      Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer 1968; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/10\">",
"      Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/11\">",
"      Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/12\">",
"      Anderson JR, Wilson BG. Carcinoid tumours of the appendix. Br J Surg 1985; 72:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/13\">",
"      Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/14\">",
"      Landry CS, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg 2008; 143:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/15\">",
"      Ponka JL. Carcinoid tumors of the appendix. Report of thirty-five cases. Am J Surg 1973; 126:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/16\">",
"      Syracuse DC, Perzin KH, Price JB, et al. Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. Ann Surg 1979; 190:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/17\">",
"      Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011; 104:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/18\">",
"      Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/19\">",
"      Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/20\">",
"      MOERTEL CG, SAUER WG, DOCKERTY MB, BAGGENSTOSS AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/21\">",
"      Kuiper DH, Gracie WA Jr, Pollard HM. Twenty years of gastrointestinal carcinoids. Cancer 1970; 25:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/22\">",
"      Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/23\">",
"      Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/24\">",
"      Aho AJ, Heinonen R, Laur&eacute;n P. Benign and malignant mucocele of the appendix. Histological types and prognosis. Acta Chir Scand 1973; 139:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/25\">",
"      Stocchi L, Wolff BG, Larson DR, Harrington JR. Surgical treatment of appendiceal mucocele. Arch Surg 2003; 138:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/26\">",
"      Nitecki SS, Wolff BG, Schlinkert R, Sarr MG. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994; 219:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/27\">",
"      Rutledge RH, Alexander JW. Primary appendiceal malignancies: rare but important. Surgery 1992; 111:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/28\">",
"      Lo NS, Sarr MG. Mucinous cystadenocarcinoma of the appendix. The controversy persists: a review. Hepatogastroenterology 2003; 50:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/29\">",
"      Miraliakbari R, Chapman WH 3rd. Laparoscopic treatment of an appendiceal mucocele. J Laparoendosc Adv Surg Tech A 1999; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/30\">",
"      Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/31\">",
"      Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998; 85:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/32\">",
"      Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992; 70:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/33\">",
"      Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \"pseudomyxoma peritonei\". Am J Surg Pathol 1995; 19:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/34\">",
"      Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/35\">",
"      Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008; 15:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/36\">",
"      Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/37\">",
"      Esquivel J, Sugarbaker PH. Pseudomyxoma peritonei in a hernia sac: analysis of 20 patients in whom mucoid fluid was found during a hernia repair. Eur J Surg Oncol 2001; 27:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/38\">",
"      Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park) 2004; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/39\">",
"      Low RN, Barone RM, Gurney JM, Muller WD. Mucinous appendiceal neoplasms: preoperative MR staging and classification compared with surgical and histopathologic findings. AJR Am J Roentgenol 2008; 190:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/40\">",
"      Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/41\">",
"      Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg 1980; 115:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/42\">",
"      Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990; 50:5790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/43\">",
"      Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/44\">",
"      Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park) 2004; 18:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/45\">",
"      Chua TC, Al-Zahrani A, Saxena A, et al. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2011; 18:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/46\">",
"      Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/47\">",
"      Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/48\">",
"      Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/49\">",
"      van Ruth S, Acherman YI, van de Vijver MJ, et al. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 2003; 29:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/50\">",
"      Stewart JH 4th, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/51\">",
"      Loungnarath R, Causeret S, Brigand C, et al. [Pseudomyxoma peritonei: new concept and new therapeutic approach]. Ann Chir 2005; 130:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/52\">",
"      Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006; 93:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/53\">",
"      G&uuml;ner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis 2005; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/54\">",
"      Chua TC, Yan TD, Smigielski ME, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009; 16:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/55\">",
"      Youssef H, Newman C, Chandrakumaran K, et al. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 2011; 54:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/56\">",
"      Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010; 36:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/57\">",
"      Bryant J, Clegg AJ, Sidhu MK, et al. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg 2005; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/58\">",
"      Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993; 36:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/59\">",
"      Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007; 14:2270.",
"     </a>",
"    </li>",
"    <li>",
"     www.surgicaloncology.com/txsites.htm (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     file://www.pmppals.org/surgeons-and-specialists.html (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/62\">",
"      Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008; 32:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/63\">",
"      Hsu C, Rashid A, Xing Y, et al. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol 2013; 107:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/64\">",
"      Pham TH, Wolff B, Abraham SC, Drelichman E. Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann Surg Oncol 2006; 13:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/65\">",
"      Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. World J Surg Oncol 2005; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/66\">",
"      Butler JA, Houshiar A, Lin F, Wilson SE. Goblet cell carcinoid of the appendix. Am J Surg 1994; 168:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/67\">",
"      Mandai M, Konishi I, Tsuruta Y, et al. Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2001; 97:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/68\">",
"      Varisco B, McAlvin B, Dias J, Franga D. Adenocarcinoid of the appendix: is right hemicolectomy necessary? A meta-analysis of retrospective chart reviews. Am Surg 2004; 70:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/69\">",
"      Park K, Blessing K, Kerr K, et al. Goblet cell carcinoid of the appendix. Gut 1990; 31:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/70\">",
"      Gouzi JL, Laigneau P, Delalande JP, et al. Indications for right hemicolectomy in carcinoid tumors of the appendix. The French Associations for Surgical Research. Surg Gynecol Obstet 1993; 176:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/71\">",
"      Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg 2003; 90:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/72\">",
"      Byrn JC, Wang JL, Divino CM, et al. Management of goblet cell carcinoid. J Surg Oncol 2006; 94:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/73\">",
"      Berardi RS, Lee SS, Chen HP. Goblet cell carcinoids of the appendix. Surg Gynecol Obstet 1988; 167:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/74\">",
"      Bucher P, Gervaz P, Ris F, et al. Surgical treatment of appendiceal adenocarcinoid (goblet cell carcinoid). World J Surg 2005; 29:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/75\">",
"      Hirschfield LS, Kahn LB, Winkler B, et al. Adenocarcinoid of the appendix presenting as bilateral Krukenberg's tumor of the ovaries. Immunohistochemical and ultrastructural studies and literature review. Arch Pathol Lab Med 1985; 109:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/76\">",
"      Yan TD, Brun EA, Sugarbaker PH. Discordant histology of primary appendiceal adenocarcinoid neoplasms with peritoneal dissemination. Ann Surg Oncol 2008; 15:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/77\">",
"      Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004; 91:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/78\">",
"      Lin BT, Gown AM. Mixed carcinoid and adenocarcinoma of the appendix: report of 4 cases with immunohistochemical studies and a review of the literature. Appl Immunohistochem Mol Morphol 2004; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/79\">",
"      Garin L, Corbinais S, Boucher E, et al. Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci 2002; 47:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/80\">",
"      Ito H, Osteen RT, Bleday R, et al. Appendiceal adenocarcinoma: long-term outcomes after surgical therapy. Dis Colon Rectum 2004; 47:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/81\">",
"      Cerame MA. A 25-year review of adenocarcinoma of the appendix. A frequently perforating carcinoma. Dis Colon Rectum 1988; 31:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/82\">",
"      Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum 1995; 38:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/83\">",
"      Kabbani W, Houlihan PS, Luthra R, et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 2002; 15:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/84\">",
"      Gonz&aacute;lez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004; 91:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/85\">",
"      Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/86\">",
"      Conte CC, Petrelli NJ, Stulc J, et al. Adenocarcinoma of the appendix. Surg Gynecol Obstet 1988; 166:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/87\">",
"      Hata K, Tanaka N, Nomura Y, et al. Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures. J Gastroenterol 2002; 37:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/88\">",
"      Proulx GM, Willett CG, Daley W, Shellito PC. Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. J Surg Oncol 1997; 66:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/89\">",
"      Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/90\">",
"      Chua TC, Al-Alem I, Saxena A, et al. Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients. Ann Surg Oncol 2011; 18:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/91\">",
"      Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 2012; 19:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/92\">",
"      Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 2008; 98:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/93\">",
"      Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/94\">",
"      Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21:799.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/96\">",
"      Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/97\">",
"      Stamou KM, Karakozis S, Sugarbaker PH. Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer. J Surg Oncol 2003; 83:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/98\">",
"      Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006; 13:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/99\">",
"      Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/100\">",
"      Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 2010; 116:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/101\">",
"      Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012; 23:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/102\">",
"      Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008; 99:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/103\">",
"      Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010; 102:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/104\">",
"      van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/105\">",
"      Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol 2013; 20:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/106\">",
"      Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2007; 14:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/107\">",
"      Carmignani CP, Hampton R, Sugarbaker CE, et al. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004; 87:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/14/36074/abstract/108\">",
"      Chua TC, Chong CH, Liauw W, et al. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg 2012; 256:342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2527 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36074=[""].join("\n");
var outline_f35_14_36074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARCINOID TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Staging and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6982135\">",
"      - Staging workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6982325\">",
"      - Assay of tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6982142\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Posttreatment follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment of metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPITHELIAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Appendiceal mucoceles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aggressive cytoreduction and intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Goblet cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Staging and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intraperitoneal hyperthermic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599450834\">",
"      Utility of tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2527|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/5/24671\" title=\"figure 1\">",
"      Surv rates appendix CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2527|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/62/993\" title=\"picture 1\">",
"      Appendix carcinoid ENDO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/23/32113\" title=\"picture 2\">",
"      Appendiceal mucocele Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2527|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/57/29595\" title=\"table 1\">",
"      Frequency appendiceal neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/2/2092\" title=\"table 2\">",
"      Frequency and survival for appendix neoplasms SEER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/59/35771\" title=\"table 3\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/7/17531\" title=\"table 4\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/18/4397\" title=\"table 5\">",
"      TNM stage append carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/9/41116\" title=\"table 6\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/6/14444\" title=\"table 7\">",
"      Incidence mets carcinoid size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/41/10907\" title=\"table 8\">",
"      Survival appendix tumors SEER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/56/27531\" title=\"table 9\">",
"      Survival postsurgery PMP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/36/13899\" title=\"table 10\">",
"      Survival DPAM versus muc cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/22/10605\" title=\"table 11\">",
"      CytoredsurgIPchem app muc tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/22/10604\" title=\"table 12\">",
"      Survival postsurgery IPHC DPAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/62/18414\" title=\"table 13\">",
"      TNM stage append CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 14\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/6/26731\" title=\"table 15\">",
"      Progn subtypes append adenoca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/8/25739\" title=\"table 16\">",
"      Contrast append colorect CAs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31077?source=related_link\">",
"      Appendiceal (ileocecal) mucoceles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_14_36075="Causes of proteinuria in pregnancy";
var content_f35_14_36075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of proteinuria in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary renal diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal change disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranous nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal segmental glomerulosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus nephritis (diffuse proliferative, focal proliferative, membranous)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive nephrosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura (TTP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection-associated glomerular disease (eg, HIV, hepatitis B/C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic vesicoureteral reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiphospholipid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic urinary tract obstruction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36075=[""].join("\n");
var outline_f35_14_36075=null;
var title_f35_14_36076="Indoor allergen reduction";
var content_f35_14_36076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Basic measures to control exposure to indoor allergens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Indoor allergen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommendations for reducing exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Animal dander",
"      </td>",
"      <td>",
"       Remove animal from house, or at minimum, keep animal out of patient's bedroom. Keep pet in a room with a HEPA filter and replace the filter as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cover air ducts that lead to bedroom with filters. Replace filters as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use air filters and vacuums with HEPA filters. Replace the filter as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Dust mites",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Less costly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Encase mattress, pillows, and boxspring in allergen-impermeable covers. Finely woven covers for pillows and duvets are preferable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wash bedding weekly in warm water with detergent or use electric dryer on hot setting.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reduce indoor humidity to &lt;50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       More costly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Remove carpets from the bedroom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Replace old upholstered furniture with leather, vinyl, or wood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Cockroaches",
"      </td>",
"      <td>",
"       Use poison bait or traps to control. Consult professional exterminator for severe infestation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periodically clean home thoroughly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Encase all food fully and do not store garbage or papers inside the home.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fix water leaks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Indoor mold",
"      </td>",
"      <td>",
"       Clean moldy surfaces with dilute bleach solution.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fix water leaks.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce indoor humidity to &lt;50 percent. Avoid use of humidifiers.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaporative (or swamp) coolers should be avoided or cleaned regularly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Rodents",
"      </td>",
"      <td>",
"       Consult a professional exterminator.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periodically clean home thoroughly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All food should be stored in sealed containers. Do not store garbage inside.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Repair holes in walls, doors, floors, and block other entry points.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The measures that can effectively reduce exposure are different for each indoor allergen. Those listed are suggested, but have not been verified to be effective in isolation. Studies showing greatest benefit from indoor allergen remediation were those that adapted the measures to each patient's individual sensitivities, and addressed all of a patient's allergies simultaneously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The Allergy Report. American Academy of Allergy, Asthma, and Immunology (www.aaaai.org).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36076=[""].join("\n");
var outline_f35_14_36076=null;
var title_f35_14_36077="Pravastatin cardiac mortality";
var content_f35_14_36077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pravastatin reduces cardiac mortality in patients with coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimate for the 9014 men with known coronary artery disease entered into the LIPID trial shows that compared to placebo, pravastatin significantly reduced the risk of death due to coronary heart disease by 24 percent (p&lt;0.001). Pravastatin also reduced total mortality by 22 percent, cardiac death and nonfatal myocardial infarction by 24 percent, and stroke by 19 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from The Long-Term Intervention with Pravastatin in Ischemic Disease [LIPID] Study Group, N Engl J Med 1998; 339:1349.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36077=[""].join("\n");
var outline_f35_14_36077=null;
var title_f35_14_36078="Direct compression bleeding";
var content_f35_14_36078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Direct manual pressure to control bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 412px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGcAWADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKTFAC0UUUAFFFFABRRRmgAooyKTcPWgBaKTevrSGRRjkelA7DqKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUGoZ7lIgSxFYt5rIGQlRKajuaQpSnsbjzIn3mFVpdQiX+IVyN1qUrn7xqFLhm6msZV+x1Rwn8x1baonamHUSehrnUck9atxnNZurJmqoRRqG9c9Kia7f1qBelNkHFJyY1CPYke9cdzVCbU5PtNum4/NPGP8Ax8U+bgVkSH/iZWhP/PZD/wCPClGTuXKnGz0PSaKKK7zyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4TUL+Vb25tpGOYnKj3Hb9MVQLk9TWl41tvs+qxXSj5J0wx/wBpf/rY/KsdWyK4aitJo9ai04Jokbmnw8Gos1IhqDVluOrsPSqETc1fhPFCJkWk6UPSLSt0pshblWb7tY0/F7bH0lT/ANCFbM/3TWNdcTRN6SKf1FKO5o9j0uiiivRPFCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8W2f2zRJto/eQ/vl/Dr+ma4G2bNerOodSrDKkYI9q8uurc2OoTW5z+7Yge47H8sVzV49Tuwc94iscU+M1DIeafCelc53FyM9Kv27cVQTtVy3NNESNBKVulNjPFPNNmZWnHFYuo/Khb+6c1uyjisTVl/cSD/ZNQtzVbHpFFR27eZbxP8A3lB/SpK9I8UKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuK8cWvlX0F0o+WVdjf7w/8Arfyrtax/Fdo13ok4jGZIv3qj6df0zUTXNGxrRnyTTOBJyKWM4NQwvvAPrUq9a4T1y9Ec1dhNZ0Jq/Cc4poiRoRHgVNUEXQVOKZmRyCsfVR8jfStmSsvUlyhqOprE6/QZfO0WxkBzmFP5VfrE8Gvu0CBD1iZ0/wDHjj9CK269GLukeRUVpNBRRRTICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACjr1oooA8u1SxOm6zc2wGIt2+P8A3T0/Lp+FRgc10vxAtCEtb9B/q28qT/dPQ/n/ADrn4cMoNcVWPLI9ahPngmOi61etz0qooANWYTzWaNJI04jxU4qrAeBVodKoyYj9DVG9XMZq8/Sq1wMoRUM0iXPA8mbe9h/uSh/zUf4V01cf4Nfy9VvIe7xhv++Tj/2auwrupO8UeZiFaowooorQxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCrqlmmoafcWsn3ZUK59D2P4HBrzK0LRloZRiSMlGHoRwa9Xrzrxbamx8QNIvEV0PMH+90YfyP41hXjdXOzCTtJxK+6pomqsDmpY+K5TvNOBuBV5DkVlQNWhC2RVIykidulQSjg1P2qKQcVLHEqaI3keJrfPAlV4/0z/Su4rzy+dra5guUHzROH/KvQYpFljR0OVYBgfUGuqg/dsceLjaSY6iiitzkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArA8aWBvNHMkYzNbN5q/T+Iflz+Fb9I6q6MrDKsMEe1Jq6sVGXK00eXQHdGDVlKrNC1jqNxZSZzE5UE9x1B/IirKDmvPas7Hsp3V0TxdavRHFUYzzVuOhMmSLqnimuRUQkCjmqF/qCQqS7AChiSH35RoyCad4R1aaCV4rmUvp5bZCzfwcdPpVC3s7jUcPOGhtj/32/0Hata4t44okhhjAwu1V7KPU1HteR+6ZVnGS5TtKKy/Dt213YEOPmgbySw/iwBz+talenGSkro81qzsFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcT46s/KvrXUEGBIPJkPuOV/TP5CsuNwQCK7HxdB9p8PXgAy0a+Yv1U5/+tXnCPqIUBLJyfUuo/rXHXSUrno4apeFn0NsP3pXvY4lyzAVlR2OqXIBnlhtk9juP+Falhp+n20gZy13OOm75sfh0Fc7mkbyqRRFA95qTYso8R9DK/C/h61o2mk28MgZ83V0v8b/dU+w6VZNzuG1vlH/PNOv4mlDs2AflTsi9/rWTqXMJTlIsF8HEWGk7uei1nXkzMHhtTl2+/Ie1W3jaYbc7E/uipY4EjXCqKhyM0jDsvtWkuZbOQ5PLqeQ/1rs9G1WDVIN0R2yr9+Inlf8A63vWRJCrdqyby1mt5lurFjHcJyCO/sfauihiHB2exE4KXqd9RWRoWrpqUOHHlXSD54if1HtWsrZ+tenGSkro5mmnZi0UUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEVxEJ7WaE8CRGT8xivMxbNDKbeaaVJY/lZMDivUa5nxlYn7P9vtiFmTCvkZBXpn65IrmxNPmjddDWlKzsc/FZQlQzM8h/22OKmEkUXyKck/wRjFU7W1mmINxOzKew4FbNpbRQ/cUCvNeh1EcNvKwzgRr6DrVuKPbxUyEYpH4OancCRQMcU0NhsGlRs0OueRTSEPxmmsoPBpEantzRYDGvrV45VuLZ2jmQ5DLWro/iWOZ1ttRAguOgk/hc/wBDRIgdcGsbUdPSRWJFbUq0qbJlBS3O+zRXFeHdamtLiOyv3L27fLHI3VD2BPp/Ku1FenTqKoro5ZRcXZhRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVdUg+06dcwjq8ZA+uOKtUUmrqwLQ840+QtEpNa8TdKypYxaaldW4PCSHH06itCBsgV4s1Z2O5O+pbDYOKc3IqB+CDU68gVJQyIkHFWAagcbTkU9DkVSExW+VqkUgimMMimI+04NMRMRioZk3KfepxzTSKGgOZvFWR5I+jr1Fdh4VvjeaWqyEmaE+W5Pf0P5VyviC3MEiXsfQfLIPbsan8O3ws9Vj5/cXWEb2b+E/0/GujDz5ZeTIqR5oneUUUV6RyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFeL7fyNXiuFHy3CYP+8P8A62Kr2j5rovFtqbjRZHUZkgPmj6Dr+hrk7STgEGvMxULTv3Ouk7xNg/MlSQNlaggbIxTom2yEGuU0LTDKmooiQxBqdaZINrZqgHjpUM6kHIqZTkUHBouIihk4wamB3VTuW8rkdKktJ1fHNNASTxLLE8ci5Vhgg965IW7QST2jk5Q7oz6jtXayFSuRXPeIIirR3S9Yzhv9009nYEdhoN79v0uGVmBlA2Sf7w6/4/jWhXF+Dp2i1aaDP7uaPeB/tD/6xNdpXq0p88EzknHldgooorQgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsiLIjI4yrDBHtXmwhazvp7V+sTlQfUdjXpdcZ4zt/I1GC8UYWVdjH/aH/ANb+Vc2KheN+xtRdnYit2wRU8gyQwqlbvuAIq4HyvNeWzpLcbZApz4K1VjlwvNORy/SgQx5vKfaelW4sPyDWfqIxFu7ioNOv/mCk00DNW6gDoR61zjzS2N1sk+6Twa6YPvAxWdrNiLm3bj5hyD6GqurgvMms7nzce9SXkSyIVcZRhtP0NYOiXWG2PwwOCPQ105Alh/CiwPQ53wxKYvEVvDIR5iF4m9+Dg/yr0SuAvbWJL5LnZiXqHBIIYf8A1sVPZeIr1JDGzrIAcDev9a9LDL3LnNVd5HcUVz1vrkrH544yPUcVak1uOBN9xEyxgZLKd2PwroMjXopFYOqspypGQaWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9dsBqOmTQD/WY3If9odP8PxrQopNXVmNO2p5vpshIKMCrqdrA9Qa0wOKd4usGs7salbr+6kIEwHZuzfjVaCdZY1ZT1FeVVp8jszrjLmV0JM5j5PSrFnOCODUFwPMjIFY8V21tetA2dwAbB7is4lM6iRRNGQRnIrlb2GSzugRkKx4robO5DAVDrlqLq0ZVO1+qt6EdKSlZgh2j3Rkjwx5FbRAePFcXpN1ld2Nrqdjr6MOtdZZTiRAc09mDOc1W3NnfrOvCOcN9e1bum3AeIc0/VrRbm2dCMgiuf0q4kgMsLjMiHH196A3NjVNpt3IPKncP61z8Q/e8da0G86Zz5nCFTx+FZ1pkkkZrvwj91o56y1TNy1fMY4/z/nFF6jX09vp8J5mOGOeijqfy/nRZIRCSfTg/wCfpU/hdRL4guXPJii2j6kj/GusxOvRQiqqjCqMAUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMniSeF4pVDRuCrA9xXml9FJo2pyWr58rOY2PdT0r06sTxXpQ1LTiUH+kQ5ZD6+orGvT54mlOfKzm7ecOBWR4ntmURX8AzJAfmH95e4p2mzEHY/Va3FVZoyrcgivL+FnWZGn3YYLg8MARW1kyRc1y0cTW1zLAAQImyv+6a6CwuFKBWNE11QGBqB/s/VkmIxbXJ2Sf7LdjW/YTGKQIx47VX1aKO5ikjIBBGR9aqWM5ktI2/jiO1vp2qrc0bivrY6qa5RI/wB4wArnN6tq+9OjAfoatSQG4CuScVUaIRX8OP7p/mKlDN7yd2c9CKw9LhAjXqSTXRKf3QPoKx9NTJTGCMZ6GuvAu/Mc9boawAWBvTH+f5VD4MBOoXcmQdwb9CB/Sp7ldtm+Bj5e1M8DoSruRj5P5kn+ld5gdXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwPi7SGsLv7bbD9xIfmA/hNUbPUUCYY8ivSLiCO5heKdA8bDBU1y194Rsoo550aTCKWVPfFcVXDOTvE6IVVa0jnZf9MuPNhXJHB9x/n+VKlpdo3yxtj6Vq2EaxoqqAD3wK1Cy+Wec9feqjhFbVidZ9DlrsTRQneMEjFU9NbLzR88pnn2rf1JFdXBA/I1zcaiDUYyDtDNtPB7irlRjGm4xIU25Js6rSiJLcA9qztZxDqVsR0ZWH8qt6I+AyHqDSeIIVZIpCPmVuDn2rzIq8rI6m7bkzXR+xyMFxGqH5vU4qppTLuXAH4j/69VbmZmsRApAXjJPOfyo0gbJMYz+FelhaTpxd+pzVZKT0N7VpNunylTk49vSrfgiMrpTMerMB+Sj/ABNZustjT3OCOD29q3fCoA0ePHcn/CukyNeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApk6eZDIn95SP0p9FAHEQfKi57fkODVnzFweuOe9QTDyp5osco5UZ9ORUiAspy3P1/wAKAILkhtxGOe2TWZfQB13KDuU5HzVulNy8tzj1NQi3D5GR+OKAKVlKI5mkHRhn8alvYne2RnJLO/T0GDUz2AyNvB9sVaW3LbQ4yBwBXnRw841E+h0OonEyxbDYOCce9OtrZkl3BcD8K11hAXgKKa80MYyXHHYZr0TnKOr86dJ67W/lW94Sbdo0ZHTPH5CuX1K+WdPIt1MjngKOfxNdX4YtJLLSkim4bOcHsMD/AAoA1qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDndc0Ca8uDNZ3AiLHLqR/Ks46FqkR+WdmH/ATXZ0UAcZ/ZusL91sn3X/A0gs9cB+6hHup/wAa7SigDjvsWvN/yzjI/wB/H9adHpWuP1a2jP8AtMT/ACrr6KAOIurQ2t9ZWeq63Db3F6WWCMJzKVAJAJ78j861ovClnkNdS3FwfR3wPyqP4g+GY/FPhuezB8u9jPn2c3eOZfunPoeh9ia5r4U+OZdXVtF14NDrdszRMJPvMy/eU/7Qx+I59apRurotRvG6O/s9OtLP/j3gRD645q3RRUkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeK/Gvw++j6pB4x0uRoMvHFelONjA4jm/A4U+xHvXtVU9X0611fS7rT7+MS2tzG0UiHuCP0PvVQlyu5cJcjuYXw+8Up4o0cySqseoW5EdzGOm7HDD2P+Irqa+YdKvtT+HXjO4tZWaSSwcRSA8farU8o31x+RH1r6V029g1Kwt7yzkElvOgkRh3BqqkOXVbMqrDld1syzRRRWZkFFFFABRRRQAUUUUAFFFFABRRTTIgkCF13kZC55P4UAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyP4++HHmsLXxNZRl5tOBju0UcvbMeT/wE8/Qn0rP+B/icW14/h66mDW8+ZrJyeM4yVHsRyPcH1r1rxFqGl6bpU0uvXFvBYSDyXM5wrbuNvvn0r5WkjOjatKulzmSGwuSbK5H8cYO5D9R0/Cuin78eVnVS/eQcGfWttdQXSu1tPFMqOY2MbhgrDqpx0I7ipq8l/Z4vGfQ9UspJGkeGdZmdurNIDuP4lSa9arGUeV2OeceSXKFFFFSSFFFFABRRVPVNStdMt/Ou5Ao6Ko5Zj6Ad6TaSuxpNuyLlZN/r9haFk83zpl48uL5jn69BXLajrF9rHyRlrW0P8Cn5mHuf6VFbWkcC/Korgq47pTR3U8H1qP5Glc6/qFwT5UcdvF9SzfnXM6pdyRP9oEjG4RgysOowe1aF9crChGeaq+GtOk1zWFZgfsduweRuzHqF/H+VcanUrTSudajTowcrWR6ipyoJGCR0paKK9w8UKKKKACiiigAoNFI3CmgDC13U57NCYWAPuua5geNdRifDxW8i+6kH9DWn4mfcxFclJCCeleRiMROM7RZ6+HoQlD3kdNB49PAnsPqUk/oRV+Hxxpj/AOtjuYj7qCP0NcMYF9Kabdazjjaq6mksFRfQ9Lt/FGjz/dvo1Po4K/zFaUF7azgGC5hkB/uODXj5tqjNuR0rWOYy6oyeXwe0j2yivFFE0ZyjupHoxFWotU1SH/V31yPYyE/zrVZiusTN5c+kj2GivKE8U61FwLtm/wB5FP8ASp4/GmrofmeF/wDejH9KtY+m+jM3l9Tuj1CivNV8c6n3jtT/AMAP+NP/AOE51LH+otD/AMBb/Gq+vUifqFU9HorzZvHepZ4gtB/wFv8AGoX8aavJ91oE/wB2P/HNDx1JDWAq+R6fRXk8niXWZCc3sg/3VUfyFVZNU1OUYe9uiPTzTWbzCHRMtZdPq0exUZHqK8UZ7hz88kjH3Ymm+XIe5qP7RX8v4l/2d/e/A9syPUUteJCJ/enATL913H0Jo/tL+7+P/AD+zv734f8ABPa6K8aju76I/uru4T/dkYf1q3FresREFL+c/wC8d386pZjHqiXl0ukj0/VdNs9XsJbLU7aK6tJRh4pV3A//AF/evnz4j/D668GF9R0cS3fhr/lrCSWks/fPVk9+o7+tehQ+LNajxueKT/fjH9MVeXxncvE0d3p8EyMCrKGIBB6gg5rop5jTT3Jjha1N6anJ/s84+162Y2DRNHCwI6Hl8V7VXk/gNNE8I3eqS2FtfxxXzhxBvV0gAydqdDjJPXPb8e5j8W6U4y0ksfs0Z/pmtZYujUldSM61Co5X5Wb9FYyeJ9HbpfIP95WH8xVqPWNNk+5f2p/7aj/GmqkHs0c7pzW6Zfoqut7at925hP0kFYfiPxCltEbfTpElu34JU5EY9T7+1KdSMI8zYQpynLlSJ/EXiKHSx5EIE18w+WIHhfdv8K5DZcX9z9pv5DLMemeij0A7UljZ4YyOS8jHLM3JJrXijCjpXk1a8qz7I9WlSjRWm5BHEEXpVa9uxEhweauz/dOKwrxX3q/liQKwYoTwwB6fjWD00NY66kukaDfa9K0rP5NnnmRhy3rtHevRtM0+30yzS2tE2Rrz7k9yT3NU9I17TtQVY4JVimxjyJPlYewHf8K169nD0YU1eOvmeViK05u0tPIKKKK6DnCisPXNVmgnW1sAnnnG52GQue2P1qnbeJJLabytWjTZ/wA94s4HuV/wrGWIhGXK2bRoTlHmSOoopqOsiK6MGRhkEHIIp1bGIU2U4Q06mTf6s0nsNbnG60N8xrGaGtvVB++NZ5WvBrfGz26TtFFBoKYYcVoFPammOsTW5nmOmmKr5jpPKoHcoGKmmH2rR8r2pPKpWHcy2t89qhe246VsGKmtDTDmMJoCKZtI61tPB7VVe39qClIznTIpIvvYNXHiqrINrUDL0URK5xUyw+op1g26MVfVAe1KxLZSEA9Kd9nHpV3yxShBRYm5REA9KPs49K0BGPSneWKdhcxm+QPSk8j2rT8sUeUPSnYOYzPI9qdEnlyo4HKkGtHyRR5IoSsHMeaWPjiG08yz1+3mF1GD5FxDHlbtQxX7o+6+QenBwehGDtWur3d1EJIfD+pFevzhI/yDMCfyrJ+LfhqS4sINQsWEBsgTGIRtcSGQNuz6D5m69frXV+CNYn13RN+pRGDV7WQ219EV24lXq2OwYYP1JHanbm17Ht4n6sqEcTRp3Um73b0faytp13t0M621i0luTb3cEtlP1CTrtOPXnt7jIHrWybFccLVzVtJttUtDBdJnB3I44aNuzKexrnfCt/cWeozaDqhBng/1T9A6HO1lHoR2/hII7gCbHG6dOvTlUoKzjq1vp3X6o0pbMKAan0u1AUN681duo8jp2qxaxhQAB0FNI4HLQsxJtFSCjtTWYAVtsYbkU7gCqMrDHNTTt1NZlxN15rKTuaxRWvI4nBaVQVFS2smpJCojv7yJP4UEpwo9KIYjMweQfKOgqyCZGKrxGOp/pRGUo7McknuiCfV9XtMMNVudx+6pAfPtgg06DxHq0jJHdanPFIexhRM/T5aZZSQvrbi4+6Ixt+mfm/8AZR+NbGsW1rdQpHIitu6BeMD19sdq3U6nK3zMycIXtyr7jJj1K5g1WQ3c5lMvzJMw6cAYOP50uqXBlUqTkscs3b6VlXSzWVwsbMZYwR5b9SM9m/xrpdO8KajqEgOof6Hb9wCC7fQdB+NTGFSs7R1KlOFJXeh0PgGWWXQf3mdiSssZP93j+ua6SoLK1hsrSK2tk2QxrtUVPXt048kVF9DxakueTkuoU2XlDTqRhlTVMhHJaouJTWecVq6yu2QmscmvErq02exRd4oU0001jTc1zs6EP4owKZmjNIY/ApMCm5ozQAuBRtppcUm8etADigI6VXnjGOKm31HK3BoAzJhjNULngZrSmPNZt2eDQaFzSXytbEZrn9FOTW/EvFMhlgdKWkXpS0iQzS5ptLTAeDS1HmlDUxWJKUVHvApPMp3FYozWM8niKG7MiNZC2aJ4mGfn3qwb9KpQW1za+PLqdIybG+s1MjAHAljbAJPT7rEetbnmCsTVI79vEej3Fqc2kYlSdfUMBg/gVH60r21R2UKkpNwk0lyta+Wq+d0rHQcVx/xGtNlna6zEH82wkBkMY+YwsRux7qcMPQius31Bewx3lnPbTDMc0bRsPYjBpvVGeDrvD1o1Oi39Ov4FexvFvtLhuFZWLryV6Z749vT2xWlB0Fea/Dm8eOzvNMnb9/ZyeW4Pqp2H8MBP1r0i3bKilF31NMww31WvKktk9PToTO+BVaabaMk1NIM1VlhD8NTk2cUUilLOZG2pk/SkitDu3zdB0Wr8cSxj5QBVe6cswjQ/Mf0qS7kLkyv5cXA7n0pYbVr8vDG7RwIduVOCxHU59BU6xiCPA61m6dqZsr57eQhQ7EoT0OTnB9DnpVwtfUTu9hup6DPbSLNYTt5qcoJDkN7Z6j8c0/TdUEqOk0ZiukGJIj1B/qPetyedpgNwCoOcZzk1zOpwrcXW+FtksfCuP5H1FE+W9kON3uTyIZBJJJ1bt7V3PgO9lutJeKZi32aTy1YnkrgED8M4/KuB0t7rU5DZ29u7XSkK4A+Vfcn0r1Hw/paaRpqWykO5O6R8Y3Mep/pXZgYSUnLoceOnHlUeppUUUV6p5YUHpRRQBz+upwTXNuQCa63W48wEiuKuJArkGvIxkbSuerhHeJIWFIWFVTKPWjzR61xHZYtbxRvFVfMFODj1osBZzTGaovMApplFFgJC3NIWqEzCm+aKLDJi3FQySmmvJUDvRYYkj81UuRuGPWpXPGaiALNzQUWdIgweOlbq4UVnWbpEgFTtcL60rkstF8d6YZapNcD1qFrj3pC5TS82kM1Z3n+9NM49aLj5TRM1NM/vWcZx600z+9Fw5TSE+e9O82sn7RjvTvtfFFw5TSM3vWdqS3k2oaZLaT+XDDKzToTw6lcYx3qJ7rPSrNtY6lec21pO6+u3A/M8U0nLRIuE/ZPm067+asaBuV9aQ3QUVNaeEtXmAMphtx/tvk/pmr9n4QgnZ1fVVlkjOJEhAyp9DycV0Rw1WXQ5ZV6Uep5Fbs1l8SL9YwBDcnk+7x7/AOcZr0mzu1MCHPOKwPEWgWul/FHSYQZJre5igLB253edsPTHZ66nXtAjivJhoc0czxgNLZLIGkjHqBnOPY0lhppPyPVzPEQqqjU7wWvppqSRThx1qQgHpXLw3rRuVYkEHBB4IrRhv9w61nfuebydjQncJGSewqrYxl3Mj9TVW6ufMZIwc55P0q5FMI0ApBayE1OTyoXYfwrUNhoVjeWbPMiyyOOWPJJx1z2HsKh1O4XymJPFQaHMywPC+5WUZABxlD0Bq4ySd2HK2hzyT2gW3kcvE4/dSE5P+6fU+/eo1ARTnr1zUWpSPPC6n5QBlfYjoa3tB8LXuoJBNqZWC0ZQ+1Gy7gjOPb+dFOlKq7RQTqRpK8jY+Hdu4tby8YEJO4VM9wuRn8yR+FdfUdvDHbwJDAgSJBtVR0AqSvcpQ9nBR7Hh1Z+0m5dwooorQgKKKKAK97F5sLCvOvEFtJBMxAOK9Nqpdadb3X+tQGsK9H2qN6Fb2TPHTdlTg5pRd5r02bwnpUpJaJwT6NUH/CE6TnpP/wB9/wD1q4vqUjt+uwPPluakE5r0FPB2kr/BMfq9Sr4U0of8sX/7+GmsFIX12J52JiaUyGvRR4X0r/ng3/fw0o8M6UP+Xcn/ALaN/jT+pSF9dieblzSeacV6avhzSl6Win6sx/rUi6Fpa9LKH8Rmj6i+4fXo9jyxpT6VC0pr1+PStPj+5ZWw/wC2QqZbW3T7sES/RAKPqHmH19djxcymlWXiva/LTGNq4+lMe2gcYeGNh6FQaHl/94azD+7+J4yJiKDcV65Lo2myg77C1Oe/lAGqreGNGY5NhH+BYf1rN5fPoy1mEOqZ5U1xTDN716yvhnRh0sIvxyf61Mmg6Un3dPtfxjBo/s+fdB/aEOzPIPN96khjnnOIYZZD/soTXskWn2cJzFaW6H1WNR/SrPTpVrLu8iXmPaJ5FBoGrz42WE4B/vjZ/PFadv4K1STHmvbwj/ack/oK9KorWOAprdtmMswqPZJHEQeA16z35PskeP1JrUtfBulQ4MiSzkf89H4/TFdHRW0cLSjtExliqst5FS202ytcfZ7SCMjuqDP51boordJLRGDberMPxLJ4hi8h/DsGn3AGfOjunZCemNpA9M9e+K8M1vxzBpWv31xDYC21C5EiSzRQhXt3EnzIHVgJRkEE8H+IEHivo+uZvvA+g3k8sz2bRtK5kkWKVlRmPVtgO3J7nGTXLiKE56wZ7+TZnhcJeOKp3Xlu/XXVfLyeh863fxDudT8SaHqmpRMx090D7GG6RFlD+wzgY966nw34u0e0uRc2uszWes3kjm7vtStWkVVd93lxqrFVUnkk+n5eny/CrwhNzPpkkj/3mupcj8mxVZPhH4Whu0uLWC4gdOgEgkGc5zhw3PvXJHC4iLu2n959FWz/ACatT9nGE4JK2ijbq7a30u9rfkdXe6Lp2sW8cl3FFM7ICJ4vlLcdQQen4mubuvATK5NhqLKn9yZN36jH8q7HTbOHTtPtbK1DCC3jWKMM2SFUYGT34FWa9CVCFT41qfCKvKnJ+zen9dDzC68Ka3ay+YkUN0AMfupMH8mxVRtO1sMc6Xdfguf5V61RWDwNN7XNljqi3SPJ28Pa5dxkCwde/wA7qv8AM0j2t/aswl0+5VyNufLJH5jivWaKTwEOjY1j59Ujy3SPDuoatOonhktrTOXeQYLD0A6/jXqEaLHGqIAFUAADsKdRXRRoRoq0TnrV5VndhRRRWxiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36078=[""].join("\n");
var outline_f35_14_36078=null;
var title_f35_14_36079="Renal abscess CT";
var content_f35_14_36079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal abscess on computed tomography scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan showing a large renal abscess with internal echoes in the right kidney (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Meyrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_14_36079=[""].join("\n");
var outline_f35_14_36079=null;
